Developing gene therapy for Duchenne

muscular dystrophy using adeno

associated virus (AAV) expressing

Estrogen related receptor gamma (ERRγ) by Al-Siyabi, Muzna
UNIVERSITY OF READING 
 
 
 
 
Developing Gene Therapy for Duchenne 
muscular dystrophy using Adeno 
Associated virus (AAV) Expressing 
Estrogen Related Receptor Gamma (ERRγ) 
 
 
Muzna AL-Siyabi 
 
 
Thesis submitted for the degree of Doctor of Philosophy 
 
 
School of Biological Sciences 
October 2018 
 
 
2 
 
 
 
 
 
 
 
Declaration 
 
I confirm that this is my own work and the use of all materials from other sources 
has been properly and fully acknowledged. However, the microarray analysis and 
Principal Components Analysis were was conducted by Dr. Bend Denecke, 
RWTH Aachen University, Aachen, Germany and Dr. David Chambers, Kings 
College London. Moreover, the titration of the virus was carried out by Dr. Helen 
Foster, Reading University.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Acknowledgment: 
Completion of this thesis would not have been possible if it was not with the 
support of many people. 
Firstly, I would like to express my sincere gratitude to my supervisor Dr. Keith 
Foster for helping me to the end of this long, difficult part journey of my life. Your 
support, encouragement and faith on me has been critical for the completion of 
this thesis in the presence of many laboratory difficulties throughout. Thank you 
for inspiring me to pass all of that.  
Secondly, the laboratory team; Dr Helen Foster and Dr Wouter Eilers. I will never 
forget your guidance, support, patience and technical assistance with my studies 
and I will always feel privileged to have been part of this team. Thank you 
I would like to thank my dear friends Aida and Wadha. I knew I have been talking 
a lot in the last 4 years on how difficult being a PhD student. I thank you for 
listening, encouraging, inspiring. To my friend (Ahmed) who was a PhD student 
and passed away just before defending his thesis, rest in peace. 
Parents play an important and large role in the development and shaping of their 
children behaviours, thoughts and life. I was and I am still fortunate to have the 
best parents that anyone could asked for. Their faith, commitment, patience and 
support to me have made all my accomplishments today possible. I will always 
be grateful for all they have done for me. I would like to express my deepest 
appreciations to my mother (Jokha), my father (Saif). I hope the finished PhD 
thesis brings you much pride.  
 
 
4 
 
To my sisters; Marwa, Waad and Mazoon, My brothers; Mazin, Mohanned, 
Zahran and Basil, thank you for constant voice messages, joyful holidays in the 
last four years, Allah bless you all.  
Aside from myself, I cannot think of anyone else more excited to see this thesis 
completed-thank you for your enthusiasm, well done.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Abstract: 
Skeletal muscle is the most abundant tissue in the body, exhibiting major 
metabolic activity by contributing up to 40% of the resting metabolic rate in adults. 
One of the most remarkable trait of skeletal muscle is its great adaptability to 
numerous environmental and physiological challenges by changing its 
phenotype profile in terms of size and composition that are brought about by 
changes in gene expression, biochemical and metabolic properties. Amongst 
these adaptations is the increase in oxidative metabolism that is supported by 
increase in blood flow and capillary density. Estrogen related receptor gamma 
(ERRγ) belongs to a family of orphan nuclear receptors. It is considered to be a 
master switch for both oxidative and angiogenic factors. ERRγ is down-regulated 
in mdx along with its target metabolic and angiogenic genes. Transgenic 
overexpressing ERRγ in mdx mice, improve sarcolemmal integrity and muscle 
perfusion with restoration of metabolic and angiogenic genes. 
Duchenne muscular dystrophy (DMD) is an X-linked, recessive neuromuscular disorder 
caused by the loss of dystrophin that causes progressive loss of muscle fibre leading to 
cardiac and respiratory failure and ultimately death within the third decade. It is 
characterized by sarcolemmal fragility, impaired blood perfusion, calcium dysregulation, 
impaired mitochondrial function and oxidative stress. Following transcriptomic analysis 
we hypothesize that postnatal over-expression of ERRγ might improve oxidative capacity 
and angiogenesis in mdx mice. We first examined the effect of intramuscular 
administration of (5X1010 vg) AAV8-ERRγ into tibialis anterior (TA) muscle of two cohorts 
of mdx male mice, initiating the experiment at either 6 or 12 weeks of age. There was no 
difference in mass, cross sectional area of muscle fibres nor was there a difference in 
myosin heavy chain fibre typing in the TAs of either cohort; however, succinate 
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dehydrogenase analysis (SDH) was significantly increased in both cohorts and H&E 
analysis demonstrated a 10% reduction of centrally nucleated fibres, but this reduction 
was restricted to the 6 week-old cohort only. This gave proof of principle data of an 
improvement in metabolic and pathological parameters in dystrophic muscle following 
ERRγ over-expression and leading to systemic administration protocols. Surprisingly, 
systemic administration of (1x1012 vg) of AAV8-ERRγ into 6 week-old mdx male mice 
showed no functional improvement of EDL muscle and no difference in any examined 
markers. Therefore, we carried out an earlier systemic administration of (2 X1012 vg) of 
AAV8-ERRγ into three week-old mdx mice for longer time and resulted in improved 
specific force of EDL muscle while the eccentric contraction-induced force deficit was 
unaffected. EDL muscles showed improvements in SDH activity, a reduction in centrally 
nucleated fibres, with no change in IgG positive fibres or CK assay. EDL muscles showed 
an increase in capillary density, increased transcript levels of PGC-1α, angiogenesis, 
inflammation markers and a reduction in transcript levels of GADD34 and 4EBP1.  
Collectively, this data provides prima facia evidence that ERRγ over-expression 
at an early time point is a potential therapeutic strategy to overcome metabolic 
and pathological problems associated with dystrophic skeletal muscles.    
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Abbreviation: 
AAV Adeno associated virus 
Ach Acetycholine  
AchE Acetycholinestrase  
AMPK AMP-activated protein kinase 
AON Antisense oligonucleotides  
ATP Adenosine triphosphate 
BMD Becker muscular dystrophy  
Ca+2 Calcium 
cGMP Cyclic guanosine monophosphate 
CK Creatine Kinase 
Cmap Connectivity map 
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DAMP Damage-associated molecular patterns  
DMD Duchenne muscular dystrophy 
EC Endothelial cells  
Enos  Endothelial nitrc oxide synthase 
ERRα Estrogen related receptor alpha 
ERRγ Estrogen related receptor gamma 
ER Endoplasmic reticulum  
ETC  Electron transport chain 
g Gram 
GABPA GA binding protein transcription factor, alpha 
Gadd34 Growth arrest and DNA damage inducible protein  
FOXO Forkhead box O  
GLUT Glucose transporter 
HIF-1α Hypoxia-inducible factor 1α  
H&E Haematoxylin and Eosin 
IGF Insluin growth factor 
IL-1β Interleukin-1β  
IL-6 Interleukin-6  
IL-10 Interleukin-10 
iNOS  Inducible nitric oxide synthase 
IP3 Inositol 1,4,5-trisphosphate  
Kg Kilogram 
L Liter 
ml 
mM 
Milliliter 
Millimolar 
MPC Myogenic precursor cells 
mtDNA Mitochondrial DNA  
MurF Muscle RING finger-1  
MYH-3 Myosin Heavy Chain 3 
ND2 NADH dehydrogenase 2 
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NK‐κB 
Nuclear factor of kappa light polypeptide gene enhancer 
in B cells 
Nnos Neuronal nitric oxide synthase 
NRF Nuclear receptor factor 
OXPHOS  Oxidative phosphorylation 
PDK Pyruvate dehydrogenase kinase  
Perm-1  PGC-1/ERR-induced regulator in muscle 1  
PGC‐1α 
Peroxisome proliferator‐activated receptor gamma 
coactivator 1‐alpha 
PI3K Phosphatidylinositol 3-kinase  
PNC  Purine nucleotide cycle 
p‐p38 
MAPK 
Phospho‐p38 mitogen‐activated protein kinase 
p38 
MAPK 
p38 mitogen‐activated protein kinase 
qRT-pcr Quantitative real time PCR 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
RYR Ryanodine receptor 
SAC Stretch activated channel  
SC Stem cell 
SDHA Succinate dehydrogenase complex, subunit A 
SERCA Sarco/Endoplasmic Reticulum Ca2+-ATPase, 
SIRT1 Sirtuin 1 
SO Sequence optimization 
Sod Superoxide dismutase 
TCA  Tricarboxylic acid cycle 
TFAM Transcription factor A, mitochondrial 
TNF-α Tumour necrosis factor alpha  
UPR Unfold protein response  
VEGF Vascular endothelia growth factor 
VSMC Vascular smooth muscle cells  
4EBP1 
Eukaryotic translation initiation factor 4E binding protein 
1  
μl Micro liter 
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1.1. Structure of muscular tissue: 
Muscle tissue is one of the four primary types of body tissues, together with 
epithelial, connective and nervous tissues. Muscle cells are highly specialized for 
contraction; they produce movement in certain organs and the body as a whole. 
There are three different types of muscle within the body, each with its own 
specific functions and different morphological features. These muscle types are 
smooth, cardiac and skeletal muscles and the structure of each type is adapted 
to its physiological role.  
Smooth muscles are a constituent of internal organs and blood vessels. Their 
muscle cells are not striated and not under voluntary control because they cannot 
contract by conscious means. This muscle type is innervated by autonomic 
nervous system and contracts very slowly. Muscle cells present in smooth 
muscle are relatively long spindle shape with a single central nucleus. The 
contraction of smooth muscle is mediated by calcium interacting with calmodulin, 
which is a calcium binding protein (Koledova and Khalil, 2006). 
Smooth muscles play variable roles in different body organs. For example; in 
cardiovascular system, they regulate blood pressure and control the distribution 
of blood. In the walls of digestive tract, extensive layers of smooth muscle cells 
play an essential role in moving materials along the tract. In addition, they can 
alter the diameter of respiratory passageways when they contract and relax 
(Martini, 2007). 
Cardiac muscles are the specialized type, exclusively found in the heart that have 
function to provide the force required for circulating blood around the body. They 
are known as striated muscles and considered involuntary. However, a typical 
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cardiac cell has one central nuclei (Martini, 2007). There is close association 
between blood flow and metabolic demand in cariac muscles. For example; in 
the presence of oxidative or metabolic stress, these muscles are essential to 
maintain blood flow. However, smooth and cardiac muscles are not the basis of 
this thesis and the focus will be on skeletal muscles.  
1.2. Skeletal Muscle development: 
Skeletal muscles are of mesodermal origin and are derived from somites during 
embryonic development. These mesodermal cells migrate and differentiate 
forming myoblasts that exists either as a single myoblast cell with mitotic potential 
or they proliferate and fuse to form multinucleated myotubes (Jones et al., 2004). 
The majority of skeletal muscle fibres are formed in two phases; 1) Primary 
(embryonic) myogenesis when myoblasts proliferate and fuse to form primary 
myotubes, followed by (2) secondary (fetal) myogenesis when myoblasts fuse 
along the surface of the primary myotubes, giving rise to a population of smaller 
and more numerous secondary myotubes (Matsakas et al., 2010). 5-10% of 
myoblast cells remain without fusion, undifferentiated, known as muscle stem 
cells (satellite cells) in the mature muscle. They lie between the plasma 
membrane and the basement membrane of muscle fibres. Each satellite cell is 
composed of a large nucleus with a thin layer of cytoplasm and they activated 
during damage and diseases to compensate the damaged fibres.  
A group of transcription factors regulate the transition from myoblast to myotubes. 
Of these, four members of the myogenic regulatory factors (MRFs) family are the 
master regulators of myogenesis; MRF4, myf5, myoD and myogenin (Endo, 
2015). Muscle fibres present in skeletal muscle are multinucleated, long 
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cylindrical cells which are arranged to form bundles. Using electron microscopy, 
50-60 myonuclei per millimetre of fibre length were found in slow and fast 
muscles in the mouse (Bruusgaard et al., 2003). Contractile proteins within the 
muscle fibre allow for powerful contractions by the muscle and also give the 
muscle its striated appearance. The contraction of skeletal muscle is voluntary 
and is controlled by somatic motor innervations. In human body, there are around 
600 individual skeletal muscles, representing around 40-50% of body mass, differ 
significantly in their size, shape and arrangement of myofibril. As a result of these 
variations, they exhibit different functions (Martini, 2007, MacIntosh et al., 2006). 
One of the interesting feature of the skeletal muscle, they are highly adaptable 
tissues, responding to different environmental and physiological stimuli, such as 
mechanical loading, unloading, inactivity, disuse and nutrient availability (Pette 
and Staron, 2000). Skeletal muscles are capable of producing various motions in 
different organs, such as gross movement in large muscles like quadriceps 
muscle as well as the extraocular muscle of the eye, which has a fine contract 
motion. Based on these characteristics of skeletal muscles, they have multiple 
important functions: 1) Support soft tissues such as abdominal wall and floor of 
pelvic cavity, 2) Maintain posture and body position, 3) Maintain body 
temperature through heat production, 4) Produce skeletal muscle movement, as 
the contractions of skeletal muscle moves the bones of the skeleton by pulling 
the tendons (Martini, 2007) and 5) Store glycogen (Jensen et al., 2011).  
1.3. Skeletal muscle structure: 
Skeletal muscles are comprised a number of different tissues such as blood 
vessels, nerve fibres and connective tissues. Each muscle is surrounded by a 
dense layer of connective tissue called the epimysium acts to give each muscle 
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its shape by surrounding entire muscle and separates the muscle from the 
surrounding environment. Muscle fibres within the muscle are held in bundles 
called (fascicles) by another connective tissue called perimysium, where blood 
vessels and nerves pass through. Individual muscle myofibre within each fascicle 
are surrounded by a third connective tissue layer called the endomysium. The 
three different connective tissues are continuous and come together at both ends 
of the muscle where they form tendons. The tendons are responsible to attach 
muscle fibres to bone. Individual striated muscle fibres are long multi nucleated, 
surrounded by a cell membrane called ‘’sarcolemma’’ and the cytoplasm of a 
myofibre is referred to as ‘’a sarcoplasm’’. Satellite cells are undifferentiated 
mononuclear myogenic cells, lying between endomysium and the sarcolemma 
and represent a reserve of precursor cells to facilitate growth and regeneration 
(figure 1.2). The sarcolemma has a narrow tubules (T-tubule) that through 
invaginations penetrates throughout the myofibres. T-Tubule is essential for 
excitation-contraction coupling by conducting impulses from sarcolemma into the 
sarcoplasmic reticulum (SR). Each Myofibril is surrounded by the SR which is 
specialized endoplasmic reticulum and represents the main calcium (Ca+2) 
reservoir that mediates muscle contraction and relaxation through ionic Ca+2 
handling. The sarcoplasmic reticulum in contact with the T-tubule forms the 
terminal cisternae (Martini, 2007, Lieber, 2009, MacIntosh et al., 2006).  
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Figure 1.1. Skeletal muscle structure       
The diagram illustrates smaller components of skeletal muscle. The muscle consists of 
fascicles, bundles of muscle fibres surrounded by the epimysium. The fascicles bundles 
are separated by the perimysium connective tissue. Individual muscle fibres are 
surrounded by the endomysium. Extension of epimysium forms tough cord of connective 
tissue, the tendons that anchor muscles to bones. 
https://www.researchgate.net/publication/313845971_Modeling_of_the_sEMGForce_r
elationship_by_data_analysis_of_high_resolution_sensor_network/figures?lo=1. (From 
Pearson Education Company 
 
Skeletal muscle is often referred to as striated muscle as the myofibres appear 
striped or ‘striated’ when they viewed longitudinally due to the arrangement of 
proteins. Muscle fibres range from few millimetres to 10 cm in length and from 5-
100 µm in diameter. Each myofibre consists of protein filaments called myofibrils, 
with a diameter of about one µm. The myofibrils are comprised of contractile 
elements called sarcomere which is the basic unit for muscular contraction 
(Aidley and Ashley, 1998, Saladin and Miller, 1998).   
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A sarcomere of 2 μm in length contains myosin, actin, and other proteins that 
regulate interactions and proteins which stabilize the positions of the filaments. 
Each sarcomere has dark bands (A) and light bands (I). The A band contains 
three subdivisions; M-line which contains proteins, functioning in connecting the 
central portion of each thick filament to its neighbours, therefore help in stabilizing 
the position of the myosin. H-zone contains only thin filaments and finally zone 
of overlap, which is the area where thin and thick filaments are surrounded by 
each other. (I) band contains thin filaments only and extend from A band of one 
sarcomere to the A band of the next sarcomere. Z-line marks the boundaries 
between adjacent sarcomeres and contains actinin proteins, which connect thin 
filaments of adjacent sarcomeres. Titin proteins extend from the tips of myosin to 
the site at the Z-line. Titin’s function in keeping actin and myosin in a proper 
alignments and also preventing extreme stretching which may disrupt the 
contractive properties of muscle (Martini, 2007, MacIntosh et al., 2006) (figure 
1.3).   
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 Figure 1.2. Structure of sarcomere 
 (http://www.easynotecards.com/print_list/51510?fs=1&dis=1&pi=on)  
 (Benjamin Cummings Company)     
Each myosin molecule composed of two-rod like tail woven around each other 
and ends into two globular heads. The head links thin and thick filaments together 
forming cross bridges. The heads contain actin binding site and ATPase enzyme 
that hydrolyse ATP to produce energy for contraction. The actin molecule formed 
by two rows of globular-actin (G-actin) molecules. Actin contains some regulatory 
proteins such as troponin, tropomyosin and nebulin. Troponin composed of three 
polypeptides; Tn-I which acts as myosin binding inhibitory, Tn-T which maintains 
binding of actin and myosin and Tn-c which binds to calcium ion. Tropomyosin 
binds to actin filaments and play roles in the activation process that leads to 
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myofilaments sliding and generation of force, whereas nebulin holds actin strands 
together (Martini, 2007). 
1.4. Skeletal muscle physiology: 
1.4.1. Excitation-contraction coupling: 
Muscle fibres respond with a rapid depolarization to an excitable signal from their 
associated alpha motor neuron. The events preceding muscle contraction begin 
with depolarization of motor neuron and subsequent action potential along the 
motor nerve. Action potential is generated when a neuron is activated by a large, 
short-lived increase in the permeability of plasma membrane to sodium ions 
(Na+2). The increase in (Na+2) permeability leads to membrane depolarization. 
However, the steps of excitation-contraction coupling are summarized in the 
following points: (Lamb, 2000) 
1. The arrival of an action potential. When the neuronal signal arrives to the 
presynaptic nerve terminal at the neuromuscular junction, an action potential 
propagates leading to flow of Ca+2 ions from the extracellular fluid, which causes 
the release of acetylcholine (ACh) into the synaptic cleft because of change in 
the permeability of the synaptic terminal membrane with the arrival of action 
potential. 
2. ACh binds at the motor end plate. ACh molecules bind to ACh receptors at the 
motor end plate at the surface of sarcolemma. These binding changes the 
permeability of motor end plate to (Na+2) ions, which influx and accumulate in the 
sarcoplasm until acetylcholinesterase (AchE) enzyme removes ACh from its 
receptors. 
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3. Action potential in the sarcolemma. The arrival of an action potential at the 
synaptic terminal lead to the appearance of the action potential in the 
sarcolemma that becomes depolarized, due to sudden inrush of (Na+2) ions. This 
depolarization in the sarcolemma spreads along a conducting T-tubule, passes 
transversely into the muscle cells and surrounds each myofibril forming a 
membranous network of the sarcoplasmic reticulum and ends at the terminal 
cisternae which releases the Ca+2 at the junction between the (A) and (I) band of 
each sarcomere (figure 1.4). 
From the initial transmission of the action potential across the sarcolemma, the 
events lead to muscle contraction are collectively called excitation-contraction (E-
C) coupling, which is a unique mechanism that gives skeletal muscle its 
contractile properties (Lamb, 2000). 
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In resting state, intracellular Ca+2 concentration is maintained at approximately 
50 nM which corresponds to inactive state of contractile apparatus in which 
tropomyosin protein winds a round actin filament and cover the myosin binding 
site on actin through forming a complex with troponin to prevent actin from 
binding to myosin (Kress et al., 1986).   
Figure 1.3. Steps involved in skeletal muscle excitation, contraction and 
relaxation 
From Martini, 2006.        
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Upon the transient release of SR Ca+2 and subsequent increase in the 
intracellular Ca+2 to 5 mM, the cytosolic Ca+ 2 ions then bind to troponin binding 
site results in conformational changes in the troponin complex, causes the 
tropomyosin to lift from actin and exposing the active site on the actin filament. 
The exposed myosin binding sites are now able to bind to myosin heads, initiating 
the energy-dependent cross-bridge cycling mechanism and inducing muscle 
contraction (Cooke, 1997).   
Cross-bridge cycling is an active process requires the hydrolysis of adenosine 
triphosphate (ATP) by myosin ATPase to adenosine diphosphate (ADP) and 
inorganic phosphate (Pi) which then provides the energy for muscle contractions. 
Myosin ATPase enzyme is stored in the globular myosin head region (Cooke, 
1997). Effective cross bridge formation requires Ca+2 entry into the sarcoplasm 
which then binds to troponin so that myosin binding site on actin is exposed 
(MacLennan et al., 1997). Following contraction, the excitation by the action 
potential terminates as the Ach are removed by AchE in the gap between motor 
neuron and sarcolemma (neuromuscular junction). Then, Ca+2 pumped back into 
SRs through Ca+2 regulatory protein, sarco (endo) plasmic reticulum Ca+2 
ATPase pump (SERCA), returning Ca+2 concentration to normal level and thus 
troponin-tropomyosin complex returns to its normal position and re-cover the 
active site of actin preventing any further cross-bridge and hence causing 
muscular relaxation (Scott et al., 2001).  
In fact, the efficient handling of Ca+2 requires a regular supply of ATP which are 
both essential molecules for E-C coupling and cross-bridge formation. However, 
ATP depletion and increased Ca+2 concentration have been involved in a variety 
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of clinical conditions. For example; Brody’s disease, which is caused by defective 
SR Ca+2 ATPase activity and increased Ca+2 concentration; central core disease 
and malignant hyperthermia are both caused by accumulation of intracellular 
Ca+2 due to a mutation in ryanodine receptor (RYR) and dystrophin muscular 
dystrophy, which is caused by a mutation of dystrophin that leads to increased 
membrane permeability and increased Ca+2 accumulation (Berchtold et al., 
2000).   
1.5. Skeletal muscle plasticity: 
Skeletal muscle plasticity can be defined as ‘’ the ability of a muscle to alter the 
amount and/or the type of protein (phenotype of isoform) in response to any type 
of stimulus that disrupts its normal homeostasis’’ (Booth and Baldwin, 2010). This 
is demonstrated more in response to endurance or resistance training, lack of 
use or disease. Such stimuli results in significant adaptations to induce muscle 
hypertrophy, muscle fibre type transitions and mitochondrial biogenesis 
(Matsakas and Patel, 2009).   
1.5.1. Plasticity of skeletal muscle mass: 
1.5.1.1. Skeletal muscle wasting: 
Loss of muscle mass and strength occurs in many clinical conditions and chronic 
diseases such as muscle disuse, aging, cachexia and muscular dystrophies. 
They are serious due to their direct effects on loss of individual independence 
and increased risk of death.  
Muscle wasting associated with cachexia can be developed in a variety of acute 
and chronic conditions, these include infectious diseases, such as HIV/AIDS, 
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malaria and tuberculosis, as well as many chronic conditions like cancer, chronic 
heart failure (CHF), chronic kidney disease (CKD), cystic fibrosis, stroke and 
neurodegenerative disease (von Haehling et al., 2009, Onwuamaegbu et al., 
2004, Mak et al., 2011). Cachexia is characterized by a loss of muscle, fat mass 
and a loss of body weight which is associated with a significant increase in 
mortality risk in patients with heart failure. Another condition is sarcopenia, which 
is age-related loss of muscle mass, associated with a reduction in lean body 
mass with an increase in fat mass. Sarcopenia is also accompanying by 
mitochondrial dysfunction, inflammation, leading to a decrease in muscle 
strength, metabolic rate and oxidative capacity (Sakuma and Yamaguchi, 2012). 
Aetiology of sarcopenia includes decreased physical activity, inflammation, 
nutritional deficiencies, metabolic homeostasis, oxidative stress and hormonal 
changes. Decreased physical activity or bedrest lead to a reduction in muscle 
mass with an increase in fat mass (atrophy accompanying with muscle disuse), 
(reviewed in (Evans, 2010)).  
Simultaneously, the term of muscle atrophy is used when a patient is subjected 
to extended bed rest and inflammatory myopathies. Generally, muscle is 
genotypically normal in all of these conditions except dystrophies in which a 
genetic mutation causes loss of muscle mass. With age, disuse and disease, the 
muscle fibres decrease in number and/or size, associated with a loss of muscle 
function. There are distinct differences in the biochemical process and wasting 
outcomes between these conditions. For example; in sarcopenia, there is a 
reduction in fibre size and number, with a transition towards fibre type I. There is 
a firm evidence that with aging, type II fibres are more vulnerable to atrophy than 
type I fibres (Brooks and Faulkner, 1994), therefore, it is a protective mechanism 
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against further muscle loss. In contrast, in atrophy resulted from disuse, although, 
the fibre number is not affected with a decrease in fibre size, it is a companying 
with a fibre type shift towards type II. Another example of difference between 
these conditions showed in muscle wasting of cachexia, which affected type II 
fibres, whereas heart failure results in a degradation of type I or type IIA fibres 
(Romanick et al., 2013). Although different aetiology causes cancer cachexia and 
MD; cancer associated muscle degenerative disease vs genetic, respectively. 
They showed similar features, for example; dysfunction of dystrophin-
glycoprotein complex, reduced dystrophin and a compensatory upregulation of 
utrophin (Acharyya et al., 2005), activation of systemic and muscle inflammatory 
pathways (Li et al., 2008) and dysfunction of regeneration potential as shown in 
the upregulation of satellite cells markers (Pax7) (He et al., 2013).These 
similarities highlight the importance of applying same therapeutic approach to 
more than one condition associated with muscle loss and weakness. In this 
thesis, the focus will be on duchenne muscular dystrophy. 
1.5.1.2. Plasticity of skeletal muscle mass: 
Under selected physiological and environmental stimuli, skeletal muscle cell 
modifies its size. One of these stimuli is sarcopenia, which is an aging-related 
decline in skeletal muscle mass that can be opposed by resistance type of 
exercise to augment muscle mass and strength. Previous studies in older adults 
have shown that the muscle adapt to resistance exercise by hypertrophy of type 
II muscle fibre (Verdijk et al., 2009). Muscular hypertrophy is an increase in 
muscle mass and cross sectional area (Russell et al., 2000). 
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Skeletal muscle growth is controlled by different factors such as growth 
hormones. Myostatin and IGF-1 are growth hormones with opposing roles on 
regulating skeletal muscle growth and size, with myostatin inhibiting regulator of 
muscle mass and IGF-1 stimulating muscle growth (Garikipati and Rodgers, 
2012).  
Myostatin is a member of transforming growth factor (TGF-β), essential for proper 
regulation of skeletal muscle mass by negatively regulating skeletal muscle 
growth (McPherron et al., 1997). Mice carrying a targeted deletion of myostatin 
have a dramatic increase in muscle mass, due to generalized hyperplasia 
(increase in number of fibre) and to lesser extent hypertrophy (increase in the 
size of muscle fibre). Myostatin mutation has shown massive increase in skeletal 
muscle tissue in sheep (Clop et al., 2006) and dogs (Mosher et al., 2007). In 
diseased states, inhibition of myostatin has become an attractive therapeutic 
strategy to enhance muscle growth. For example; blocking myostatin via 
systemic administration of monoclonal antibodies in adult mice enhance muscle 
growth by 30%, suggesting a therapeutic effect to induce muscle mass and whole 
body metabolism in aged muscle (LeBrasseur et al., 2009, Zhang et al., 2011). 
Despite the increase in muscle mass in the absence of myostatin, there is a 
reduction in specific force coupled with a decrease in mitochondrial DNA and 
mitochondrial number, suggesting a potential negative effect on oxidative 
characteristics, capillary density of skeletal muscle and fatigue extremely rapidly 
(Amthor et al., 2007). In aged muscle, inhibiting myostatin resulted in conflicting 
results in terms to muscle mass such as no change in mice at the protein level 
(Carlson et al., 2008), a decrease in rats at the mRNA level (Haddad and Adams, 
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2006) and an increase in humans at the mRNA and protein levels (Leger et al., 
2008).  
IGF-1 is a circulating polypeptide hormone secreted essentially in liver and 
regulated by growth hormone (GH). In skeletal muscles, IGF-I plays a major role 
in growth, differentiation and regulating homeostasis. As shown by Sakowski et 
al., mice muscles of amyotrophic lateral sclerosis (ALS) model have large fibres 
and become stronger following over-expression of IGF-I using viral delivery. ALS 
muscle fibres are characterized with a decrease in the muscle mass (Sakowski 
et al., 2009). On the opposite side, transgenic mice with IGF-IR deficiency, a 
receptor that regulate IGF-1 activity, die after short period of birth due to muscle 
hypoplasia which in turn disable lung inflation (Powell-Braxton et al., 1993). In 
addition, dozens of studies have been focusing on studying the role of IGF-I in 
muscle hypertrophy and regeneration after damage. For example; over-
expression of IGF-1 using adeno associated virus (AAV) in aged mice showed 
induced skeletal muscle force, hypertrophy and preventing the loss of muscle 
fibre type IIB (Barton-Davis et al., 1998), suggesting a role of IGF-1 to maintain 
the symptoms associated with age. 
1.5.2. Plasticity of skeletal muscle fibre type: 
Skeletal muscle exhibit a unique features due to its composition of a large 
number of different types of muscle fibres that contribute to different functions. 
These muscle fibre types differ in their metabolic, molecular, structural and 
contractile properties. The progress of fibre type classifications has imply 
different technologies. Using myosin ATPase and mitochondrial NADH-
tetrazolium reductase activities as marker for the oxidative potential, the muscle 
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fibres can be classified into slow-twitch and fast-twitch fibres with ATP reaction, 
and the fast-twitch subdivided into fast oxidative glycolytic and fast glycolytic 
fibres by NADH-TR activities (Barany, 1967, Armstrong and Phelps, 1984). In the 
beginning, a combination of different pH with ATPase activity revealed four types 
of fibres; I, IIA, IIX, IIB. Then, the development of MHC antibodies enabled the 
detection of four types of myosin isoforms (Brooke and Kaiser, 1970). To date, 
the most accepted  method to distinguish between fibre types is based on specific 
myosin profile (Pette and Staron, 2001). For example; the contractile properties 
depend on the composition of myosin heavy chain isoform (MHC). MHC encoded 
by a multigene family, which is the major component of the contractile apparatus 
combining with actin to form the actomyosin complex, responsible for the elastic 
and contractile properties of muscle (Kammoun et al., 2014). Collectively, MHC 
are subdivided based on the expression of (pure) MHC isoform or (hybrid) which 
is more than one MHCs isoforms. In limb muscles of small mammals, the major 
isoform in slow twitch muscles is the slow MHC-I, whereas the abundant isoforms 
are IIA, IIB and IIX. Moreover, skeletal muscles include different fibre types which 
co-express hybrid isoforms for example; I and IIA, IIA and IIX, IIX and IIB. 
Distribution of myosin isoforms in muscle varies between animals and depends 
on the function of that muscle and the diversity of muscle fibres is reflected in 
part by motor units where motor unit is made up of a motor neuron and the 
skeletal muscle fibres that neuron innervates (Greising et al., 2012).  
Innervation ratio represent the number of muscle fibre innervated by a single 
motor neuron, which differ between muscle and helps giving a gradual response. 
For example; a muscle required for fine control, its motor units may have an 
innervation ratio as (10:1), which makes it more capable of finer and gradual 
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change in contraction, such as, eyes and fingers. Compared with a muscle 
required for course contraction such as gastrocnemius, its motor unit will have a 
high innervation ratio that has been estimated to be (2000:1).    
Motor units are classified into smaller (slow) motor units innervate slow-twitch 
muscle fibres or larger motor units that innervate fast-twitch muscle fibres 
(Greising et al., 2012). The motor units are the driving force behind fibre type. 
The slow-twitch fibres are recruited when the input is slow and they generates 
less force than the fast twitch but they are able to maintain the force for longer 
time. However, when the largest motor neurons are activated, the fast-twitch are 
recruited and produce large amount of force, but fatigue rapidly (Floeter, 2010).  
However, the metabolic requirement of each muscle fibre differs markedly, 
aerobic (type I), termed as slow-twitch fibres, exhibit slow contraction due to the 
ATPase activity associated with the type I myosin, small cross sectional area, 
large mitochondrial number, have more capillaries surrounding each fibre, exhibit 
oxidative metabolism, and high resistance to fatigue. In contrast, anaerobic (type 
II), fast twitch fibres, exhibit quick contractions and fatigue rapidly, have large 
cross sectional area, few mitochondria and are considered glycolytic (Bassel-
Duby and Olson, 2006).  
Additionally, fibre types differ in their expression of other proteins such as; 
tropomyosin, myosin light chain, troponin subunit and (SERCA). Quantitative 
differences do not lead to precise determination of fibre type but lead to overlap 
between the different myosin isoforms based on their enzyme activity levels. 
However, based on metabolic enzyme classification, fibre types are divided into 
three main types; fast twitch-glycolytic (FG), fast-twitch-oxidative-glycolytic 
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(FGO) and slow-twitch oxidative (SO). Therefore, MHC-IIB fibres equal to FG and 
MHC-IIA equal to FGO. Type MHC-I represent the highly correlated fibres 
between the two classification types where it equal to SO (Pette and Staron, 
1997) (Table 1.1).  
Table 1.1. Skeletal muscle fibres and physiological performances 
Modified from (Pette and Staron, 1997) 
The plasticity of skeletal muscle fibres in response to metabolic stress is afforded 
through induction of slow type oxidative phenotype fibres (Timpani et al., 2015). 
It is well established that skeletal muscle myofibres undergo phenotypic transition 
in aging, in response to physical activity and in chronic disease (Schiaffino and 
Reggiani, 2011, Yan et al., 2011). Remodelling phenotypic profiles of skeletal 
muscle fibres is of great interest in terms of chronic disease via transforming 
myofibres into more oxidative, more resistant to damage. The experiment of 
cross innervation study where slow-twitch muscle fibres were innervated with 
nerve fibres that supply fast-twitch muscle caused an increase in contractile 
speed of the muscle and conversely, innervation of fast twitch muscle with nerve 
normally found on slow-twitch muscles resulted in slow contraction, initiated 
studies in understanding the underlying mechanisms of muscle fibre type 
Type I fibres Type IIA fibres Type IIX fibres Type IIB fibres
Contraction time Slow Moderately fast Fast Very fast
Size of motor neuron Small Medium Large Very large
Resistance to fatigue High Fairly High Intermediate Low
Force produced Low Medium High Very High
Mitochondrial density High High Medium Low
Capillary density High Intermediate Low Low
Oxidative capacity High High Intermediate Low
Glycolytic capacity Low High High High
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transition (Buller et al., 1960). Endurance exercise, specifically, is the most 
studied area in inducing fibre type transformation. Researches have 
demonstrated that endurance exercise induces transformation of glycolytic fibres 
into oxidative phenotype within the fast twitch fibre types (IIb to IIx to IIa) in 
rodents and (IIx to IIa to I) in humans (Andersen and Henriksson, 1977, Green et 
al., 1979).   
Subsequently, studies have established that activation of calcineurin, which 
activates nuclear factor of activated T cells (NFAT), results in inducing expression 
of slow twitch muscle genes, through transgenic animal studies as well as studies 
targeted deletion/ activation of calcineurin (Chin et al., 1998, Yan et al., 2011). 
Additionally, Ca+2/calmodulin-dependent protein kinase (CaMK) activation of 
myocyte enhancer factor-2 transcription factors-(MEF2) through de-repression of 
class II histone deacetylase such as HDAC proteins (4, 5, 9), is also involved in 
the transformation of myofibres to those more oxidative (Potthoff et al., 2007). 
Furthermore, AMP-activated protein kinase (AMPK) and peroxisome proliferator 
activated receptor-γ coactivator-1α (PGC-1α) have been linked to muscle 
adaptation in response to metabolism and contractile activity. AMPK has been 
shown as an essential regulator of fibre type transformation in response to 
exercise, whereas PGC-1α maintains slow twitch-type I fibres independent of 
exercise and induces mitochondrial biogenesis (Geng et al., 2010, Rockl et al., 
2007) (figure 1.5).  
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Figure 1.4. Signalling pathways activates skeletal muscle fibre type    
transformation.  
Signalling pathway leading to altered muscle fibre type. These signals include Ca+2, 
NFAT, PGC-1α, AMPK and MEF2. 
 
1.5.3. Plasticity of skeletal muscle oxidative capacity: 
Mitochondria are pivotal for aerobic ATP synthesis and proper cell function. In 
skeletal muscle, mitochondria quantity and quality is required for performance 
and health. Mitochondrial biogenesis is growth and division of pre-existing 
mitochondria in terms of size, number and mass and can be altered in response 
to environmental stress such as exercise, nutrition and oxidative stress (Baker et 
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al., 2007). The regulation of mitochondrial biogenesis and function is controlled 
via different mechanisms including transcriptional regulators that sense 
metabolic and energetic demands associated with physiological states 
(Matsakas and Patel, 2009, Hock and Kralli, 2009).  
1.5.3.1. Cellular energy metabolism and mitochondrial biogenesis: 
DNA-binding transcription factors such as nuclear respiratory factor-1 and 2 
(NRF-1 and NRF-2) have been found to activate the expression of oxidative 
phosphorylation (OxPhos) genes, mitochondrial transporters, mitochondrial 
ribosomal proteins and mitochondrial transcription factor A (TFAM) (Scarpulla, 
2008). In addition, they have been reported as part of energy-sensing pathways 
in mammalian cells, where their expression is induced in response to increased 
Ca+2 flux in skeletal muscles (Ojuka et al., 2003) and to the activation of AMPK 
(Bergeron et al., 2001).  
Peroxisome proliferator activated receptors (PPARα, PPARγ, PPARδ) control the 
expression of uncoupling proteins (UCPs), that play roles in oxidative capacity, 
reactive oxygen species (ROS) production and thermogenesis and enable the 
mitochondrial adaptation to metabolic demands through interaction with other 
regulators of mitochondrial biogenesis such as; NRF-1 and 2, peroxisome 
proliferator activated receptor-γ coactivator-1α (PGC-1α) and PGC-1β (Hock and 
Kralli, 2009). PPARδ is highly abundant in skeletal muscles and heart, and the 
role of PPARδ in skeletal muscle mitochondrial biogenesis has been investigated 
through transgenic mice specifically express PPARδ in muscle and resulted in 
increased expression of oxidative metabolism genes and a shift towards 
oxidative fibres (Wang et al., 2004). Moreover, over-expression of PPARδ 
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promotes mitochondrial biogenesis and expression of UCPs, glucose transporter 
(GLUT4) and PGC-1α, possibly via induction of PGC-1α expression in muscle 
(Tanaka et al., 2003).  
Another important regulator of mitochondrial biogenesis is PGC-1α. The PGC-1α 
proteins are important for the mitochondrial biogenesis because of their abilities 
to bind to NRF-1, NRF-2, PPARs, and estrogen related receptors (ERRs) (Hock 
and Kralli, 2009). Over-expression of PGC-1α in many cells results in induction 
of genes related to mitochondrial biogenesis and enhanced respiration for 
example; TFAM, UCP and ATP synthase (Handschin and Spiegelman, 2006). 
Transgenic over-expression of PGC-1α in skeletal muscles increases 
mitochondrial genes expression, mitochondrial content and promotes a shift 
towards slow oxidative fibres (Lin et al., 2002). Conversely, inactivation of PGC-
1α using null mice of PGC-1α results in a decrease in the mitochondrial 
enzymatic activities, reduces exercise performance and decreases expression of 
mitochondrial genes (Lin et al., 2004). In response to exercise, PGC-1α 
expression has increased in null mice and induced the expression of NRF-1 and 
NRF-2 (Baar et al., 2002).  
Energetic demands vary between cell types as well as in different physiological 
status. For example, in response to a single bout of exercise, the level of PGC-
1α, NRF-1, PPARδ, estrogen related receptor α (ERRα) and mitochondrial target 
genes were increased (Baar et al., 2002). In response to a nutrient restriction 
such as fasting and caloric restriction, SIRT1 is induced in muscle and promotes 
the expression of PGC-1α, ERRα, TFAM and genes involved in OxPhos, fatty 
acid oxidation and tri carboxylic acid cycle (TCA) (Gerhart-Hines et al., 2007). 
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Moreover, AMPK senses energetic deficiencies in skeletal muscle as in fasting 
via adiponectin, where the activated AMPK turns off ATP-consuming process 
such as synthesis of lipids, carbohydrates and proteins and turns on ATP 
synthesis pathways including mitochondrial biogenesis (de Lange et al., 2006).  
Feeding rats with a pharmacological activator of AMPK (β-guanadinopropionic 
acid) β-GPA for 8 weeks leads to activation of AMPK in skeletal muscle. 
Therefore, activation of AMPK induced expression of PGC-1α, NRF-1, 
cytochrome c protein and mitochondrial content and consequently mitochondrial 
biogenesis through PGC-1α and NRF-1 by sensing energy status of the muscle 
cell (Bergeron et al., 2001). Also, AMPK has been shown to activate other 
mitochondrial genes independent of PGC-1α such as (Ucp3) which is a 
mitochondrial enzyme and pyruvate dehydrogenase kinase isoenzyme 4 (Pdk4), 
which involves in glucose metabolism (Jäger et al., 2007).  
Calcium-regulated signalling pathways also involve in the control of mitochondrial 
biogenesis. Observations from in vitro studies showed that calcium/calmodulin-
dependent protein kinase IV (CaMKIV) influences gene expression in oxidative 
fibres (Wu et al., 2000). Transgenic over-expression of CaMKIV in skeletal 
muscle showed an increase in mitochondrial DNA (mtDNA) as well as increased 
mitochondrial number. It is accompanied by increased mRNA level of cytochrome 
b and carnitine palmitoyltransferase (CPT) (Wu et al., 2002). On the other hand, 
CaMKIV null mice showed similar protein level of PGC-1α and COX IV compared 
to wild type, suggesting that CaMKIV may not be required for mitochondrial 
biogenesis (Akimoto et al., 2004). Similarly, transgenic mice specifically 
expresses p38 mitogen activated protein kinase (p38 MAPK) in skeletal muscle 
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showed increased protein expression of cytochrome oxidase IV and PGC-1α. 
Moreover, exercised mice showed induced expression of p38 MAPK and hence 
increased PGC-1α activation, this suggest that the latter is working downstream 
of AMPK (Akimoto et al., 2005).  
1.5.4. Plasticity of skeletal muscle angiogenesis: 
Vasculature of skeletal muscles can remodel itself to enhance oxygen delivery to 
the active muscles. Remodelling occurs when the excited vasculature is 
insufficient to meet the muscle activity or metabolic demand of the tissue. 
Vascular remodelling can occur in two types; arteriogenesis and angiogenesis. 
The first refers to an increase in the diameter of exciting arterial vessels, whereas 
the latter is the increase in the number of capillaries necessary for blood/muscle 
oxygen exchange (Lloyd et al., 2005).   
Angiogenesis is the formation of new capillaries from existing capillaries. It has 
been shown that endurance exercise induces angiogenesis through two main 
mechanisms; intussusception and sprouting angiogenesis. The first mechanism 
defines as the process by which a single capillary splits into two capillaries within 
the lumen and the second mechanism refers to the branching out of endothelial 
cells from an existing capillary. The capillary network is responsible for the 
diffusive exchange of oxygen, carbon dioxide and nutrients between the vascular 
space and the intracellular space of the muscle fibres. It has been reported that 
endurance exercise training results in increased capillary density (angiogenesis). 
In response to exercise, there is an increase in the oxygen and nutrient supply to 
the muscle by expanding the capillary network (Prior et al., 2004). Additionally, 
vascular endothelial growth factor (VEGF) has been found as the most important 
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mitogen of endothelial cells to induce angiogenesis. Muscle specific deletion of 
VEGF showed a reduction in the endurance exercise capacity and capillary 
density (Olfert et al., 2009). The literatures has supported a correlation between 
oxidative capacity of mitochondria and the capillary density in different skeletal 
muscles (Maxwell et al., 1980).  
Hypoxia has been shown as a stimulus of angiogenesis in which a transcription 
factor, hypoxia inducible factor-1 (HIF-1α) lead to an increase in the activity of 
VEGF promoter in cell culture (Forsythe et al., 1996). Signalling cascade that 
emerge to regulate angiogenesis in skeletal muscle involves (PGC-1α) under the 
condition of hypoxia in HIF-1α-independent manner through co-activation of 
ERRα (Arany et al., 2008). Further, muscle specific deletion of PGC-1α displayed 
a reduced angiogenesis and VEGF expression in response to endurance 
exercise (Geng et al., 2010). Mechanistically, the role of PGC-1α on 
angiogenesis and exercise induced-VEGF is under the control of the upstream 
p38γ AMPK, mediated through ERRα (Chinsomboon et al., 2009).  
Therefore, the understanding of these muscle plasticity processes are important 
in the condition where oxidative metabolic and vascular density is compromised, 
such as in Duchenne muscular dystrophy.  
1.6. Duchenne muscular dystrophy: 
Muscular dystrophy is a group of more than 30 hereditary disorders which results 
in progressive loss of skeletal muscle fibres, causes muscle weakness and 
respiratory failure (Emery, 2002). Duchenne muscular dystrophy (DMD) is 
caused by out of frame mutation with complete loss of dystrophin protein (Kunkel, 
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2005). DMD is an X-linked, recessive neuromuscular disorder with an incidence 
of 1:3500-5000 new born males and it is the most common type of muscular 
dystrophies in childhood (Mah et al., 2016). DMD is initially characterized by a 
delay in motor function, calf hypertrophy and a marked elevated serum levels of 
creatine kinase (CK). The progressive muscle weakness results in a loss of 
ambulation between 7-12 years leading to a reduced life expectancy due to 
respiratory and/or cardiac failure (Allen et al., 2016).  
Other allelic conditions exists; Becker muscular dystrophy (BMD) is a milder form 
caused by in frame mutation lead to expression of partially (truncated) but 
functional dystrophin protein, whereas X-linked dilated cardiomyopathy is a rare 
disorder related to dystrophinopathy and caused by mutation in the dystrophin 
gene, presenting with a cardiac pathology only (Nakamura, 2015).   
Dystrophin protein is expressed in muscle and connects the γ-actin of the 
subsarcolemmal cytoskeleton system to proteins in the surface membrane 
forming dystrophin protein complex (DPC). Function of DPC can be divided into 
two main categories; mechanical and signalling roles. Mechanical role in which 
DPC protects the sarcolemma from damage following repeated cycles of 
contractions and acts as a crucial link between extracellular matrix and 
intracellular actin cytoskeleton. Dystrophin binds to actin and β-dystroglycan, 
which is connected to laminin via α-dystroglycan. The second signalling role of 
DPC initiated with the fact that signalling molecules related to muscle function 
such as nitric oxide synthase (NOS) is in contact with DPC. Proteins that play 
roles in the signalling function of DPC are sarcoglycan, α-dystrobrevins, 
syntrophins, sarcospan, biglycan, integrin and neuronal nitric oxide synthase 
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(nNOS). Further, DPC is linked to contractile elements via intermediate filaments; 
desmin, syncoilin and desmuslin. In addition, DPC has been shown to link to Z-
disc via filamin-C protein through interaction with δ and γ sarcoglycan (Allen et 
al., 2016) (figure 1.6). 
 
Figure 1.5. Dystrophin glycoprotein complex 
Dystrophin-glycoprotein complex composed of dystroglycan α and β subcomplex which 
connect the basal lamina proteins; agrin, laminin and perlecan to the sarcolemma 
cytoskeleton F-actin. The sarcolemma proteins composed of dystrophin, syntrophin α, 
β, and dystrobrevin (DTNA). In addition, nNOSµ is linked to the complex by interacting 
to both the dystrophin and syntrophin. Sarcoglycan-sarcospan sub-complex stabilizes 
the DGC to the sarcolemma and comprises of α, β, γ and δ sarcoglycan and sarcospan 
(SSPN) (Allen et al., 2016). 
1.7. Changes in the absence of dystrophin: 
Dystrophin has a major role in signalling pathways for example; activation of nitric 
oxide (NO) production, regulation of Ca+2 and production of (ROS) as well as 
transmission of force laterally across the muscle and helps in maintaining the 
association between intracellular cytoskeleton and extracellular matrix. Loss of 
dystrophin leads to complete loss of DPC and disruption of costameres that 
makes muscle fibre more susceptible to contraction-induced damage and 
increases loss of calcium homeostasis, which in turn causes on-going 
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degeneration and regeneration of muscle fibres and eventually necrosis. At early 
stage of the disease, the regenerative process could compensate the 
degenerated muscle fibres and fibrotic cells, with time, however, the capacity of 
this process starts to dissipate and therefore the adipose and connective tissue 
replace the muscle fibres (Allen and Whitehead, 2011). Multiple factors contribute 
to muscle damage in DMD; loss of Ca+2 homeostasis, increased level of ROS, 
inflammation and necrosis (Shin et al., 2013).These factors in combination 
impact on the regenerative capacity of the muscle by compromising satellite cells 
that become exhausted by the progression of the dystrophy with time (Abou-
Khalil et al., 2010).  
1.7.1. Oxidative stress: 
It has been established that a disruption of redox signalling is a characteristic of 
dystrophic muscles where the increased susceptibility of dystrophic muscles to 
oxidative stress is likely occur as a combination between a reduction of the 
endogenous antioxidant and increased ROS-activated pathways (Shkryl et al., 
2009, Whitehead et al., 2010).  
Oxidative stress is increased in dystrophic muscle as shown by increased level 
of lipid peroxidation, glutathione status and superoxide (Whitehead et al., 2008, 
Burdi et al., 2009, Dudley et al., 2006). In DMD, oxidative stress leads to damage 
of muscle function, atrophy, reduced regenerative capacity and eventually 
muscle weakness (Barbieri and Sestili, 2012) 
The exact impact of oxidative stress on dystrophic muscle is uncertain. Some 
researchers suggested the elevation of ROS is the primary occurrence in 
dystrophic muscle, due to deregulation of NO (Thomas et al., 1998, Wehling et 
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al., 2001). Others have suggested it is occurring following excessive Ca+2 influx 
and inflammation (Yeung et al., 2005). However, abnormal uptake of calcium by 
mitochondria in mdx mice induce greater production of ROS. Increased level of 
protein oxidation (measured by carbonyl group) and lipid peroxidation (measured 
by isoprostanes) has been detected in DMD and mdx samples as an evidence of 
increased ROS (Haycock et al., 1996, Grosso et al., 2008, Hauser et al., 1995, 
Messina et al., 2006). Mechanical distension of the sarcolemma induced by 
contraction causes the formation of superoxide radicals by the cation of 
nicotinamide adenine dinucleotide phosphate oxidases (NADPH-oxidase), NOX, 
which cannot be processed by NO due to low bioavailability in DMD muscles. 
NOX is a major source of ROS during muscle contraction with presence of 
different isoforms (1-5) expressed in a wide range of tissues (Bedard and Krause, 
2007). (NOX2) isoform is located in skeletal muscle at the sarcolemma and T-
tubules of muscle fibres and more importantly is a dystrophin associated protein 
(Khairallah et al., 2012). Therefore, loss of dystrophin leads to a highly 
disorganized microtubule network and induces activation of NOX2, which is a 
major source of ROS in mdx during exercise (Khairallah et al., 2012). Elevated 
levels of ROS by NOX2 induction may be involved in the opening of stretch 
activated channels (SACs) and Ca+2 entry into myofibres. Consequently, 
increased Ca+2 leads to elevated mitochondrial Ca+2 levels, an increase in 
mitochondrial ROS production and dysfunctional mitochondrial, which perturb 
muscle function  (Whitehead et al., 2010).  
NOX2 is up-regulated at early stage of the disease during the oxidative stress 
period when the inflammatory cells such as macrophages and neutrophils utilize 
NOX2 to produces superoxides, which increase ROS production (Lawler, 2011). 
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However, further ROS production contribute to disruption of cell signalling, in 
particular, through activation of NF-κB that increases activation of pro-
inflammation cytokines such as tumour necrosis factor α (TNFα), which are found 
to be elevated in mdx mice (Altamirano et al., 2012, Acharyya et al., 2007, Kumar 
and Boriek, 2003).  
Increased ROS production and down regulation of antioxidants such as 
glutathione (Renjini et al., 2012) and NRF-2 (Petrillo et al., 2017) in mdx mice, 
make regulation of ROS activity and stimulation of antioxidants response 
pathway important targets for the modulation of dystrophic pathology. Initial 
therapies to maintain Ca+2 homeostasis included the use of Ca+2 blockers such 
as diltiazem, however this did not demonstrate any benefits in clinical trials (Shin 
et al., 2013). On the other hand, antioxidants treatments, for example; Pyrollidine 
dithiocarbamate (PDTC) has been used through minimizing the effect of NF-κB 
(Carlson et al., 2005). 
1.7.2. Calcium influx: 
Ca+2 is essential to the function, maintenance of skeletal muscle and 
physiological transduction pathway of excitation-contraction coupling, which 
effectively regulates skeletal muscle contraction (Berchtold et al., 2000, Goll et 
al., 2003) and regulation of mitochondrial function (Das and Harris, 1990, 
Brookes and Darley-Usmar, 2004). As a result of significant roles of Ca+2 in all 
cellular events, its concentration is regulated tightly in skeletal muscle fibres 
through SR, mitochondria, a number of ion channels such as calcium channel 
ryanodine receptor 1 (RyR-1) and sarcoplasmic/endoplasmic reticulum calcium-
ATPase 1 (SERCA-1) and intermediate binding proteins that move Ca+2 between 
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the SR and the storage reservoirs (Berchtold et al., 2000). In DMD, the fibres are 
more susceptible to intracellular Ca+2 and damage (Culligan and Ohlendieck, 
2002). It has been accepted in the literatures that Ca+2-dependent muscle 
necrosis is responsible for the severe wasting characteristic in mdx and DMD. 
Ca+2 is thought to flow into myocytes leading to an increase in intracellular Ca+2 
level and subsequent down-regulation of various Ca+2-binding proteins that 
initiate Ca+2 dependent proteolysis such as calpains that alters mitochondrial 
function and apoptosis. However, it is still widely debated on the exact mode of 
Ca+2 entry and primary cause of dystrophic pathology. At the same time it is 
generally accepted that dystrophin provides a degree of protection to the 
sarcolemma against mechanical injury and without it the membrane is disposed 
to tear and subsequent Ca+2 leak (Bodensteiner and Engel, 1978, Whitehead et 
al., 2006).  
As shown in Fong et al., both mdx mice and cultured biopsies of DMD patients 
have greater levels of intracellular Ca+2 compared to control muscle (Fong et al., 
1990). It has been reported that calcium permeability of the sarcolemma is 
affected through; 1) Mechano-sensitive voltage-independent calcium channel 
(MSC), which increases leaking channel activity, resulting in calcium overloading 
and excessive ROS production (Turner et al., 1991). 2) Store-operated calcium 
channel (SOCE), which is activated by SR Ca+2 depletion and calcium leak 
channels due to hypernitrosylation of ryanodine receptor (RyR-1) (Berg et al., 
2002, Davies and Nowak, 2006, Bellinger et al., 2009). 3) SR Ca+2 pump 
(SERCA-1), which functions to return Ca+2 from the sarcoplasm to the SR and 
causes relaxation. Controversial data have been reported in the literatures of 
SERCA-1 in mdx, with decreased function (Kargacin and Kargacin, 1996), 
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increased function (Robin et al., 2012) and unchanged function (Takagi et al., 
1992). However, studies have shown improvement of the dystrophic phenotype 
such as central nuclei, fibrosis and a reduction in creatine kinase level following 
over-expression of SERCA-1 in mdx (Goonasekera et al., 2011). Goll et al., has 
proposed that abnormal Ca+2 overloading causes activation of calcium-
dependent proteases such as calpains which involve in protein degradation, fibre 
necrosis and eventually cell death at a rate cannot be compensated by progenitor 
satellite cells and regeneration (Goll et al., 2003).  
1.7.3. Metabolic system defect: 
Defects in cellular energy system have been reported in skeletal muscles from 
mdx and DMD patients where the capacity of mitochondrial oxidative 
phosphorylation is impaired (Kuznetsov et al., 1998, Even et al., 1994, Timpani 
et al., 2015). Adequate ATP production is required to maintain integrity and 
function of all cells. ATP is generated via the creatine phosphagen system, 
metabolism of glucose through glycolysis and fatty acid oxidation via β-oxidation. 
Products of glucose and fat metabolism, pyruvate and acetyl CoA, are 
transported into tricarboxylicacid (TCA) and electron transport chain (ETC) in the 
mitochondrial and ATP is generated via oxidative phosphorylation (OXPHOS)  
process (Rybalka et al., 2015). As a consequence of ATP-dependent Ca+2 
buffering, satellite cell-mediated muscle repair, dysregulation of redox system 
and autophagy, there is a huge demand for ATP production in dystrophic muscle, 
which is an environment with impaired metabolic system. Reduced glucose 
availability due to loss of NO signalling is another factor that contributes to the 
reduced ATP producing capacity of mitochondria in dystrophic muscle (Rybalka 
et al., 2015). Glucose uptake is maintained by Glut4, which is reduced in 
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dystrophic muscles and therefore affect the ability to bring sufficient glucose into 
the muscle fibres to maintain energy production (Olichon-Berthe et al., 1993, 
Timpani et al., 2015). Glucose transport into the cells occurs through 
translocation of Glut4 from cytoplasm to the sarcolemma/T-tubules, in response 
to contraction. Due to alteration in Glut4 level or localization within the cells, as 
shown in mdx and DMD, it is likely that reduced substrate availability is a 
precursor to energy system de-regulation that impact the overall glucose 
metabolism, contributing to the metabolic stress in dystrophic muscle (Rybalka 
et al., 2015, Schneider et al., 2018). In addition, various metabolic defects have 
also been demonstrated in dystrophic muscle; impairments of  fatty acid 
metabolism (Lin et al., 1972), glycolysis (Di Mauro et al., 1967), TCA, ETC (Chi 
et al.) and purine nucleotide cycle (PNC) (van Bennekom et al., 1984). All of 
these lead to 50% reduction in resting ATP level within dystrophin-deficient 
myofibres, which are incapable to meet the huge demand of ATP (Austin et al., 
1992).  
Reduced ATP in dystrophic muscle has been accompanied by reduced 
regeneration capacity, exacerbated muscle degeneration and promoted muscle 
wasting (Rybalka et al., 2015). Impaired ATP production capacity by 
mitochondria is thought to be linked to deficiency in complex I function whereby 
ATP production rely on NADH-mediated shuttling of H+ into the (ETC) through 
complex I. It was shown the complete inhibition of complex I with rotenone and 
activation of complex II with succinate at the same time results in partial recovery 
of mitochondrial-ATP production (Rybalka et al., 2015) (figure 1.7). 
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  Figure 1.6. Role of ATP in healthy and dystrophic skeletal muscle 
(A)
(B)
 
 
53 
 
A) Eccentric contraction in healthy muscle potentiate Ca+2 influx into the intracellular 
matrix which in turn increased in concentration and then activate protease that rupture 
mitochondria, SR and sarcolemma. Ca+2 uptake into the mitochondrial activates 
OXPHOS and ATP production to support ATP-fuelled Ca+2 pumps thus restoring Ca+2 
homeostasis and mitigate the severity of damage. ATP also fuels satellite cell replication 
and skeletal muscle repair. B) The increased propensity for membrane rupture following 
eccentric contraction causes the same degenerative events. Mitochondrial dysfunction 
coupled with insufficient ATP production lead to failure in ATP-dependent Ca+2 buffering 
to alleviate damage, therefore, degenerative capacity is amplified (Rybalka et al., 2015). 
 
1.7.4. Blood flow dysregulation: 
In healthy muscles, NO acts as a paracrine signal to regulate blood flow through 
diminishing sympathetic (α-adrenergic) vasoconstriction. The mechanism by 
which NO attenuate α-adrenergic possibly involves cyclic guanosine 
monophosphate (cGMP) (Francis et al., 2010). However, the ability of skeletal 
muscles of mdx mice to reduce α-adrenergic vasoconstriction is defective due to 
the miss localization of nNOSμ, leading to muscle ischemia. NO has been 
suggested as antagonism of α-adrenergic vasoconstriction since NO diffuses to 
arterioles and results in vasodilation that increases blood flow (Thomas et al., 
1998). Evidence showed that mdx has impaired vascular density and 
angiogenesis. Immunostaining of arterioles in mdx has revealed a reduction in 
vascular density of heart and gracilis muscles (Loufrani et al., 2004). Matasakas 
et al., have used microfil-perfusion for tibialis anterior (TA) in mdx and showed 
reduced vasculature in mdx compared to wild type (Matsakas et al., 2013). 
Moreover, images of hind limb muscles with Laser Doppler perfusion showed 
compromised blood flow in mdx (Palladino et al., 2013). Therefore, in the context 
of DMD, which is suffered from oxidative stress, this lack of vascularisation, will 
increase the stress, leading to overt pathology. However, it is believed that loss 
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of dystrophin causes translocation of nNOSμ from sarcolemma to accumulate in 
the cytosol (Brenman et al., 1995).  
Skeletal muscles expressed three different types of nitric oxide synthase (NOS); 
NOS1 (nNOS), NOS2 (iNOS), NOS3 (eNOS). Splicing of nNOS results in four 
different isoforms; nNOSα, nNOSβ, nNOSγ and nNOSμ, the latter is the most 
predominant isoform in skeletal muscles. Association of nNOSμ with DPC 
requires α-syntrophin and dystrophin where nNOSμ converts L-arginine to nitric 
oxide (NO), which functions in regulating glucose uptake, vascular perfusion 
during muscle contraction, maintaining mitochondrial function and regulation of 
(RYR) function (Allen et al., 2016). These physiological functions result from the 
ability of NO to stimulate guanylate cyclase, therefore enhances the production 
of cGMP (Francis et al., 2010).  
Understanding the factors involve in the regulation of angiogenesis has been of 
a significant value for the DMD therapy. Vascular endothelial growth factors exist 
in several isoforms; VEGF121, VEGF145, VEGF-165, VEGF-183, VEGF-189 
and VEGF-206 (Tammela et al., 2005a). Specific blockade of VEGF in skeletal 
muscles resulted in reduced capillary density compared to wild type (Olfert et al., 
2009). In normal skeletal muscle, VEGF is expressed in vascular structure but 
not in muscle fibre. Following muscle damage, VEGF expression was detectable 
in regenerating muscle fibre and satellite cells which highlights the pro-myogenic 
effect of VEGF in skeletal muscles in promoting muscle regeneration through 
neovascularisation of necrotic area (Arsic et al., 2004). Over-expression of VEGF 
via adeno associated virus (AAV) gene transfer in mdx mice resulted in 
increasing capillary density, regenerative fibre areas and reducing necrosis in 4 
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weeks treated mdx. In the same study, over-expression of VEGF was shown to 
increase strength of forelimb muscles which highlighted the importance of VEGF 
as a pro-regenerative factor in skeletal muscles (Messina et al., 2007).  
To stimulate nNOS, administering L-arginine (NO precursor) in combination with 
metformin (pharmacological activator of AMPK) into DMD patients resulted in an 
increase in cGMP and mitochondrial proteins in skeletal muscles as a result of 
increasing level of NO (Hafner et al., 2016).  
1.7.5. Inflammation: 
Inflammation process is divided into two main classifications, acute or chronic. 
Acute inflammation is an immediate non-specific response that is considered the 
first line defence against injury by removing the dead and damaged myofibres 
and promote activation of resident satellite cells, which mediate replacement of 
injured muscle. Skeletal muscle of DMD is characterized by chronic inflammation 
(Tidball, 2005). However, the newly formed myofibres contain the defective gene 
and are subjected to further degeneration. As a result, the satellite cells 
population becomes exhausted or unable to mediate repair, resulting in 
continued cycles of regeneration and degeneration followed by a chronic 
inflammatory response due to abnormal presence of inflammatory cells. All of 
these events lead to replacement of muscle tissue by adipose and fibrotic tissue 
(Serrano et al., 2011).   
As described earlier, dystrophin deficient muscles are more susceptible to 
mechanical injury as the plasma membrane is damaged easily during muscle 
contraction that allow extracellular Ca+2 influx and release of endogenous 
ligands. The upregulated Ca+2 in DMD leads to calpains activation, which 
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degrades IκB (inhibitory of NF-κB) and then activates NF-κB inflammatory 
pathway, which stimulates cytokine release such as TNF-α and IL-1β which in 
turn further augment the activity of NF-κB and impair muscle regeneration. In 
inactive condition, NF-κB is retained in the cytoplasm binding to the inhibitory 
protein IκB. The activation of NF-κB is regulated by IκB kinase that stimulates 
translocation of NF-κB to the nucleus, which then regulates transcription of 
cytokine genes (Kumar and Boriek, 2003, Acharyya et al., 2007).  
A number of studies showed a higher expression of genes involved in 
inflammatory responses in DMD muscles such as TNF-α, IL-1β and IL-6. TNF-α 
can further stimulate production of ROS and therefore create positive feedback 
loop where ROS can increase production of NF-κB (Whitehead et al., 2006). 
Hodgetts et al., showed the role of neutrophils in dystrophic myofibres by 
depleting them using antibodies, and results in reducing fibre necrosis and 
inflammatory cells (Hodgetts et al., 2006). Mast cells are infiltrating inflammatory 
cells, which surrounds injured muscle. They can contribute to fibre necrosis by 
releasing histamine and TNF-α and mediate necrosis through producing pro-
inflammatory cytokines (Tidball, 2005).  
A pro-inflammatory cytokine, TNF-α has been reported to induce a shift towards 
more glycolytic myofibres in skeletal muscles, reduce mitochondrial and ATP 
contents, thus compounding dystrophic metabolic stress. The activation of TNF-
α reduces the expression of regulatory genes of skeletal muscle oxidative 
phenotypes for example; PGC-1α, PGC-1β, PPARα and TFAM and the activation 
of NF-κB by TNF-α reduced expression of TFAM, NRF-1 which are regulators of 
mitochondrial biogenesis. In addition, activation of IL-1β induces the expression 
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of NF-κB and hence reduced expression and activity of slow oxidative fibres. 
Therefore, activation of NF-κB signalling results in impairment of cellular 
oxidative phenotype (Remels et al., 2010, Remels et al., 2013). Gene therapy 
using AAV to inhibit NF-κB via the over-expression of dominant-negative forms 
of IKKα and IKKβ showed significant results through reducing necrosis and 
enhancing muscle regeneration in older mdx (Tang et al., 2010).   
1.7.6. Autophagy: 
Autophagy is a critical homeostasis process in clearing defected and damaged 
organelles from the cells and it has been found to be severely impaired in muscle 
biopsy from DMD patient and mdx mice (De Palma et al., 2012). A reduced 
expression of autophagy markers were shown in mdx compared to wild type in 
(TA) and diaphragm muscles. For example, the level of LC3II in mdx mice, which 
is the network form of the microtubule-associated protein-1 light chain 3, was 
found significantly lower than in normal muscles. On the other hand, the level of 
p62 was increased in muscles from mdx mice (De Palma et al., 2012). Activation 
of autophagy improves dystrophinopathy in mdx mice where maximal force 
generating capacity was improved by AICAR (5-aminoimidazole-4- carboxamide-
1-β-d-ribofuranoside) (Pauly et al., 2012).   
1.7.7. Fibrosis: 
Fibrosis is the deposition of extracellular matrix components; collagen and 
fibronectin during repair of the damaged fibres which leads to loss of tissue 
structure, function and replacement of normal tissue with connective tissues in 
response to inflammation and chronic injury which in turn impairs tissue function 
(Goyenvalle et al., 2011). The imbalance of different cell types lead to production 
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of growth factors, angiogenic factors, proteolytic enzymes and fibrogenic 
cytokines that destroy, remodel and replace normal tissue with connective tissue 
elements (Serrano et al., 2011). Accumulation of connective tissue has negative 
impact on therapeutic intervention as the amount of target tissue available for 
therapy is reduced. A superfamily of TGF-β cytokines contribute to pathogenesis 
associated with muscular dystrophy where TGF-β1 signalling disrupts muscle 
membrane by blocking nutrients from reaching to myofibres (Zhou and Lu, 2010) 
through stimulating interleukin 11 (IL-11) (Johnstone et al., 2015). During chronic 
damage in DMD, increased and persistence of different inflammatory-
macrophages cells types could modify the kinetics level of cytokines, resulting in 
altered satellite cells function with progressive fibrosis. Fibro/adipogenic 
progenitor (FAP) cells are thought to persist if the regeneration fail and therefore 
they differentiate into adipocytes and control pro-differentiation signals with great 
tendency to generate adipose cells (Mann et al., 2011).  
1.7.8. Impact on muscle function in the absence of dystrophin: 
In normal myofibres, dystrophin and associated proteins are found in a rib like 
structure called costameres linked to sarcomeres’ Z disc of the myofibrils located 
all along the whole fibre (Pardo et al., 1983). Costameres are located ideally to 
transmit the forces developed by activated fibres throughout a muscle (Brooks 
and Faulkner, 1988). The DPC provides the connection between the sarcomeres, 
laterally through the sarcolemma and basement membrane into the extracellular 
matrix (ECM) (Goldstein and McNally, 2010). In aged and mdx mice, the lateral 
force is severely impaired and correlated to the loss of dystrophin, which 
highlighted the critical role of DPC in lateral force transmission in skeletal 
muscles (Ramaswamy et al., 2011). A number of investigators have proposed 
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the important role of dystrophin in the stability of muscle fibres. For example, the 
skeletal muscle from mdx and humans exhibit high levels of contraction induced 
injury following the protocol of lengthening contraction. Ex-vivo assessment of 
force deficit following eccentric contractions in normal muscles showed a 10% 
reduction compared to mdx muscles which showed a round 70% decrease 
(Petrof et al., 1993a) that reflect the compromised lateral force transfer between 
fibres and the critical role of costameres in the maintenance of sarcomere stability  
(Rybakova et al., 2000, Bloch et al., 2004). This reduction was attributed to loss 
of dystrophin and hence disorganized costameres that enhanced membrane leak 
of cytosolic Ca+2 and consequently increased mitochondrial production of ROS 
and NADPH oxidase which contribute to muscle force loss (Whitehead et al., 
2006). ROS are thought to directly oxidize contractile proteins or sarcolemmal 
lipids and they may activate signalling via NF-κB leading to inflammation and 
altered cytoskeleton (Goldstein and McNally, 2010, Whitehead et al., 2008). In 
total, the exacerbated microenvironment of the DMD muscles with increased 
inflammatory markers, increased oxidative and metabolic stress, the 
replacement of contractile tissue with fibrotic scar tissue make the extracellular 
matrix stiffer, leading to a reduction in the force capacity of the muscle (Lieber 
and Ward, 2013).  
As mentioned before, due to absence of dystrophin, nNOS delocalize from the 
sarcolemma to the cytosol. As a result, the activity of cytosolic nNOS is elevated 
(Lai et al., 2009). Opposing studies shown differential effects of NO on muscle 
force and pathology associated with DMD. For example; several studies revealed 
a beneficial effect of NO releasing agents (arginine) in mdx mice (Voisin et al., 
2005) and DMD patients (Hafner et al., 2016), however, supplementation of 
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arginine has exacerbates fibrosis in mdx mice (Wehling-Henricks et al., 2010), 
whereas convincing data has suggested that NO inhibits muscle force (Kobzik et 
al., 1994). Specifically, NO impair muscle function through nitrosylation of RYR1 
(Bellinger et al., 2009, Bellinger et al., 2008), as it has been proposed that 
nitrosative stess induced by delocalized nNOSµ in mdx mice inhibits muscle 
force. When nNOSµ activated by Ca+2, nNOS generates excessive NO. ROS in 
dystrophic muscle convert NO to reactive nitrogen species (RNS) that lead to 
global dysregulated nitrosylation state. Specifically, s-nitrosylation of RYR 
compromises the contractile proteins that reduces the already compromised 
force (Li et al., 2011). S-nitrosylation of RYR-1 causes depletion of calstabin1 
(FKBP12), resulting in leaky channel (Lamb and Stephenson, 1996). Deletion of 
calstabin1 specifically in skeletal muscles, can cause a loss of depolarization-
induced contraction and impaired excitation-contraction coupling because of 
reduced maximal voltage-gated SR Ca+2 release (Tang et al., 2004) (figure 1.8).  
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Figure 1.7. Pathways involve in loss of muscle function 
 
1.8. Mdx mice as a model of DMD: 
In 1984, Bulfield et al., first described the existence of a mutation in the dystrophin 
gene of C57BL/10 strain, with elevated levels of serum pyruvate kinase and 
creatin kinase, which they proposed as a possible investigatory animal model of 
X-linked human disease of DMD (Bulfield et al., 1984). Analysis of cDNA from 
mdx and wild type muscles revealed single base substitution in exon 23 in the 
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mdx mice. In the mdx, a cytosine is replaced by a thymine at nucleotide position 
3185, resulting in a termination codon (TAA) in place of a glutamine codon (CAA) 
(Sicinski et al., 1989). 
mdx mice have minimal clinical symptoms comparing to human DMD and their 
life span is reduced by 25% where the individual life span reduced by 75% 
(Chamberlain et al., 2007). Severe dystrophic phenotypes such as heart failure 
do not occur until mice are 17 months or older (Quinlan et al., 2004). The mdx 
muscle degeneration appears in waves not a continuum. Skeletal muscles in mdx 
exhibit different phases; in the first 2 weeks they are not distinguishable from 
normal muscles, then between 3-6 weeks of age, the limb muscles become 
hypertrophic, they undergo extensive degeneration/regeneration cycle, indicated 
by newly differentiated fibres with centralized nuclei (as a sign of regeneration) 
and heterogeneity in fibre size. In parallel, the muscles undergo necrosis at this 
early stage which then decreases around 10 weeks of age (McGeachie et al., 
1993).  
Despite sharing the same genetic defect as DMD, mdx mice have a slowly 
progressive pathology which does not lead to loss of muscle mass and spread 
formation of fibrous connective tissue that characterize human disease. The 
diaphragm is the only exception and shows progressive deterioration with 
extensive replacement of muscle fibres with fibrous connective tissue, similar to 
what seen in DMD patients. In addition, mdx mice do not loss their ability to walk 
(Chamberlain et al., 2007). On the other hand, pathology in DMD boys is difficult 
to diagnose during the first years of life, but they show symptoms of pseudo-
hypertrophy followed by onset of muscle wasting around 4 years of age. Pseudo-
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hypertrophy means damage of muscle fibres accompanied by necrosis followed 
by the activation of satellite cells, which play a role in muscle fibre regeneration. 
The poor cycle of regeneration and degeneration, produce large but weak 
muscles. Muscle wastage occurs as the degeneration process overtakes the 
capabilities of satellite cells for muscle regeneration (Morgan and Zammit, 2010). 
DMD boys loss the ambulation around 10 years of age and die as a result of 
respiratory or cardiac failure (McGreevy et al., 2015, Chamberlain et al., 2007). 
The slowly progressive phenotype of mdx mice is explained by four different 
reasons; first, the active process of regeneration due to the ability of satellite cells 
to divide rapidly and allow repair of damaged fibres (McGreevy et al., 2015). 
Second, the increased expression of utrophin, a homolog to dystrophin, which is 
suggested to compensate for the loss of dystrophin in these mice (Tinsley et al., 
1998). Third, the presence of the cytidine monophosphate sialic acid hydroxylase 
gene (CMAH) in mice; this gene is inactivated in humans and appeared to worsen 
the consequence of dystrophin absence in humans (Chandrasekharan et al., 
2010). Fourth, the protective small size of mice where the force produced by 
muscle fibres are reduced and then muscle damage is reduced as well (Bodor 
and Mcdonald, 2013). In mdx mice, the percentage of oxidative type I fibres in 
the oxidative soleus muscles is reduced. Moreover, the percentage of type IIa in 
the fast, more glycolytic EDL muscle and TA muscles is also lower in mdx mice 
(Ljubicic et al., 2014). On the other hand, the percentage of glycolytic type II fibres 
is increased in mdx muscles (Selsby et al., 2012, Whitehead et al., 2015).   
Recently, another mouse model of DMD carrying the mdx 23 mutation on the 
DBA2/J background (DBA/2-mdx) showed more severe skeletal muscle damage, 
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reduced muscle function by 7 weeks, and an earlier onset of cardiac disease at 
28 weeks when compared with mdx mice. Moreover, D2-mdx showed less 
central nuclei and increased calcification in the skeletal muscle, heart and 
diaphragm (Coley et al., 2016). DBA/2-mdx mice are better representing human 
disease because they exhibit increased fat, fibrosis, TGFβ signalling and 
inflammation (Fukada et al., 2010). Note that the DBA/2 mdx mice are a poor 
model for cardiomyopathy (Hakim et al., 2017). However, they were available 
after my study has started.  
Despite the histopathological differences between mdx and DMD patients, the 
mdx mouse has been the cornerstone of pre-clinical research for DMD and 
remains an appropriate mouse model. 
1.9. Gene therapeutic approaches for DMD: 
Gene therapy is the complementation of the defective gene by a functional copy 
using gene transfer. Over the last decade, adeno associated virus (AAV) 
emerged as one of the promising approach for DMD therapy. Several studies 
showed improvements in muscle functions following reinsertion of full or partial 
length of dystrophin, utrophin into mdx mice using viral gene therapy (Konieczny 
et al., 2013, Wang, 2010, Hirst et al., 2005, Phelps et al., 1995, Chakkalakal et 
al., 2003). Different approaches are used to ameliorate dystrophic diseases, for 
example; non-viral, such as plasmid or antisense oligonucleotides (AON) and 
viral, such as adeno virus (AV) and AAV. For gene therapy, a number of 
challenges remain to overcome; addressing advantages and disadvantages of 
gene replacement, immune challenges, determination of optimal mode of gene 
delivery and also the disease advancement (Rodino-Klapac et al., 2007).  
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1.9.1. Non-viral gene therapy 
Non-viral therapy relies on introducing the transgene without using a viral vector. 
Non-viral gene approaches are based on replacement and repair of the defective 
gene. The replacement involves delivery of dystrophin by using plasmid whereas 
the repair approaches are based on injection of antisense oligonucleotides 
(Rando, 2007). Although, there is limited immune response due to absence of 
viral proteins, the transfection efficiency is limited with the transgene size 
(Pichavant et al., 2011).  
1.9.1.1. Plasmid-based therapy 
Plasmid-based approach acquires several advantages; simplicity, cheaper and 
easier to produce in larger a mounts (Mali, 2013). In DMD, the simplest way is 
directed intramuscular injection of full length or micro-dystrophin, however, the 
transfection efficiency obtained was very low with full length dystrophin 
(Pichavant et al., 2011). Transfection efficiency of intramuscular injection of 
plasmid in combination of electroporation leads to 50% gene expression 
(McMahon et al., 2001). The difficulty of the previous method has directed the 
attention to a systemic or regional delivery of plasmid, where intra-arterial 
delivery into mdx mice showed 1-5% expression of dystrophin in limb muscles 
(Zhang et al., 2004). A phase I clinical trial of DMD used the full length dystrophin 
resulted in rare dystrophin positive fibres in six out of nine patients only with no 
adverse immunological effects (Romero et al., 2004). However, the main issue 
remains to be resolved is to the maximize persistence of the plasmid (Fairclough 
et al., 2011). Plasmid-DNA has established methodology for DNA vaccinations 
as economic factors are more favourable compared to recombinant-protein 
vaccines. DNA-based vaccination exhibit features of live-attenuated, synthetic 
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peptides or proteins (Hasson et al., 2015). DNA vaccination involves introduction 
of nuclei acid into host cells where it directs the synthesis of its own polypeptides 
to stimulate immune response. The immune response can be directed to elicit 
either cellular or humoral immune response or both. Further, DNA-based vaccine 
is highly specific and the immunized antigen underwent the same modification as 
natural viral infection. DNA-vaccination differ from DNA-based gene therapy in 
that the former is designed to permit localised, short term expression of the target 
antigen (Hasson et al., 2015).   
1.9.1.2. Antisense oligonucleotides induce exon skipping for dystrophin 
restoration: 
Antisense oligonucleotides (AON) is an RNA based approach, designed on 
synthesizing oligonucleotides with different chemical backbones that hybridize to 
the complementary target. Specifically for DMD, AONs can target a section of the 
pre-messenger mRNA and lead to exclusion of the specific exons from the 
dystrophin mRNA transcripts to circumvent mutations, restore the open reading 
frame and then protein production (Scully et al., 2013). As 60-80% of DMD 
patients have a frame-shifting deletion, exon skipping approach results in 
production of truncated, yet functionally dystrophin protein (Aoki et al., 2012). It 
has been noted that exons 45-55 cover the main mutation in DMD (hot spot 
region), therefore, in theory, any therapy able to skip the entire 45-55 exon region 
can rescue more than 60% of deletion mutation and generate mild symptoms like 
BMD (Aoki et al., 2012). AONs are 20-30 nucleotides in length and 
complementary to regions in mRNA transcripts to skip specific exons either by 
blocking splice enhancer sequence or by modifying secondary mRNA structure 
folding. Examples of differing AONs chemistries include; 2’O-methyl-
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phosphorothiate-AONs (2OMePS), phosphorodiamidate morpholino oligomer 
(PMO) (Scully et al., 2013, Fairclough et al., 2011). Both drugs target dystrophin 
exon 51 and both elicited the expected skipping of exon 51 (Hoffman and 
McNally, 2014). Preclinical studies in mdx mice showed that intravenous and 
intramuscular injections of 2MePS have successfully induced dystrophin 
expression (Mann et al., 2001, Lu et al., 2005). Surprisingly, in 2013, a large 
phase III study of (PRO51/Drisapersen) running by (GSK and Prosensa 
therapeutic; Netherlands) based on 2OMePS failed to show any improvements 
in the primary outcome measure of 6 minutes walking test at primary endpoint, 
in the presence of detectable dystrophin (Goemans et al., 2011, Goemans et al., 
2018). Interestingly, most preclinical studies have reported higher efficiency of 
exon skipping with the PMO chemistry than with 2OMePS chemistry (Wu et al., 
2010, Lu et al., 2005, Wu et al., 2011). 3 dogs were tested with the same 
approach and showed enhancement in the protein levels in all skeletal muscles 
up to 20% with no toxicities (Hoffman et al., 2011). A phase I/II clinical trials of 
AVI-4658/Eteplirsen, initiated by (Sarepta, Bothwell, WA, USA) using (PMO) 
showed no adverse effects with variable restoration of dystrophin-positive fibres 
expression in 7 out of 19 patients enrolled in the trial with no improvement in a 6 
minutes walking test. This finding was associated with increased expression of 
α-sarcoglycan and NOS (Cirak et al., 2011). Another clinical trial based on 
(Eteplirsen) by Sarepta resulted in a 20% dystrophin expression of normal levels 
(Mendell et al., 2013). Although, concerns on clinical efficacy and limited 
dystrophin level delayed the approval, Food and drug administration (FDA) 
recently approved Eteplirsen in 2016 to be the first oligonucleotide to be 
commercialized (Aartsma-Rus and Krieg, 2017). Despite these successful 
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restorations of deficient dystrophin expression, there are hurdles that still remain, 
for instance; the poor uptake to muscle and the lack of uptake to other affected 
tissues; heart and brain (Nakamura, 2017).  
1.9.2. Viral gene therapy-adeno associated virus (AAV): 
AAV is a small, single stranded member of Parvoviridae family which requires a 
helper virus for replication and life cycle completion, is now received a major 
attention for DMD treatment. Interest in AAV for gene therapy research began 
with awareness of its potential advantages for example; non-pathogenicity, long 
term persistence, diverse tissue tropism, ability to transduce dividing and non-
dividing cells, lower immunological response comparing to other viral vectors for 
example adeno-virus and non-pathogenic to human (Kay, 2011, Daya and Berns, 
2008, Chakkalakal et al., 2005, Konieczny et al., 2013).  
Wild type (WT) AAVs have a non-enveloped icosahedral capsid of about 25 nm 
in diameter. The capsid contains a single strand DNA of 4.7 kb with three open 
reading frames (ORF), which composed of; 1) Rep that encodes Rep78, Rep68, 
Rep52, and Rep40, responsible for viral DNA replication , 2) Cap gene composed 
of three capsid protein; VP1, VP2 and VP3 and 3) Assembly activating protein 
(AAP), which acts along the capsid proteins to localize and facilitate capsid 
assembly in the nucleus (Daya and Berns, 2008). They are flanked with two 
inverted terminal repeats (ITRs), which are base-paired hairpin structures of 145 
nucleotides length. They are required for priming the single stranded to double 
stranded DNA conversion during replication and package the viral DNA into the 
capsid (Xiao et al., 1997). They are naturally defective in replication, which mean 
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they require the presence of an auxiliary virus to achieve their productive cycle 
for example; AV or herpes simplex virus (Merten et al., 2005) (figure 1.9). 
 
 Figure 1.8. Structure of adeno associated virus 
(A) The 4.7-kb single-stranded DNA genome of adeno-associated virus (AAV). The AAV 
genome contains three open reading frames (ORFs) flanked by inverted terminal repeats 
(ITRs). The rep ORF encodes (Rep40, Rep52, Rep68 and Rep78) that are essential for 
viral replication and transcriptional regulation. The Cap ORF encodes 3 proteins (VP1, 
VP2 And VP3) that form viral capsid. (B) Recombinant AAV is generated by inserting a 
gene of interest between the ITRs and replace both rep and cap, which are provided in 
adenoviral helper gene that are necessary for replication. The viral capsid determines 
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the ability of the resulting AAV vector to transduce cells, from binding to cell surface 
receptor to nuclear entry and genome release, which lead to stable transgene 
expression in post mitotic tissue. Adapted from (Kotterman and Schaffer, 2014).  
The concerns about the ability of AAV to integrate specifically into chromosome 
19 as a function of integration efficiency element (IEE) and the ability of rep gene 
to express cellular genes led to construction of recombinant AAV rAVV that lack 
both rep, cap genes and IEE. Therefore, rep and cap can be replaced by a 
therapeutic expression cassette, with the ITRs being retained as they are 
essential for packaging. Thus, the (rAVV) are considered as extrachromosomal 
elements that ensure long term transgene expression in post mitotic tissues such 
as skeletal muscle (Daya and Berns, 2008). The limited cloning capacity of only 
4.7 Kb has restricted the application of rAAV for DMD as the full length dystrophin 
cannot be packaged, which represent the major limitation of rAAV (Konieczny et 
al., 2013, Wang, 2010). However, all of the rAAV advantages make it more 
resourceful for muscle therapy. AAV binds to the host cells by using heparin 
sulphate proteoglycan structure on the cell surface and utilize (FGFR1), co-
receptor on the cell surface to internalize via receptor-mediated endocytosis 
(Konieczny et al., 2013). Different AAV serotypes are produced to date targeting 
specific tissues and organs (Chahal et al., 2014). Currently, rAAV capsid 
serotype selection for a specific clinical trial is based on effectiveness in animal 
models. However, preclinical animal studies are not always predictive of the 
human outcome (Manno et al., 2006, Nietupski et al., 2011). As shown by 
preclinical and clinical trials, rAAV2 vectors transduced mouse and human 
hepatocytes at equivalent but relatively low levels. However, rAAV8 vectors, 
which are effective in many animal models, transduced human hepatocytes 
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relatively poorly at about 20 times less than mouse hepatocytes (Lisowski et al., 
2014).  
Different rAAV candidates employed in diverse clinical trails are reviewed in 
(Naso et al., 2017). In human clinical trials, AAV vectors is a promising approach 
for gene delivery into post mitotic tissues for instance; retina and brain. AAV8 has 
been used for years in liver clinical trials for hemophilia B (Nathwani et al., 2011). 
The first AAV clinical trial was conducted in the subject of cystic fibrosis, today 
more than 70 approved clinical trials worldwide for different diseases (Clément 
and Grieger, 2016). In 2012, based on the safety profile and outcomes, Glybera, 
an rAAV1 based drug for treatment of familia lipoprotein lipase (LPL) deficiency 
was this first rAAV to be market-approved in Europe (Gaudet et al., 2010, 
Clément and Grieger, 2016). In 2017, Luxturna, which is developed by Sparks 
Therapeutic to treat patients with an inherited retinal disease (IRD), that may lead 
to blindness, was the first AAV2 gene medicine to be approved by FDA (Smalley, 
2017). However, in the area of DMD, due to limited carrying capacity of AAV, a 
new mini or micro-dystrophins that lack multiple regions of the rod domain and 
maintain amino and carboxyl domains including the nNOS binding site was 
synthesized (Gao and McNally, 2015). These constructs can be inserted into 
AAV and delivered into mdx mice where they can induce expression and reduced 
pathology associated with DMD (Wang et al., 2009, Zhang and Duan, 2012).  
Although, phase I clinical trial on mini-dystrophin gene using optimised AAV2.5 
vector has been completed, minimal expression of dystrophin was detected and 
immune response was reported against minidystrophin (Mendell et al., 2012, 
Rodino-Klapac et al., 2013). Because AAV is approved medicine in multiple 
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conditions as mentioned earlier with no known disease association, it becomes 
one of the leading gene delivery approach.    
1.10. Viral gene therapy approaches that target oxidative capacity and      
mitochondrial biogenesis in DMD: 
Energy is vital to all living organisms. In human and mammals, the vast majority 
of energy is generated by oxidative metabolism in the mitochondria. The cellular 
demand for energy varies under different physiological conditions in different 
cells. There is great interest in mitochondrial oxidative metabolism in general 
biomedical field. Therefore, a regulatory network of transcription factors controls 
the quantity and activity of mitochondria. Understanding these molecular 
mechanisms regulating mitochondrial biogenesis and function provides 
potentially important therapeutic targets in mitochondrial dysfunction associated 
with pathogenesis of numerous conditions such as aging, type 2 diabetes and 
DMD, which is the main focus in this thesis (figure 1.10). 
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Figure 1.9. Schematic representation of signalling pathways that target oxidative 
metabolism and mitochondrial biogenesis  
Adapted from (Komen and Thorburn, 2014) 
 
1.10.1. PGC-1α  
Peroxisome proliferator-activated receptor (PPAR) s (PPAR α, δ and γ) is a large 
family of nuclear receptors that interact with transcriptional coactivator PGC-1α 
and binds to wide numbers of transcription factors known to be involved in 
mitochondrial biogenesis, glucose and fatty acid metabolism, adaptive 
thermogenesis, heart development and muscle fibre types transition (Liang and 
Ward, 2006). According to the above mentioned biological response, PGC-1α is 
highly expressed in tissues active in oxidative metabolism and where 
mitochondria are abundant for example; the heart, slow-twitch skeletal muscle, 
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kidney, brain and brown adipose tissue (BAT) (Puigserver et al., 1998, Liang and 
Ward, 2006, Finck and Kelly, 2006). PGC-1α is a protein that induce the 
probability of gene transcription through binding to transcription factors 
(Puigserver and Spiegelman, 2003). However, it has been shown that PGC-1α 
also plays as a coactivator of NRF-1 and -2 (nuclear respiratory factor) which are 
required for regulating expression of genes essential in mitochondrial structure 
(TFAM) (Wu et al., 1999). In terms of skeletal muscle, over-expression of PGC-
1α is well known in switching glycolytic fibres into oxidative types I and IIa and 
the level of PGC-1α gene is increased by endurance and short-term exercise as 
shown in human and rodents models (Baar et al., 2002). Moreover, transgenic 
mice with overexpressed PGC-1α showed more resistance to contraction-
induced fatigue (Lin et al., 2002) and deficient mice of PGC-1α exhibited reduced 
number of mitochondria and low level of oxidative capacity (Leone et al., 2005). 
Therefore, PGC-1α has been investigated as a therapeutic approach in treating 
DMD. Using mdx mice, administration of rAAV- PGC-1α drives more expression 
of dystrophin homologue (utrophin), increases expression of myosin type 1 heavy 
chain (Pendrak et al., 2012). Moreover, increased over-expression of oxidative 
proteins for example; cytochrome C, UCP-1 and Cox IV compared to the control, 
indicates the enhanced ability of the treated muscles to produce more ATP and 
increased either number or size of mitochondria which suggested increased 
endurance capacity following over-expression of PGC-1α (Pendrak et al., 2012). 
PGC-1α is regulated by numbers of upstream pathway in skeletal muscle, 
calcineurin A,  calcium calmodulin-dependent protein kinase (CaMK) and AMP-
activated protein kinase AMPK (Finck and Kelly, 2006). PGC-1α exerts its 
regulatory functions by interacting with transcription factors such as NRF1, 
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estrogen related receptor α (ERRα) and GA-binding protein, and subsequently 
activating the expression of the genes targeted by these factors (Handschin and 
Spiegelman, 2006).  
1.10.2. PERM1 
The pathways targeted by PGC-1α and ERRs include genes working either 
downstream or in parallel, for example; PGC-1/ERR-induced regulator in muscle 
1 (PERM1) gene which is expressed selectively in muscles and is required for 
the expression of selective genes involved in mitochondrial biogenesis and 
oxidative metabolism (Cho et al., 2016). In C2C12 cells myotubes, PERM1 has 
been shown to induce a subset of genes involved in oxidative metabolism 
induced by PGC-1α and estrogen related receptor γ (ERRγ) (Cho et al., 2013). 
However, gene based therapy of AAV mediated expression of PERM1 into 4 
weeks old C57BL/6J mice increased expression of genes involved in oxidative 
function (PGC-1α and ERRα) but not (ERRγ), mitochondrial biogenesis (TFAM, 
SIRT3,Tf2bm), angiogenesis (VEGFa), glucose metabolism (Glut4), and fatty 
acid metabolism (Cpt1b). In addition, over-expression of PERM1 via AAV 
enhanced capillary density and im proved fatigue resistance without altering fibre 
types in wild type mice (Cho et al., 2016). As PERM1 shares overlapping actions 
to those of PGC-1α, it is a possible targeted therapy for DMD.  
1.10.3. SIRT1 
In mdx mice, the level of nicotinamide adenine dinucleotide (NAD+) is significantly 
reduced and repletion provides protection from metabolic disease and 
mitochondrial dysfunction in a SIRT1 dependent manner (Ryu et al., 2016). 
Sirtuins is an NAD+-dependent histone/protein deacetylase that play role in 
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cellular antioxidant stress, metabolism and cell survival and are highly conserved 
within species. There are seven members of sirtuins where SIRT1 is the best 
characterized member them (Horio et al., 2011). SIRT1 senses changes in 
intracellular NAD+ levels, which reveal energy level, and uses this information to 
adapt the cellular energy output to matches cellular energy requirements (Cantó 
and Auwerx, 2012). In DMD, multiple studies showed the beneficial effect of 
SIRT1 activation on metabolic, degenerative and inflammatory diseases (Tonkin 
et al., 2012, Vinciguerra et al., 2010, Lavu et al., 2008). Transgenic mice 
specifically overexpress SIRT1 in skeletal muscle exhibited a fast to slow fibre 
types conversion, induced expression and activity of PGC-1α, induced utrophin 
expression, increased mitochondrial contents and mitigated pathology 
associated with dystrophic muscles such as fibrosis, centrally nucleated fibres 
and creatine kinase level (Chalkiadaki et al., 2014). For DMD, specifically, the 
activity of SIRT1 is attenuated in mdx mice as shown in a study using resveratrol 
and found the deacetylation target of SIRT1, the histone H3 acetylation at 
lys9/Lys14 was increased in mdx mice and resveratrol can reverse this effect 
(Imai et al., 2000). Resveratrol treatment of mdx mice resulted in inducing a shift 
towards more oxidative fibres in soleus muscles and a restoration of type IIa in 
EDL and TA muscles, through increasing SIRT1 expression which reduce PGC-
1α acetylation level (Ljubicic et al., 2014). These findings suggested that over-
expression of SIRT1 results in deacetylation of PGC-1α which then mediate the 
induction of mitochondrial biogenesis (Chalkiadaki et al., 2014). Therefore, 
SIRT1 has been suggested as a potential target in DMD.  
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1.10.4. PPARδ 
Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear 
receptors that play important roles in energy metabolism. There are three 
different isoforms (α, γ and δ) with specific roles in metabolism. However, PPARδ 
has been shown to play a role in skeletal muscle metabolism as shown in studies 
of gain and loss of- function (Angione et al., 2011). Knockdown of PPARδ 
specifically in skeletal muscle resulted in metabolic disorders and impaired 
oxidative capacity as it showed a reduction in the expression of PGC-1α (Luquet 
et al., 2003), whereas mice overexpress PPARδ showed a shift towards oxidative 
type I fibres and consequently resulted in promoting oxidative capacity (Schuler 
et al., 2006). However, mdx mice treated with GW501516 agent (a PPARδ 
agonist) showed an increase in the forelimb and hind limb grip strength in addition 
to the increase in mitochondrial mass and over-expression of PGC-1α and Cyt c, 
together with an increase in type I/IIA oxidative fibres (Jahnke et al., 2012). 
Therefore, PPARδ is another possible target for DMD.    
1.10.5.  Estrogen related receptors: 
Nuclear receptors are ligand-dependent transcription factors that regulate the 
expression of specific genes related to metabolism, reproduction and 
development. Orphan nuclear receptors are those which no physiological 
ligands. Three known receptors belong to this family have been identified to date; 
estrogen related receptors (ERR) α, β, γ (Giguère, 1999). None of these 
receptors binds estrogen due to the presence of amino acid side chain within the 
ligand-binding pocket (LBD), which maintains transcription without addition of 
exogenous ligand in converse with the other typical nuclear receptors (NRs) that 
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require ligands to enable gene activation. The amino acid mimic a ligand bound 
conformation, which is essential for cofactor binding (Giguère, 1999). 
Selective estrogen receptor modulators such as tamoxifen, 4-hydroxytamoxifen 
and diethylstilbestrol (DES) have been identified as synthetic ligands to one or 
more ERRs and act as agonist or inverse agonists. Diethylstilbestrol (DES) and 
4-hydroxytamoxifen (4-OHT) function to inhibit ERRγ activity (Greschik et al., 
2004). In addition, bisphenol A, 2,2-bis (hydroxyphenyl) propane (BSA) has 
strong interaction with ERRγ and functions as an inverse agonist on ERRγ to 
maintain its highly constitutive activity (Liu et al., 2007).  
Structural studies provided evidence that ERRs are active constitutively. As 
shown in (figure 1.11), ERRs contain N-domain, a transcription activation function 
domain (AF)-1 that is involved in the transcriptional regulation of the receptor 
through a conserved motifs (Tremblay et al., 2008). ERRs contain zinc finger 
DNA-binding domain (DBD), a highly conserved in all three receptors which may 
explain that several genes can be targeted by more than one of the ERR 
isoforms. They bind to the same DNA element which is known as the ERR 
response element (ERRE), TCAAGGTCA. ERRE involves in DNA recognition 
and protein-protein interaction. Structure also contains ligand-binding domain 
(LBD) and a C-terminal AF-2 domain that interacts with co-activators and co-
repressors (Huss et al., 2015). Diverse roles of ERRs are determined by 
variations in both DNA and ligand binding specificities in addition to specific 
interaction with co-activator and co-repressor that mediate transcription. 
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Figure 1.10. Structure of Estrogen related receptor 
ERR contains NH2 terminal region which contains transcriptional activation factor 1 
(AF1), DNA-binding domain (DBD), a hinge region that anchored the protein flexibility 
required for receptor dimerization and ligand binding domain LBD) which contains a 
conserved AF-2 helix motif. Modified from (Huss et al., 2015). 
Although ERRα and ERRγ are expressed in tissues associated with metabolic 
activity, ERRγ is more selectively expressed in metabolic and vascularized 
tissues such as; brain, liver, kidney, adipose, placenta, and skeletal muscle 
tissues. ERRα and ERRγ modulate cellular energy metabolism by directing 
mitochondrial biogenesis and function (Huss et al., 2015, Deblois and Giguère, 
2011, Giguere, 2008). They promote oxidative capacity in skeletal and cardiac 
muscles (Alaynick et al., 2007, Wang et al., 2015). They are crucial components 
of cellular glucose metabolism by regulating genes involved in glycolysis, 
including glucose uptake, glucose to pyruvate conversion and pyruvate entry in 
the Krebs cycle (Zhang et al., 2006, Deblois and Giguere, 2013). Further, they 
regulate lipid synthesis through fatty acid oxidation in the mitochondria and 
importantly they target genes involved in mitochondrial biogenesis and activity, 
including genes of electron transport chain (Giguere, 2008).  
ERRβ functions during development of placenta, endolymph of the inner ear and 
retina and mutations have been associated with hearing loss in humans (Collin 
et al., 2008, Onishi et al., 2010). ERRβ also involves in the expression of genes 
important in self-renewal (Chen et al., 2008). In addition, the increase in their 
AF1 DBD
H
in
g
e
LBD/AF2NH2 COOH
TCAAGGTCA
 
 
80 
 
expression causes an increase in mitochondrial biogenesis and activity, which 
stimulates oxidative capacity (Eichner et al., 2010, Cai et al., 2013, Huss et al., 
2004, Rangwala et al., 2010). 
Studying ERRs-null mice showed different phenotypes for example; ERRγ-null 
mice die shortly after birth (Alaynick et al., 2007), ERRα-null mice are viable and 
fertile and the mouse embryonic fibroblasts exhbit normal growth and 
proliferation, suggesting that ERRα by itself is not essential for mitochondrial 
biogenesis (Luo et al., 2003b) and ERRβ-null mice results in embryonic lethality 
at day 10, however, ERRγ can substitute for ERRβ to promote mouse fibroblasts 
and prevent the need for ERRβ during embryonic lineage (Luo et al., 1997). 
Because these receptor share similar target genes (Giguere, 2008), it is likely 
there is some functional redundancy between ERRs. Interestingly, ERRs are 
shown to work in a compensatory manner in heart, for example, ERRγ is 
upregulated in ERRα-null mice; furthermore, in ERRγ-/- mice, ERRα and ERRβ 
are upregulated. A complete inhibition of individual ERR isoform does not prevent 
mitochondrial biogenesis or activity due to presence of a compensatory 
mechanism through increased expression of other isoforms (Murray et al., 2013, 
LaBarge et al., 2014). The functions of ERRβ and ERRγ are overlapping by 
controlling genes important for ion homeostasis in the trophoblast, skeletal 
muscle, kidney, liver and stomach (Alaynick et al., 2007, Luo et al., 2013, Gan et 
al., 2013).  
Significantly, ERRγ regulate metabolic processes, which do not involve ERRα 
and β. For example; specific over-expression of ERRγ ameliorates impaired 
hepatic insulin signalling via increasing expression of LIPIN1 gene (Kim et al., 
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2011). Moreover, ERRγ stimulates expression of fibroblast growth factor (FGF) 
in hepatocytes, which is important regulator of angiogenesis (Jung et al., 2016).    
In skeletal muscle, ERRα and ERRγ are both positively associated with 
mitochondrial biogenesis. However, the effects of ERRα is dependent on PGC-
1α to activate the transcription of mitochondrial genes such as ATP-synthase 
(Atp5) and cytochrome c oxidase (Cox5), whereas ERRγ exert its effect 
independent of PGC-1α and rather linked to activation of AMPK (Narkar et al., 
2011). When ERRγ is expressed ectopically in glycolytic muscle, it drives a 
switch towards oxidative fibres and induces mitochondrial biogenesis and 
angiogenesis. This is accompanied by induction of  genes associated with fatty 
acid oxidation, TCA and OXPHOS (Narkar et al., 2011). In the basal state, 
knockout of ERRα in skeletal muscle, does not lead to any phenotypic changes 
(Luo et al., 2003b), whereas ERRγ-null mice are lethal (Alaynick et al., 2007), 
suggesting that ERRγ is potentially required for basal mitochondrial function. 
Therefore, the next section will discuss the regulation of ERRγ. 
1.10.5.1. Regulation of ERRγ: 
Expression and activity of ERRγ is controlled by different cellular stress and 
membrane receptors, such as, insulin and glucagon receptors. These two 
receptors play opposite roles in regulating ERRγ expression. For example; in 
response to nutrient availability, hypoxia, endoplasmic reticulum stress, pro-
inflammatory cytokine interleukin (IL-6) and energy demands, these two 
receptors have been speculated to regulate ERRγ expression (Misra et al., 
2017). As a result, ERRγ could be instrumental in cellular energy surveillance. 
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Moreover, post-translational modification functions as a major mechanism 
regulating activities of orphan nuclear receptors independent of ligands. ERRγ 
activity is altered by phosphorylation, ubiquitination and sumoylation; that inhibit, 
increase or stabilize the transcriptional activity of ERRγ during various 
physiological conditions (Misra et al., 2017). Furthermore, ERRγ transcription 
depends on co-regulators that respond to different cell signals. PGC-1α functions 
as transcriptional coactivators for ERRγ in various metabolic pathways. It binds 
to AF-2 domain of ERRγ ending up in a conformational change that maintain the 
assembly of an active transcriptional complex (Sever and Glass, 2013). Wang et 
al., suggested a feed-forward loop where ERRγ activates PGC-1α by activating 
the latter promoter, and PGC-1α then activates ERRγ (Wang et al., 2005). 
Likewise, GRIP-1 enhances the transcriptional activity of ERRγ (Hong et al., 
1999). In addition, there are co-repressors, which inhibit ERRγ activation by 
competing with the binding of co-activators to the AF-2 domain. SHP, DAX-1, 
SMILE and GNL3L repress ERRγ transcriptional activity. Furthermore, receptor-
interacting protein 140 (RIP140) acts as co-activator and co-repressor depending 
on the target genes (Misra et al., 2017).  
1.10.5.2. Downstream targets of ERRγ (Mitochondrial biogenesis, 
oxidative transformation and angiogenesis):  
An integral part of skeletal muscle differentiation is a dramatic increase in 
mitochondrial number and oxidative capacity, which are hallmark features of 
myocyte differentiation (Murray et al., 2013). Gene array analysis run by Narkar’s 
group showed that in the absence of exercise, ERRγ from transgenic mice 
regulated a total of 1123 genes in skeletal muscles, of which 623 genes were 
induced. The majority of the upregulated genes belong to either mitochondrial 
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biology (90) or oxidative metabolism (43) encoding several components of fatty 
acid oxidation pathway, oxidative respiratory chain, contractile genes especially 
those associated with slow fibres (Narkar et al., 2011). In skeletal muscles, ERRγ 
is exclusively and highly expressed in oxidative myofibrils and control an 
induction of genes associated with oxidative metabolism (LPl, Cytc, Pdk4, Ucp3) 
(Huss et al., 2002, Narkar et al., 2011). On the other hand, mdx mice showed 
reduced expression of ERRγ by (60-85%) in addition to compromised gene 
network regulating oxidative metabolism and angiogenesis. However, transgenic 
over-expression of ERRγ in mdx mice reprogram the induction of genes involved 
in oxidative metabolism such as pyruvate dehydrogenase (Pdk4), Ucp3, 
cytochrome C (Cytc) and lipoprotein lipase (Lpl). In addition, there is an induction 
of angiogenesis program; VEGF-189, VEGF-165 and FGF and promoting switch 
towards more slow oxidative fibres, which are rich in mitochondria and capillary 
density in the absence of exercise. All these changes are independent of PGC-
1α by recruiting the alternative factor AMPK, which is upregulated in the 
transgenic muscle of ERRγ (Matsakas et al., 2012, Matsakas et al., 2013).  
ERRγ heterozygous mice (ERRγ+/-) compared to wild type exhibited reduced 
expression of genes related to fatty acid oxidation and fatty acid uptake such as 
cpt1b, and lpl and oxidation gens such as Idh3a which indicate impairment in 
utilizing fatty acids as fuel (Rangwala et al., 2010). Furthermore, ERRγ null mice 
(ERRγ-/-) die shortly after birth and showed defects in cardiac oxidative capacity 
as an example of pathways controlled by PGC-1α. Characteristics of cardiac 
muscle from completed knockout mice showed reduced expression of genes 
involved in TCA and ETC complex I enzymes (Alaynick et al., 2007). Therefore, 
ERRγ has important roles in energy metabolism and skeletal muscle growth.  
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Further, angiogenesis induction in skeletal muscle possibly occurs in response 
to paracrine signals following ERRγ activation. Conditioned medium from ERRγ 
overexpressing C2C12 cells was able to induce formation of endothelia cell tube 
in culture (Liang et al., 2013, Narkar et al., 2011), which indicate that ERRγ 
induce angiogenic factors in a paracrine fashion. ERRγ has important roles in 
angiogenesis as muscle specific ERRγ over-expression in a murine model of hind 
limb vascular occlusion showed enhancement in re-vascularisation and 
neoangiogenesis, which contribute to the reparative function in skeletal muscle 
ischemia and maximize restoration of blood perfusion (Rangwala et al., 2010). 
Thus, taken together, ERRγ is a possible target in mdx mice to overcome 
ischemic issues.  
Furthermore, ERRγ stimulates the VEGF promoter containing putative ERR 
binding sites which is known to transcribe all VEGF isoforms (Arany et al., 2008). 
However, induction of angiogenesis by ERRγ is not dependent on VEGF 
induction only as there are other factors induced such as FGF1, known to control 
endothelial cell migration and proliferation (Forough et al., 2006), along with 
Efnb2, possibly recruit mural cells such as vascular smooth muscle cells and 
pericytes, required for vessel formation (Foo et al., 2006). Interestingly, this effect 
of ERRγ in angiogenesis is PGC-1α independent and not involved hypoxia 
inducible factor (HIF-1α), which negatively regulates oxidative metabolism 
(Mason et al., 2007) and showed unchanged expression in transgenic muscle of 
ERRγ (Narkar et al., 2011). Conversely, HIF-2α was upregulated in response to 
exercise of ERRγ transgenic muscle, which is then proposed as a downstream 
target of ERRγ (Rangwala et al., 2010) (figure 1.12). 
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1.11. The potential impact of ERRγ in DMD: 
In vivo ERRγ loss or gain of function studies show changes in mitochondrial ETC/ 
OxPhos gene expression and oxidative capacity (Narkar et al., 2011, Rangwala 
et al., 2010). ERRγ-/- myocytes showed increased reliance on medium chain fatty 
acid (MCFA) as a substrate for energy production, which generates fewer ATPs 
per molecule than long chain fatty acid (LCFA). However, increased flux of fatty 
acid through ETC would cause more ROS production (Murray et al., 2013). 
Therefore, downstream pathways are induced in response to elevated ROS; 
Foxo1, NF-κB and their downstream targets, Atrogin-1 and MuRF1 (Murray et 
al., 2013). In normal physiological condition of elevated ROS, NF-κB directly 
activate antioxidant genes such as superoxide dismutase (SOD1 and SOD2) 
(Morgan and Liu, 2011). Foxo1 activation is known to reduce type I fibres and 
decrease muscle mass (Kamei et al., 2004). Thus, over-expression of ERRγ may 
have a protective role in these pathways during dystrophin loss.  
Figure 1.11. Schematic representation showing the role of ERRγ in the 
transcriptional network regulating muscle oxidative capacity and angiogenesis 
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Activation of other nuclear receptors such as PGC-1α and PPARδ have been 
shown to improve pathology associated with DMD by eliciting a fast to slow 
muscle fibres, stimulate utrophin expression, affecting neuromuscular junction 
and activating metabolic reprogramming in mdx mice (Handschin et al., 2007, 
Selsby et al., 2012, Hollinger et al., 2013, Jahnke et al., 2012). Activation of 
AMPK has also been reported to reverse mitochondrial deficit and induce a 
switch towards oxidative fibres ameliorating the dystrophic phenotype (Ljubicic 
et al., 2011). In parallel, induction of molecules that regulate angiogenesis/ 
vascular density for example VEGF and FGF and vasorelaxation/ blood flow such 
as NO, PDE5 inhibitor have shown to promote regeneration and improve the 
dystrophic phenotype of mdx mice (Messina et al., 2007, Tidball and Wehling-
Henricks, 2004).  
However, to date, a simultaneous rescue of both metabolic and angiogenic gene 
networks by any of the factors has not been established yet. Therefore, ERRγ is 
the only identified transcription factor that regulate both metabolism and 
angiogenesis in the skeletal muscle based on data obtained from transgenic mdx 
mice, demonstrating a significant advantage over other approaches (Narkar et 
al., 2011, Matsakas et al., 2013). Together, ERRγ can be considered as a 
‘gatekeeper’ of transcriptional program controlling the activation of oxidative 
metabolism, mitochondrial biogenesis and angiogenesis genes and its over-
expression becomes an appropriate pipeline in an attempt to ameliorate 
muscular dystrophy pathologies. 
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1.12. Hypothesis: 
The general hypothesis is that adeno associated virus delivery of ERRγ, a key 
enhancer of the oxidative metabolism and angiogenesis is able to restore muscle 
function and improve oxidative capacity and angiogenesis in mdx mice (a model 
of duchenne muscular dystrophy) during postnatal life.  
1.13. Aims: 
Study 1: Assess the gene expression profile following intramuscular 
administration of AAV8-ERRγ into 6 week-old mdx and assess the short-term 
changes of pathology, biomarker profiling in dystrophic skeletal muscle following 
AAV8 mediated ERRγ expression using intramuscular administration of 1X1010 
vg into two cohorts of 6 and 12 week-old mdx and recover 4 weeks post 
administration.  
Study 2: Assess the short-term changes of pathology, function and biomarker 
profiling in dystrophic skeletal muscle following AAV mediated ERRγ expression 
using intravenous administration of AAV8-ERRγ of 1X1012 into 6-week old mdx 
and recovered 4 weeks later. 
Study 3:  Assess the short-term changes of pathology, function and biomarker 
profiling in dystrophic skeletal muscle following AAV mediated ERRγ expression 
using intraperitoneal administration of AAV8-ERRγ of 2X1012 into 3-week old 
mdx and recovered 6 weeks later. 
Study 4: Develop a sequence-optimized form of ERRγ and assess the short-
term effect of pathology, function and biomarker profiling in dystrophic skeletal 
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muscle following intraperitoneal administration of AAV9-ERRγ of 2X1012 into 3-
week old mdx and recovered 6 weeks later. 
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2. Chapter 2 
Materials and Methods 
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2.1. Tissue culture: 
Murine skeletal muscle cells (C2C12) (Yaffe and Saxel, 1977) and human 
embryonic kidney cells (HEK-293T) were cultured in Dulbecco’s modified Eagles 
medium (DMEM), 10% Fetal calf serum (FCS) in a humidified incubator at 5% 
CO2, 37oC. 
2.1.1. Sub-culture of cell lines: 
Aseptically, (10% FCS, DMEM) growth medium was discarded and cells were 
washed twice with 10 ml phosphate buffered saline (PBS). Then, PBS was 
discarded aseptically and 2.5 ml of trypsin/EDTA (0.05%) was added. Cells were 
incubated for 5 minutes at 37oC and monitored under the microscope until most 
of the cells have detached and free in the media. Sometimes, gentle tapping the 
sides of the flasks aids in detaching the cells (depending on the surface area, 
degree of confluence and cell types). Immediately, 10 ml of 10% FCS, DMEM 
was added and gently pipetted up and down to obtain homogenous cell 
suspension which was transferred into 50 ml tube and spun down for 5 minutes, 
1000 rpm at room temperature (RT). The supernatant was discarded and 1 ml of 
10% FCS DMEM medium was added to the pellet and re-suspended. For cell 
counts, 10 μl of the cells was mixed with 10 μl of trypan blue dye and counted 
using Countess Cell Counter machine. Depending on the required number of 
cells, the required volume was transferred to a flask in appropriate volume of 
media, incubated at 37 oC in 5% CO2 incubator.   
2.1.2. Evaluation of transfection efficiency: 
In 6 well plates, 50,000/cm2 of C2C12 cells were seeded per well in 2 ml of 10% 
FCS DMEM and grown for 24 hour. Subsequent, cells were transfected with 4 μg 
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of eGPF plasmid using linear polyethylenimine (PEI) (linear, MW=25000). 
Different ratios were used from (1:1-1:6) by changing the amount of PEI. In a total 
volume of 200 μl of serum free DMEM, eGFP plasmid and PEI were diluted 
together, mixed well and incubated for 15 minutes at RT. Then, 200 μl of the mix 
were added to each well. The next day, the transfection efficiency was visualized 
with fluorescent inverted microscopy (figure 2.1). 
 
  Figure 2.1. Optimization of transfection efficiency 
1:1 1:2
1:3 1:4
1:61:5
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Evaluation of transfection efficiency showed (1:2) of (DNA: PEI) ratio is highly efficient      
in transfection compared to other ratios. C2C12 cells were seeded per well in 2 ml of 
10% FCS DMEM and grown for 24 hour. Following that, cells were transfected with 4 
ug of eGFP plasmid using PEI. After 24 hour, the transfection efficiency was visuliazed 
using fluorescent inverted microscopy.    
2.2. Proliferation assay (MTS): 
C2C12 cells were seeded as 3000/cm2 in 96-well plates with 100 μl of 10% FCS 
DMEM and grown for 24 hours. Cells were transfected with (0.2 μg) of a murine 
estrogen related receptor-gamma plasmid under the control of spc5-12 promoter 
plasmid (ERRγ) PEI. The ratio was (1:2), plasmid DNA: PEI. After 24 hrs, the 
proliferation assay was performed following manufacturer’s instructions. Briefly, 
20 μl of CellTiter 96® AQueous one solution reagent was added into each well 
of the 96-well assay plate. The plate was incubated for 1 hour, 5% CO2. 
Subsequently, the absorbance was recorded at 490 nm using 96-well plate 
reader. The control cells were received the same amount of PEI and there were 
wells with DMEM 10% FCS only, used as a blank.  
2.3. C2C12 viral transduction: 
Cells were plated 3000/cm2 in 96-well plates until they were 70% confluent. Then, 
they were induced to differentiate by changing serum to 2% horse serum. Later, 
virus was added to the medium at 1x1010 vg for three days.   
2.4. Plasmid production: 
pDP8 helper plasmid was transformed into XL-10 competent bacterial cells via 
heat shock, where 50 ng of plasmid was added to bacteria on ice for 5 minutes 
and then heat shocked for 1 minute (42oC), then on ice again for 1 minute. Then, 
bacteria was grown in 1 ml of LBSOC medium (20 mM glucose, 10mM MgSO4, 
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10Mm MgCl2, 2.5 mM KCl, 10 mM NaCl, 2% Tryptone and Yeast extract) for 45 
minutes with shaking. 200 μl of bacterial culture was plated on ampicillin (50 
μg/ml) LB agar (LB broth and agar) plates and incubated overnight at 37oC. Next 
day, one colony was picked and grown in 5 ml starter culture of LB (ampicillin) 
and grown through the day. Overnight a large 2.5 L culture was inoculated at 
1/1000 with the starter culture. Qiagen Giga preparation kit (endotoxin free) was 
used to purify the plasmids. To confirm the identity of the pDP8 helper plasmid, 
1% agarose gel (0.8 g of agar, 80 ml of TAE buffer and SYBR safe dye) was 
prepared. Restriction enzyme (RE) (HindIII) was used to check the pDP8 helper 
plasmid fragments. Restriction digestion reaction contained 10 μg of the plasmid 
DNA, 1 unit/μg of RE, 3 μl of buffer and make the total volume to 20 μl with water. 
All of them were mixed and incubated for 1 hour at 37oC. Loading dye of 5 μl was 
added to the sample and 1 Kb ladder was used. Gel was run at 90 V, 400 Am for 
1 hour. 
2.5. AAV8-ERRɣ virus: 
2.4.1. AAV production: 
Virus production included several steps, firstly HEK-293T cells were plated to 
reach 80% confluency in DMEM 10% FCS. Then, the cells were transferred to 
roller bottle with 200 ml of 10% FCS DMEM. The bottles were incubated in roller 
incubator with rotor at 0.5 rpm overnight. Then, the rotor was turned up to 1 rpm 
for two more days. The second step was transfection, which firstly included 
changing medium in the cells to DMEM/ free of serum (SF) and preparation of 
the complex which included 500 μg of plasmids; pPDP8 (375 μg) and pAAV-Ha-
ERRγ (125 μg) in (1:1) ratio, diluted in SF DMEM. The transfection of the cells 
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was carried out using PEI. The ratio was (5:1) PEI to plasmids (pDP8 and pAAV8-
ERRγ) in DMEM/SF. 20 ml of the mix was added to the bottle and cells were 
cultured for 3 days. AAV was harvested by shaking the flasks to detach all cells 
and the supernatant was decanted to 250 ml corning tubes. Cells were pelleted 
and frozen. Then to every 200 ml of supernatant, 50 ml of 40% PEG was added, 
mixed, inverted 10-20 times and put overnight at 4oC. Following, the supernatant 
was centrifuged for 30 minutes at 3000 rpm at 4oC. The supernatant was then 
removed and the pellet was re suspended in 9 ml lysis buffer. This lysate was 
then added to the cell pellet. Then, the lysate was frozen, thawed three times 
using dry ice/ethanol. After these freze/thaw cycles, benzonase was added to the 
final concentration of 50 U/ml and incubated for 30 minutes at 37oC. The lysate 
was clarified by centrifugation at 3700 g for 20 minutes at RT and passed through 
0.45 um filter. The lysate was layered to an iodixanol gradient into a Beckman 
Quick-Seal Ultra-Clear 25X77mm tube. The iodixanol solution was layered using 
a pasteur pipette in the following order; 6.9 ml of 15% iodixanol, 4.6 ml of 25% 
iodixanol, 3.84 ml of 40% iodixanol and 3.83 ml of 60% iodixanol ( Table 2.1).  
 Table 2.1. Layers components of iodixanol 
     
Then, the lysate was layered on the top and the tube was filled to the bottom of 
the neck with lysis buffer using a syringe fitted with a small gauge needle to avoid 
bubbles formation, the tube was then sealed with a Beckman tube heat sealer, 
Layer Iodixanol 5M NaCl 5x PBS-MK H2O Phenol 
Red
15% 12.5 ml 10 ml 10 ml 17.5 ml 100 ml
25% 20.8 ml 10 ml 10 ml 19.2 ml 100 ml
40% 33.3 ml 10 ml 10 ml 6.7 ml 100 ml
60% 50 ml 10 ml 10 ml 6.7 ml 100 ml
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and centrifuged for 1 hour at 18oC in a type 70Ti rotor at 69000 G. After 
centrifugation, the tube was clamped in a stand and a 18-19 gauge needle was 
inserted into the interface between the 60 and 40% iodixanol layers and removed 
the AAV fraction (40% layer) which then can be stored in fridge overnight. 
Desalting and concentration was the third step which was carried out in Amicon 
Ultra-15 100,000K (PL100) (Millipore) centrifugal filter device. Firstly, the filter 
was rinsed with 5 ml of PBS-MK by centrifuge at 4000 g for 15 minutes. Then, 5 
ml of PBS-MK was added to AAV fraction and the total volume was added to the 
filter device, centrifuged for 20 minutes at 4000 g until the volume was reduced 
to 2 ml. Another 15 ml of PBS-MK was added to the filter and the step was 
repeated 3 times to desalt AAV preparation. During the last step, the volume was 
reduced to 1-2 ml. Finally, the concentrated, desalted AAV was collected by 
rinsing the sides of the filter after removing the retentant from the filter. The virus 
was aliquoted in 100 μl volumes and stored at -80 oC.  
2.4.2. AAV titre by Dot blot quantification 
The last step in preparing the virus was quantification by dot blot and it is divided 
into two steps; preparation of viral DNA and preparation of dot blots. 1 and 5 μl 
sample of AAV were treated with DNase I (5 U) I in a final volume of 200 μl of SF 
DMEM for 1 hr at 37oC. The sample was then treated with 100 μg of proteinase 
K for 1 hr at 37oC to digest viral capsid. Double extraction/ purification of viral 
DNA was accomplished by using an equal volume of 25:24:1 of 
phenol/chloroform/ isoamyl alcohol, mixed and centrifuged at 13000 rpm for 10 
minutes at 4oC, then the top layer was removed to a new tube. The DNA was 
precipitated with 40 μl of 3 M sodium acetate, 40 μg glycogen (2 μl) and 2.5 
volumes of 100% ethanol and incubated at -80oC for 30 minutes followed by 
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centrifugation at 13000 rpm for 20 min at 4oC. The DNA pellet was washed in 
70% ethanol and re suspended in 400 μl of 0.4 M NaOH/10 mM EDTA. A 2-fold 
serial dilution of AAV vector plasmid corresponding to the AAV virus stock to be 
titred, was prepared in a volume of 20 μl (160 ng-0.3125 ng). All dilutions were 
mixed with 400 μl of 0.4 M NaOH/10 mM EDTA (pH 8.0) solution. The samples 
were denatured at 100oC for 5 minutes and then cooled on ice for 2 minutes. To 
prepare the blot, wet a single sheet of 3MM paper and hybridization membrane 
(Hybond N+) with water. Then, they were placed in dot-blot apparatus and 
secured with clips. All denatured DNA was added and then vacuum was applied. 
The wells were washed with 400 μl of 0.4 M NaOH/10 mM EDTA and vacuum 
was applied to dry. After that the membrane was rinsed with 2X SSC and placed 
in bottle with hybridization buffer for 1 hour at 42oC. A HRP labelled nucleic acid 
probe was prepared by diluting the probe of a promoter (Spc5-12), which were 
PCR fragments to a concentration of 10 ng/ul in sterile water (10 μl) followed by 
denaturation for 5 minutes in a boiling water bath. Immediately DNA was cooled 
on ice for 5 minutes. An equal volume of DNA labeling reagent was added and 
mix with 10 μl glutaraldehyde and added to the cooled probe and incubated for 
10 minutes at 37oC. The probe was added to the hybridization buffer. The 
hybridization was run overnight at 42oC. Blot was washed in primary wash buffer 
for 40 minutes and washed twice with 2X SSC for 5 minutes. Using ECL 
chemiluminescence, the blot was developed by adding a volume of 1:1 ratio from 
each solution in the ECL chemiluminescence kit.   
The virus was titered by serial dilution (12.5, 6.25, 3.125, 1.56 and 0.78 μl). To 
calculate the number of AAV particles number; first we calculated the MW of 
pAAV8-ERRγ plasmid in Daltons by multiplied the size of the molecule in base 
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pair (bp) which is (7700 bp) by 650 (average MW of one bp in Daltons). For 
example; for pAAV8-ERRγ plasmid (7700 bp) MW=7700 X 650 =5.01 X106 
Daltons. Then, we calculated the number of particles present in gram of DNA 
using Avogadro’s number (6.023 X1023). For example; there were 6.023 X1023 
molecules in 5.01 X106 g of this DNA which translated as 1.20 X1017 pAAV8-
ERRγ molecules per g DNA (6.023 X1023/ 5.01 X106). Then, to calculate the 
number of molecules in ng of this DNA, divided 1.20 X1017 by 109 which gave 
1.20 X108 molecules per ng of pAAV8-ERRγ DNA.  
We compared the intensity of the control and sample dots, then we estimated the 
amount of DNA in ng of the sample dots. The resulted number was multiplied by 
calculated number of molecules/ng and then by a factor of two, as the control 
plasmid is double stranded. Standard curve obtained was used to measure the 
amount of virus. 
2.6. Generation of Sequence-optimised ERRγ plasmid and viral vector: 
Optimized ERRγ sequence of mouse was generated by Geneart (Regensburg, 
Germany). We theoretically designed two plasmids expressing the same sequence-
optimized ERRγ construct. We modified the plasmids to include; 3-FLAG sequence 
(ATG-GAC-TAC-AAA-GAC-CAT-GAC-GGT-GAT-TAT-AAA-GAT-CAT-GAT-
ATC-GAT-TAC-AAG-GAT-GAC-GAT-GAC-AAG) either at 5’ or 3’end, a consensus 
Kozak sequence, GC content was increased to promote RNA stability and codon usage 
was modified according to transfer RNA frequency. Then, the two different plasmids 
expressing the same optimized sequence of ERRγ were sent for synthesis to Geneart 
Eurofins Company. Then, the two new plasmids of 5’Flag and 3’Flag codon optimized 
ERRγ were returned back with a vector backbone (PEX-K4). Both plasmids were 
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amplified following manufacturer instruction using (EndoFree Plasmid Maxi Kit, 
QIAGEN). pAAV vectors were made by excising sequence optimized genes from 
parental plasmid using (AgeI and PacI) restriction enzymes and cloned into pAAV vector 
of non-optimized sequence.  
To synthesize the codon-optimized 5’F and 3’F plasmids, double restriction digestion was 
carried out using (AgeI and PacI) restriction enzymes of noncodon-optimized ERRγ and 
the two codon optimized plasmids in order to use the back bone from the noncodon 
construct and the insert of the codon-optimized ERRγ. 
2.5.1. Restriction digestion: 
20 μg of non-optimized ERRγ plasmid and 5’F and 3’F ERRγ plasmids were 
double digested with AgeI (1 unit/ug ) and PacI (1 unit/ug ) restriction enzymes 
with 7 μl of buffer and make the total volume to 70 μl with water. The reaction 
was either incubated either for 1 hour or overnight at 37oC and then the fragments 
were separated on 1% gel (0.8 g agarose, 80 ml 1% TAE and 8 μl of syBR safe). 
After that, the bands of the backbone (6155 bp) from the non-optimized ERRγ 
plasmid and the insert (1466 bp) from the two codon-optimized plasmids were 
extracted following gel extraction kit.  
2.5.2. Ligation: 
Different ratios of the backbone to the insert were mixed with (1 μl) of ligase, (2 
μl) of T4DNA ligase buffer and make the total volume to 20 μl with water. The 
ligation reaction was incubated for 2 hr at 14oC.  
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2.5.3. Transformation: 
On ice, the ligation mix was transformed into XL-10 gold competent cells by heat 
shock (as described in section 2.3). Bacteria were plated on ampicillin agar plates 
overnight. The following day colonies were picked and added into 5 ml LB 
medium with ampicillin and incubated overnight at 32oC with shaking. 2 ml of the 
mix was run on miniprepration kit, following manufacturer instructions.  
2.5.4. Confirmation of the plasmids: 
Confirmation of the plasmids was carried out using different restriction enzymes. 
Firstly, to confirm the linearized product, single digestion using XhoI restriction 
enzyme was run and the expected size was 7617 bp. To further confirm the size, 
BsrgI and BstxI restriction enzymes were used to differentiate between the new 
codon-optimized constructs and the non-optimized plasmid. BsrgI showed two 
bands at 5587 and 2030 bp for the new constructs and single band for the non-
optimized. BstxI resulted in two bands at 4117 bp and 3583 bp for the non-
optimized plasmid and three bands at 4177 bp, 2592 bp and 908 bp for the 
sequence optimized plasmids. To confirm the presence of ITRs; the following 
restriction enzymes were used; MscI, XbaI, BsHII and SmaI. All restriction 
enzymes have been ordered from New England Biolabs.   
2.5.6. Sequencing: 
Codon-optimized ERRγ plasmids were sent to source bioscience for sequencing 
and ApE Software was used to check the sequence.  
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2.7. β-galactosidase assay: 
HEK-293T cells were seeded for 24 hours (as described in section 2.1) and then 
co-transfected with either non-codon-optimized mouse ERRγ plasmid or codon-
optimized 5’Flag or 3’Flag ERRγ and β-gal plasmid using PEI (as described in 
section 2.2). Using the kit β-galactosidase assay was performed following 
manufacturer instructions. Firstly, the cells were washed for three times with pre-
cooled PBS after removing the DMEM medium. Then, lysis buffer was added to 
the cells and incubated for 30 minutes at RT to extract all cell components. After 
that, the cell extracts were transferred to a microfuge tube and centrifuged for 15 
minutes at maximum speed to remove any cellular debris. Then, an aliquot of the 
supernatant was used for protein concentration measurement using BSA assay 
(kit) and the rest was frozen at -80oC. To run the assay, six concentrations in 
duplicate were prepared to obtain a standard curve using β-Gal stock solution 
and sample buffer using the concentrations recommended by the manufacture.  
Then, 200 μl of the β-Gal standard working dilutions and cell extracts were 
pipetted per well using the microplate provided with the kit and then covered with 
the adhesive cover and incubated for 1 hour at 37oC. The solutions were then 
removed and the wells were washed 3 times with 250 μl of washing buffer for 30 
seconds and removed washing buffer carefully. Then, 200 μl of anti- β-Gal-DIG 
working dilution were added to each well and the plate was covered with foil and 
incubated for 1 hour at 37oC. Then, the washing step was repeated. Following 
that by pipetted 200 μl of anti-DIG-POD working dilution per well, covered the 
plate with foil and incubated for 1 hour at 37oC. Then, another washing step was 
performed. Next, 200 μl of substrate with enhancer were pipetted into each well 
and incubated at RT until colour development was detectable for photometric 
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detection (approximately 30 minutes). The absorbance was measured at 405 nm 
using a microplate (ELISA) reader. For results interpretation, the β-Gal 
concentration (ng/ml) of the calibration standards were calculated and plotted on 
the x-axis against the absorbance values on the y-axis. The result was a linear 
calibration curve and used to measure the concentration for the unknown 
samples.  
2.8. Animal Housing: 
Wild type (C57BL/10 ScSnOlaHsd) and dystrophin-deficient mice (C57BL/10 
ScSn-DMDmdx/J mice) were housed in a temperature-controlled environment with 
water and food ad libitum. In vivo experimentation was conducted under statutory 
Home Office recommendation, regulatory, ethical and licensing procedure, and 
under the Animals (Scientific Procedures) Act 1986. All the animals were bred in 
the Biological Resources Unit, University of Reading. 
2.8.1. In-vivo gene delivery: 
The system was checked to ensure adequate amounts of gas supply and 
isoflurane for the duration of the procedure and the flow was set to induction 
chamber. The recovery box was adapted to 35oC. The solution to be injected was 
prepared in 19G, 1 ml syringe. The oxygen valve was adjusted to 3 L/min. The 
isoflurane was turned on to 4.5% and mouse was monitored until recumbent and 
then isoflurane flow was adjusted to 2.5% during the procedure. The mouse was 
then removed from the chamber and put gently on tissue where the oxygen flow 
was adjusted to the mouse mouth. In all experiments, no empty vector control 
was used. For intramuscular administration, skin covering mouse tibialis anterior 
(TA) muscles was shaved to allow more accurate orientation.  
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The first injection was carried out with 2.5X1010 vg of AAV8 ERRɣ in 50 μl of 
saline solution, contra-lateral TAs were injected with 50 μl of saline solution. 
Animal was moved to the recovery chamber.  
For intravenous administration, mice were warmed for 10 minutes in a hot box at 
40°C. Then, a mouse was removed and placed inside a tail-vein animal restrainer 
and the tail was sterilize with 70% ethanol. 1 X1012 vg if AAV8-ERRγ in 100 μl of 
saline solution was injected in the treated animals and similar volume of saline in 
the control animals using a 1.0 mL syringe with a 27G needle. After removing the 
needle, to stop any bleeding, the site of injection was held with gauze before the 
mice were returned to their cages. 
For intraperitoneal experiment. Mice were injected with 2 X1012 vg of AAV8 ERRɣ 
in 100 μl of saline solution just off the midline in the lower left quadrants. Control 
mdx were injected with 100 μl of saline solution. Sex and age of mice will be 
mentioned in each experiment.  
2.8.2. Tissue processing: 
Mice were sacrificed via cervical dislocation. Muscles were excised from tendon 
to tendon, weighed, blocked on a cork disc using (OCT) and rapidly frozen in 
liquid nitrogen-cooled iso-pentane. The frozen blocks were stored in -80oC. To 
assess muscle pathology, 10 µm transverse cryo-sections for each muscle were 
obtained and transferred to a clean slide and stored at -80oC. For intramuscular 
experiment, tissues were collected for RNA and protein analysis from frozen 
blocks used for histology. For all systemic experiments, one muscle leg was used 
for histology purposes and the second one was frozen for RNA and protein 
analysis. Muscles were stored at -80oC.  
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2.8.3. Muscle Function: 
Experiment was performed on EDL muscles from 9 weeks old mdx (6 weeks 
post-AAV administration) for intraperitoneal experiment and from 10 weeks old 
mdx (4 weeks post-AAV administration) for intravenous experiment. Mice were 
killed according to Schedule 1 of the animals (Scientific procedures) Act 1986, 
United Kingdom. Muscles were bathed in oxygenated Ringer solution containing 
(137 mM NaCl, 24 mM  NaHCO3, 5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 1 mM 
NaH2PO4, 11 mM Glucose; pH 7.4) kept at 25°C and continuously perfused with 
5% CO2/95% O2. Muscles were mounted in the organ bath, flanked by plate 
electrodes and attached between an adjustable clamp and a dual-mode muscle 
lever (Aurora Scientific), and were stimulated using a computer-controlled 
stimulator (Aurora Scientific). Muscles were electrically stimulated to twitch and 
gradually increased the stimulation voltage to establish supramaximal stimulation 
and then the voltage was set to 110% for the remainder of the experiment. 
Optimum length (Lo) was determined with twitch stimulation (pulse duration: 100 
msec), and muscle length was altered gradually until maximum twitch force was 
reached. A digital caliper was used to measure the distance between the 
proximal and distal myotendinous junctions (Lopt). To determine maximal 
isometric muscle force (Fmax), each muscle perform 500 msec tetanic contraction 
with 2 minutes between each contraction. EDL muscles, then, were subjected to 
ten lengthening contractions (150 Hz for 500 msec, followed by 200 msec at a 
110% Lo). After completion of the muscle measurements, muscles were weighed 
and frozen in liquid nitrogen-cooled isopentane. Force traces were analyzed with 
Dynamic Muscle Analysis v5.100 software (Aurora Scientific).  
 
 
104 
 
2.9. Creatine kinase assay (CK): 
Serum CK was assayed in blood collected from mice via cardiac puncture while 
the mice under terminal anaesthesia induced by CO2. Blood was allowed to clot 
on ice and then serum has been collected by centrifuge the blood at 8000 rpm 
for 15 minutes and stored at -80oC. The assay was run in 96 well plate using 
spectrophotometry plate reader at 37oC. 6 μl of the blood samples and 300 μl of 
the buffer (from the kit) were added into each well. The absorbance was 
measured was measured at 340 nm and readings were taken at 4 intervals; 0 
min, 1 min, 2 mins, 3 min and 4 minutes. The first reading was ignored and then, 
the absorbance was blotted against the time points. Finally, the CK level for each 
sample was measured using the following equation; CK level= (∆ab/min) X 8095.  
2.10. Histology: 
2.10.1. Succinate dehydrogenase staining:  
The largest sections from the midportion were selected for all analysis. Firstly, 
sections were air dried for 30 minutes and incubated with incubation medium; 
NBT stock, succinate stock and phenazine methanosulfate. The medium should 
be prepared freshly. NBT stock; phosphate buffer, 6.5 mg KCN,185 mg EDTA 
and 100 mg nitroblue tetrazolium, succinate stock (500 mM sodium succinate). 
For each 2 ml of NBT stock, 0.2 ml of succinate stock was added in addition to 
tiny crystal of nitroblue tetrazolium. Muscles were incubated with the stain until a 
purple colored developed. Then, sections were washed for 1 minute with distilled 
water followed by fixation in formol calcium for 15 minutes. Slides mounted with 
hydro-mount medium.  
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2.10.2. Haematoxylin and Eosin Staining: 
Sections were dried at RT for 30 minutes, then they were placed in Mayers 
haematoxylin solution for 3 minutes, slides were bluied up by washing them in 
running tap water for at least 3 minutes. Slides were then placed in 1% eosin for 
3-5 minutes. Sections were dehydrated in 100% alcohol for 3 times for 1 minute 
and cleared in xylene for minimum of 10 minutes and mounted in DPX. 
2.10.3. Immunohistochemistry protocol:  
The following protocol was used to stain laminin, IgG, embryonic myosin (MYH-
3) and myosin heavy chain (MHC) type I, IIA and IIB. Generally, sections were 
air dried for 30 minutes. Slides were washed twice in PBS-T for 5 minutes. Then, 
permeabilization buffer was added for 15 minutes. Slides were washed three 
times with PBS-T followed by incubation in washing buffer for 30 minutes. 
Primary antibody was diluted in washing buffer for 30 minutes and added to the 
sections for 1 hour at RT. After that, primary antibody was washed with washing 
buffer. Then, secondary antibody was diluted in washing buffer for 30 minutes 
and added to the section for 45 minutes at RT in the dark. Secondary antibody 
was removed by performing 3 washes with washing buffer. Following the same 
protocol, MHC type IIA and IIB myofibres were stained together on the same 
slide, however, MHC type I myofibres was stained on a serial section. The first 
primary antibody was incubated overnight and the next day the secondary 
antibody was added followed by the same procedure for the second primary 
antibody. Finally, sections were mounted with fluorescent mounting medium 
(Dako fluorescent medium).  
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Capillary density was investigated with an antibody against CD31, as a marker 
of endothelial cells and was performed by firstly blocking the sections with avidin 
for 15 minutes followed by biotin blocking solution for another 15 minutes (Vector 
Labs). Then, sections were washed with PBS-T for 5 minutes and then blocking 
the non-specific binding with 3% milk-PBS for 30 minutes. After that, the sections 
were incubated with CD31 antibody for 1 hr at RT following by washing with PBS-
T and then incubation with biotinylated secondary antibody (rabbit anti rat HRP), 
followed by washing as mentioned above. Sections were incubated with ABC-
HRP for 10 minutes, followed by washing. Sections were developed for 6 minutes 
using DAB kit (2 drops from and 4 drops from DAB substrate reagent). Next, the 
substrate was washed off with water for 1 minute and dehydrated in 100% 
ethanol three times, each for 1 minute, cleared in xylene and mounted in DPX, 
List of antibodies (Table 2.2). 
Table 2.2. List of immunohistochemistry antibodies 
 
     
Primary antibody Species Dilution Supplier Secondary antibody Dilution Supplier
Laminin Rabbit 1.200 L9393
(Sigma)
Goat anti rabbit (Alexa 633) 1.200 A11037 (Life 
Technology)
IgG Rabbit 1.200 AB6709
(Abcam)
Goat anti rabbit 
(Alexa 488)
1.200 A11034
(Life Technology)
MYH-3 Mouse 1.200 F1.652
(Santa Cruz)
Goat anti-mouse
(Alexa 488)
1.200 A11029
(Life Technology
CD31 Rat 1.150 MCA2388GA Polyclonal Rabbit anti rat 
Immunoglobulins/ HRP
1.200 (P0450)
Dako
Type I (A4.840) Mouse 1:1 DSHB Goat anti-mouse (Alexa 633) 1.200 A11037 (Life 
Technology
Type IIb (BF-F3) Mouse 1:1 DSHB Goat anti-mouse (Alexa 633) 1.200 A11037 (Life 
Technology
Type IIA
(A4.74)
Mouse 1:1 DSHB Goat anti-mouse
(Alexa 488)
1.200 A11029
(Life Technology
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2.11. Laminin image analysis: 
To calculate the cross sectional area of the muscle fibres, analysis was 
performed on the largest muscle cross sectional area using SigmaScan software. 
The intensity threshold was set to identify the area of interest. From the software, 
the number of pixel, smallest length and area were highlighted to count and 
identify each object. Then, all identified objects have individual identified number 
and the area represented by the number of pixels is determined. Then, the 
smallest fibre was identified to define its area. The spread sheet generated by 
the software contained the number of fibre with their corresponding pixels. All 
objects which were not larger than the area of the smallest fibre were 
disregarded. In the object, all objects identified by the software and did not 
corresponded to a fibre were deleted. Finally, the smallest length of each muscle 
in pixel was used to find out the area in um2. Firstly, the length was divided by 
two to calculate the radius. Secondly, the radius was multiplied by 1.255 which is 
the power of the 5X object used in the microscope and the value was used in the 
equation. Finally, the area was calculated using the equation [3.14 X (radius)2].  
2.12. RNA extraction: 
First, muscles were grounded using cooled pestle and mortar and then 
transferred into a clear tube with a flat base. After that, 500 μl of TRI reagent was 
added into each tube and homogenized using homogenizer. RNA was extracted 
Tri-reagent according to manufacturer’s instructions.    
2.13. Complementary DNA (cDNA) synthesis: 
RNA concentration was determined by spectrophotometry using Nanodrop. 
According to the RNA concentrations, 0.5 to 1 μg of RNA was reverse transcribed 
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with oligo DT using QScript cDNA Synthesis Kit following manufactory 
instruction. 
2.14. Quantitative real time polymerase chain reaction PCR (Qpcr):  
Housekeeping genes were obtained from (Primerdesign). 6 housekeeping genes 
were tested to select the highly two stable genes. 5 treated samples and 5 control 
were run for each gene. The most stable Housekeeping genes were chosen 
using (qbase Biogazelle) software, with best stability of less than 0.5. Two 
primers with highest stability were used to normalize the genes of interest. TA 
and EDL muscles were normalized to Htatsf1 and Csnk2a2, Diaphragm and 
gastrocnemius muscles to Csnk2a2 and cdc40, heart to Csnk2a2 and AP3d1, 
quadriceps to Paklip1 and Htatsf. From each sample, 5 μl are used to prepare 
arbitrary dilutions of 5 standards. Set of six primers were checked to choose the 
most stable genes among all samples. In brief, for each reaction, 7.5 μl of the 
master mix (5 μl of syprgreen, 0.5 μl of primer and 2 μl of RNAse/DNAse free 
water) and 2.5 μl of the template are run in X25 thermofast96 FastPCR Nuetral 
plates. The optimal efficiency of all primers (Housekeeping genes or gene of 
interest) falls between 90 and 110%. Relative mRNA levels were determined by 
Quantitative PCR following the cycling protocol; 3 minutes at 95oC, 15 seconds 
at 95oC and 60 seconds at 60oC, using the Perfecta SYBR Green Fast Mix). 
Primers were designed using the Blast software.  
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2.15. Western blotting: 
Muscles were powdered on dry ice and lysed using RIPA lysis buffer.  
2.15.1. Determination of protein concentration: 
Protein concentration was measured with Bio Rad DC Lowery Assay. Protease 
and phosphatase inhibitors were added to the lysis buffer. Briefly, to prepare the 
standard curve assay, two fold serial dilutions was prepared of BSA (1.4 mg/ml) 
(Bovine serum albumin) containing from 0.12mg/ml to 1.0mg/ml apart from one 
standard without BSA in order to calibrate the absorbance to zero. Into each 
standard, 2 μl of lysis buffer was loaded and the total volume make up to 20 μl 
with water. The samples were prepared with 1:10 dilution. 
200 μl of reagent A’ (200 μl and 4 μl of reagent A and reagent S) were added to 
each sample and standards followed by 800 μl of reagent B. The samples were 
left for 15 minutes then absorbance of protein samples were measured using 
spectrophotometer at 750 nm absorbance. The BSA concentration (mg/ml) of the 
standards were blotted on the x-axis against the absorbance values on the y-
axis. The resulted linear curve was used to measure the concentration of the 
unknown protein samples.  
2.15.2. Western blot protocol: 
The samples were vortexed and boiled for 5 minutes at 95oC before loading into 
the gel. Protein ladder was run alongside the samples. 20-40 μg of protein 
samples were separated by electrophoresis on TruPAGE Precast Gel for 1 hour 
at 170 volt. For transfer step, nitrocellulose membrane was used and run for 2 
hours at 50 volt. To visualize the total protein per lane, the blot was covered in 
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methanol for 1 min and then in ponceau stain for 5 minutes with shaking. 
Followed by washing in distilled water for another 5 minutes and then imaged 
using Image J software. Then, blocking buffer of non-fat milk in Tris buffered 
saline tween 20 (TBST) was used for 1 hour to block unspecific proteins. 
Immunoblotting was performed using primary antibodies against; ERRγ, Flag, 
PGC-1α, Oxpho cocktail and PERM1 diluted in 5% non-fat milk-TBST overnight 
at 4oC. The next day, blots were washed three times for 5 minutes in TBST 
followed by addition of HRP labelled secondary antibodies diluted in 5% non-fat 
milk TBST at RT for 1 hour (Table 2.3). The blots were then visualized with Clarity 
western ECL substrate detection system using Image quanta and densitometry 
analysis were then performed using Image J software.     
Table 2.3. List of western blot antibodies 
    
2.16.  Microarray analysis: 
Total RNA was extracted using the Stratagene MicroRNA kit and RNA 
resuspended in nuclease-free water. The integrity of the RNAs were assessed 
using a Bioanalyser and 5 ng used for the preparation of biotin-labeled cell extract 
using the Nugen Ovation amplification system (www.nugen.com). For each 
Primary 
antibody
Species Dilution Supplier Secondary antibody Dilution Supplier
ERRγ Rabbit 1.1000 Proteintech Rosemont, USA) 
(14017-1)
Polyclonal Goat anti-rabbit
immunoglobulins/HRP
1.2000 AP307p Merck Milipore
Flag Mouse 1.1000 Sigma, F1804 Polyclonal Rabbit anti-
mouse
immunoglobulins/HRP
1.2000
P0260
Dako
Oxphos cocktail Mouse 1.2000 Abcam, ab110413 Polyclonal Rabbit anti-
mouse
immunoglobulins/HRP
1.5000 P0260
Dako
PGC1α Rabbit 1.1000 Abcam, 54481 Polyclonal Goat anti-rabbit
immunoglobulins/HRP
1.2000 AP307p Merck Milipore
PERM1 Rabbit 1.1000 Sigma, C1orf170 Polyclonal Goat anti-rabbit
immunoglobulins/HRP
1.2000 AP307p Merck Milipore
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representative biological replicate group, 7 μg of labeled extract was hybridized 
to Affymetrix Chicken GeneChips for 20 hours. The hybridized arrays were 
washed, stained, and scanned according to the protocols set out by Nugen and 
Affymetrix.  
2.17. Statistical analysis: 
Statistical comparison between treated and control groups for all experiments 
except fibre sizing  was performed by 2-tailed student’s t test on paired samples 
in muscles from the same animal and un-paired when comparing muscles from 
different animals using sigma plot software (version 12.3). P values<0.05 were 
considered significant (* indicates p<0.01, **p<0.001, *** p<0.0001. Fibre size 
results were performed by chi-square test.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
 
 
 
 
 
 
 
 
3. Chapter Three 
Intramuscular administration of AAV8-ERRγ into 6 and 
12 week-old mdx 
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3.1. Introduction 
DMD is a genetic disorder with impaired energy homeostasis in which the 
capacity of mitochondria to produce ATP is impaired in skeletal muscles of 
human DMD and mdx mice (Even et al., 1994, Kuznetsov et al., 1998, Austin et 
al., 1992, Timpani et al., 2015). ATP is synthesized via the creatine phosphagen 
system, metabolism of glucose via glycolysis, and fatty acid oxidation. Pyruvate 
generated by glucose metabolism and acetyl CoA generated by fatty acid 
metabolism are shuttled into tricarboxylic acid (TCA) cycle and electron transport 
chain (ETC) in the mitochondria and ATP is produced by oxidative 
phosphorylation (OXPHOS) process (Rybalka et al., 2015). Dystrophin deficient 
skeletal muscles exhibit a reduction in the availability of glucose due to loss of 
NO signalling regulated by neuronal nitric oxide synthase (nNOS) due to reduced 
expression of nNOS (Ennen et al., 2013). nNOS becomes a target of calpain in 
dystrophic muscles, leading to reduced levels of NO, which is a strong regulator 
of glucose uptake and flux during muscle contraction (Hong et al., 2014). In 
addition to defects in glycolysis, dystrophic muscles exhibit defects in the TCA 
cycle, fatty acid oxidation, mitochondrial electron transport chain and the purine 
nucleotide cycle (PNC), have all been reported leading to 50% reduction in 
resting ATP level (Rybalka et al., 2015). Furthermore, loss of dystrophin disrupts 
sub sarcolemma mitochondria pool density (SSM) which in turn impair the control 
of mitochondrial localization and the capacity to generate ATP that serve to 
diminish ATP availability and promote cell death (Percival et al., 2013).   
In addition to diminished level of ATP, dystrophic muscle of mdx mice also have 
an abnormal vasculature density and an impaired blood flow. Vascular 
abnormality occurs as a result of; lower NO-dependent flow in endothelial cells 
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(EC), reduced nNOS and endothelial nitric oxide synthase (eNOS) expression 
and decreased vascular density (Loufrani et al., 2004, Palladino et al., 2013, Asai 
et al., 2007). Data have shown that the loss of (nNOS) from the sarcolemma 
caused a reduction in nNOS activity in the cytosol and a significant reduction in 
the level of NO (Tidball and Wehling-Henricks, 2014). Many mechanisms have 
been identified through which nNOS deficiency contributes to miss regulation of 
muscle development, fatigue, blood flow, inflammation and fibrosis. In skeletal 
muscle, NO could diffuse to nearby arterioles, resulting in vasodilation and 
increasing blood flow by antagonizing α-adrenergic vasoconstriction via cGMP 
mediated pathway. Therefore, NO production has been suggested to play roles 
in blood flow, vasorelaxation and angiogenesis (Tengan et al., 2012). However, 
in dystrophic muscles, due to inadequate level of NO, the sympathetic 
vasoconstriction unopposed, and the muscle is subject to ischemia (Tidball and 
Wehling-Henricks, 2014).   
Furthermore, vascular abnormality occurs in response to lower expression of 
dystrophin in vascular smooth muscle cells and EC (Ito et al., 2006). NO 
produced by (eNOS), expressed in EC, is involved in the regulation of blood 
pressure through relaxation of vascular smooth muscle cells and vasodilation of 
blood vessels (Palmer et al., 1987, Suhr et al., 2013).  
However, intracellular free calcium concentrations within SMC controls vascular 
tone. Contraction of SMC is triggered by receptor-mediated generation of the second-
messenger inositol 1,4,5-trisphosphate (IP3). IP3 mediates release of Ca+2 from 
intracellular stores and stimulates influx of extracellular Ca+2 via voltage and non-voltage-
gated Ca+2 channels (Tsai and Kass, 2009). The elevation in intracellular calcium 
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activates calcium/calmodulin-dependent myosin light chain kinase (MLCK) which 
phosphorylates myosin light chain (MLC) to activate myosin ATPase and trigger 
SMC contraction, thus increasing blood flow (Tsai and Kass, 2009). Therefore, 
the vasculature depends on the level of free Ca+2 in the cytosol of vascular 
smooth muscle cells and the sensitivity of the contractile proteins to Ca+2, which 
is determined by the extent of myosin light chain phosphorylation. It has been 
hypothesized that in vascular smooth muscle cells, the reduction in intracellular 
Ca+2 due to a defect in L-type channel leads to the hyperpolarization of the SMC 
membrane potential, followed by a reduction in the sensitivity of the contractile 
machinery by decreasing the Ca+2 sensitivity of myosin-light chain 
phosphorylation, this in turn decreases the vascular tone of SMC (Perez-Zoghbi 
et al., 2009). In addition, dystrophin deficiency in vascular endothelial cells has 
been implicated in impaired NO-dependent flow (shear stress). Consequently, an 
impaired blood flow results in ischemia and a decreased capacity of the 
vasculature to respond to flow. Shear stress is the main stimulus inducing the 
release of vasoactive agents by vascular endothelial cells for angiogenesis, 
vascular remodelling and vascular cell growth (Ando and Kamiya, 1993, Wragg 
et al., 2014). However, dystrophin was found to form a complex with caveolin-1 
calcium channel and eNOS in EC (Palladino et al., 2013). In vascular endothelial 
cells, cGMP-PKG regulates angiogenesis and vascular permeability. In the 
absence of dystrophin, the NO production and cGMP-PKG signalling are 
impaired in EC of mdx mice, leading to low responsiveness to shear stress 
(Palladino et al., 2013). Therefore, new blood vessel formation could be 
downregulated due to defects in mechanotransduction (Thomas et al., 2003, 
Sander et al., 2000, Palladino et al., 2013).  
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Moreover, NO was shown to improve protein level of VEGF in cardiomyocytes 
following treatment with NO donor, S-Nitroso-N-acetylpenicillamine (SNAP) via 
HIF-1α (Kuwabara et al., 2006). As a consequence of diminished NO in mdx 
mice, the expression of VEGF is reduced. Further, reduced blood flow leads to 
low eNOS expression, which normally exert feedback loop to induce VEGF 
expression (Baum et al., 2004); thus compounding vascular flow in dystrophic 
muscle. Together, there is a close association between reduced blood flow and 
defected angiogenesis leading to insufficient vascular density in mdx mice that 
mismatched to the metabolic need of the muscles. Augmenting angiogenesis by 
inducing the density of vascular architecture would be one way to improve muscle 
perfusion and potentially positively impact on dystrophic pathology (Loufrani et 
al., 2001, Matsakas et al., 2012). 
In skeletal muscle, dystrophin is involved in the arrangement of the microtubule 
lattice. In dystrophic muscle, the pattern of microtubule is disorganised and 
becomes denser due to absence of dystrophin. It is thought that in response to 
membrane stress such as eccentric contraction, mdx myofibres induce ROS 
production by activation of NADPH (reduced-form nicotinamide adenine 
dinucleotide phosphate) oxidase 2 (NOX2). Further, NOX2 amplify Ca+2 influx 
through stretch activated channel (SAC) (Khairallah et al., 2012). ROS production 
has also been identified following Ca+2 entry into the mitochondria (Whitehead et 
al., 2006).    
Other consequences of poor Ca+2 homeostasis in dystrophic muscle is an 
activation of necrosis. The necrotic fibres activate and release neutrophils and 
damage-associated molecular patterns (DAMPs) that promote inflammation 
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process. Then, M1 macrophage attack the necrotic myofibres and increase the 
secretion of pro-inflammatory cytokines such as tumour necrosis factor alpha 
(TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6). It has been reported that 
serum of the DMD patients shows over-expression of pro-inflammatory cytokines 
with the presence of the two phenotypes of macrophages; M1 and M2. Pro-
inflammatory cytokines play roles in regenerating myofibres which ultimately 
replaced by connective and adipose tissues when the capacity of regeneration is 
exhausted (De Paepe and De Bleecker, 2013). In addition, increased levels of 
ROS in dystrophic tissues induce pro-inflammatory cytokines, for example NF-
κB leading to activation of TNF-α and IL-1β (Figari et al., 1987, Remels et al., 
2010).  
As a consequence of the dysregulation of redox signalling and calcium 
homeostasis, the system is under high demand of ATP production for Ca+2 
buffering, satellite cell cycling and muscle regeneration which together with 
reduced capacity for ATP synthesis, reduced glucose transport and the reduced 
level of NAD results in metabolic stress in dystrophic muscle (Rybalka et al., 
2014). Therefore, it is important to improve ATP synthesis as dystrophin-
deficiency-mediated damage could be mitigated if the availability of ATP is 
improved. 
However, targeting metabolism as a therapy may have a beneficial effect on the 
pathophysiological course of DMD. Improving the oxidative phenotype of muscle 
fibres may overcome many of the pathological changes in DMD, as glycolytic 
fibres are more prone to damage due to the faster and larger accumulation of 
force during contractile activity, thus increasing susceptibility to sarcolemma 
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damage. The lower abundance of mitochondria might also accelerate the 
degeneration of glycolytic fibres due to decreased capacity to maintain Ca+2 
homeostasis (Webster et al., 1988, Pedemonte et al., 1999), as slow, oxidative 
muscle fibres are more resistant to the dystrophic pathology (Head et al., 1992, 
Webster et al., 1988). In this context, selective transgenic over-expression of 
ERRγ, PGC-1α, PPARγ in skeletal muscles of mdx mice allowed transition of the 
muscle phenotype into more slow, oxidative fibres and hence more protection 
against damage and DMD pathology (Matsakas et al., 2013, Reilly and Lee, 
2008, Summermatter et al., 2012).  
The muscles of mdx mice exhibit diminished expression of ERRγ. Matsakas et al 
demonstrated that ERRγ is expressed in highly metabolic tissues and that the 
over-expression of ERRγ in skeletal muscle of mdx mice resulted in a mitigation 
of the muscle pathology, such as a shift towards a more oxidative phenotype, 
upregulation of angiogenic factors, improved perfusion and a reduction of 
centrally nucleated fibres (Matsakas et al., 2013). Therefore, the key question in 
this study is to address the impact of the post-natal over-expression of ERRγ by 
AAV gene transfer on the muscle pathology of mdx. 
Despite the fact that (DMD) is caused by mutations in the dystrophin gene 
(Hoffman et al., 1987), the understanding of the molecular pathogenesis of 
disease and the responses to therapy remain incomplete. Hence, large scale 
parallel gene expression analysis allows the investigation of the molecular 
pathophysiological pathways and comparison of how these pathways are differed 
from healthy muscle (Haslett et al., 2002). The analysis of gene expression in the 
mdx mouse has the potential to identify potential therapeutic targets, novel genes 
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involved in disease pathology and candidates disease biomarkers relevant to 
DMD. Many expressing profiling techniques have been developed, which include 
quantitative polymerase chain reaction (Qpcr), microarray and RNA sequencing 
(RNAseq) (Roberts et al., 2015).  
Nowadays, there is increasing desire to find a connection between diseases, their 
mode of action, pathophysiology and the impact of therapeutic molecules on 
them. A connection map (cMap) is a developing technique designed to find 
connections between genes, drugs, and diseases. It is based on implying 
genomic signature such as mRNA levels, protein expression or metabolic 
patterns (Lamb et al., 2006). In other words, the effect of each selected molecule 
has been robustly defined by the cognate change in the transcriptome of the 
treated cells. Given that characteristic alterations in gene transcription (a 
signature) underpins most diseases, drugs that can ameliorate or reverse these 
transcriptional shifts will have therapeutic potential. In this way, a series of 
readily-available drug candidates can be bio-informatically generated, scored 
and ranked by their likelihood of ability to restore the normal biological state, or, 
in case of muscular dystrophy protect against further muscle loss. Accordingly, 
the c-Map resource has the potential to connect human diseases and the drugs 
that treat them (Huang et al., 2015). The main advantage of cMap is that cMap 
is agnostic to the drug targets or drugs mode of actions, as historically described; 
thus allowing a reductive process of candidate drugs that have already had 
regulatory approval. On the other hand, gene expression microarrays allows the 
measurement of genome-wide transcriptional expression levels (Yap et al., 
2007). The C-Map approach maximizes the chances of success by basing the 
search on defined factors (changes in gene transcription). This approach 
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demonstrates the power of transcriptional signature-based drug repurposing and 
highlight several advantages over other drug discovery methodologies including 
reduced time to clinic, known tolerability and toxicity profiles, non-target 
dependent mechanisms as well as potentially identifying new pathways for future 
discovery (Lamb et al., 2006). 
In this chapter, we aim to assess the effect of overexpressing ERRγ on metabolic 
activity in vitro and in vivo. Firstly, we used the mouse myoblast C2C12 cell line to 
assess the metabolic capacity of the cells following transfection with a plasmid 
expressing a murine ERRγ transgene under the control of the spc5-12 promoter. 
At the in vivo level, firstly, 6-week old mdx has been used for microarray analysis 
(n=3) to assess short term effect of ERRγ over-expression on global gene 
expression profiles in dystrophic muscle and to create a cMap. Then, we aim to 
assess the short term changes in pathology such as oxidative capacity, 
angiogenesis in tibialis anterior (TA) muscles following intramuscular 
administration (IM) of 2.5X1010 vg AAV8 ERRγ expression under the control of 
the spc5-12 promoter. (TA) is one of the most active, fast-twitch skeletal muscles. 
TA is a well defined muscle with a strong connective tissue fascia that retain fluid 
injected into the muscle. The muscle is also easy to inject percutaneously, thus 
avoiding the need for surgical exposure. Moreover, the muscle lies in the anterior 
compartment in the lower region of the hind limb. The ability to evaluate the effect 
of a treatment provides a significant rationale to demonstrate the efficacy of a 
treatment in high scale (Dellorusso et al., 2001). TA exhibits high resistance to 
fatigue during periods of intense running, making it interesting system to 
investigate the secondary consequence in DMD (Jones et al., 2009). Here, 
AAV8-ERRγ was injected into the TA muscle and recovered after 4 weeks of 
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treatment in order to examine the effect of overexpressing ERRγ on oxidative 
capacity and angiogenesis. Two main cohorts of mdx males were used; 6 week 
old (during active necrosis) and 12 week old (after the peak of active necrosis), 
(n=6). TA muscles from 12 week old mice (n=6) were blocked in groups (mounted 
on the same piece of cork) of three and TA muscles of 6 week old mice were 
blocked in groups of two. Therefore, histological analysis for mdx and mdx-ERRγ 
had n=6. However, as molecular analysis was performed on samples from the 
blocked tissues, the effective n value for this analysis is n=2. All genes in both 
aged groups (n=2) showed similar pattern of increase or decrease. Therefore, for 
molecular analysis, we grouped the data from mdx and mdx-ERRγ of 6 and 12 
weeks ending up in (n=5). Following the first study and based on the observations 
from microarray and histological analysis, another study was carried out using 6 
week-old male mdx only (n=6). Intramuscular administration of 2.5X1010 vg AAV8 
ERRγ was carried out into TA muscles. Muscles were recovered 4 weeks post 
injection and were blocked individually to assess the changes at the molecular 
level in a large number of samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
3.2. Results:  
3.2.1. C2C12 cells treated with pAAV-ERRγ plasmid or AAV8-ERRγ virus 
increase NADPH activity without increasing the cell number: 
A proliferation/MTS assay was run to examine whether over-expression of ERRγ 
using the pAAV ERRγ plasmid had an effect on increasing either the metabolic 
activity or proliferative capacity of mouse myoblast C2C12 cells. The impact on 
metabolic activity of over expression of ERRγ was also assessed in C2C12 
myotubes following transduction with AAV8-ERRγ. 
C2C12 cell proliferation assay is based on the conversion of tetrazolium 
compound into formazan product in the presence of NADH or NADPH produced 
in the metabolically active cells by dehydrogenase enzyme. C2C12 cells myoblast 
transfected with ERRγ plasmid (p=0.001) and C2C12 myotubes transduced with 
AAV8-ERRγ virus (p=0.001) showed a significant increase in the cell activity 
represented by the increase in the NADPH activity compared to the 
myoblasts/myotubes treated with control (eGFP) plasmid/virus under the same 
conditions (figure 3.1). Cell counting resulted in no difference in the number of 
cells between the control and treated myoblast groups following treatment (figure 
3.2).  
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Figure 3.1. MTS assay of C2C12 cells 
A) Transfection of C2C12 cells with (1:2) pAAV-ERRγ: PEI induced NADPH activity of 
C2C12 myoblast cells compared to control cells transfected with pAAV-GFP plasmid, 
(n=8, p=0.001). B) C2C12 myotubes were transduced either with 1 X1010 vg/well of AAV8-
ERRγ or AAV8-GFP virus for three days and showed increase in the NADPH activity of 
the transduced myotubes with AAV8-ERRγ (n=8, p=0.001, un-paired student t-test).   
 
 
Figure 3.2. C2C12 myoblast cells viability 
Transfection of C2C12 cells with (1:2) pAAV-ERRγ: PEI compared to the cells transfected 
with pAAV-GFP plasmid showed no difference in the number of cells between the two 
treatments (n=8, p=0.131, un-paired student t-test).  
NADPH Assay (Myoblast)
C
on
tr
ol 
ER
R
0.0
0.2
0.4
0.6
0.8
1.0
**
A
b
s
o
rb
a
n
c
e
 a
t 
(4
9
0
n
m
)
(A) NADPH Assay (Myotube)
C
on
tr
ol 
ER
R
0.0
0.5
1.0
1.5
2.0
2.5
**
A
b
s
o
rb
a
n
c
e
 a
t 
(4
9
0
n
m
)
(B)
 
 
124 
 
3.2.2. Principal component analysis (PCA) showed distinct expression 
profiles of mdx-ERRγ treated TA’s compared to mdx:  
Every signal from each GeneChip represented a gene expression value. Scatter 
plots of fluorescent intensity of cDNA products analysed by microarray 
hybridization (figure 3.3). Figure 3.3 A showed 0.9669 to 0.9680 interval of 
spread for mdx vs wild type; however, the interval of spread of mdx-ERRγ vs wild 
type is 0.9760 to 0.9769 (figure 3.3 B). Then, the suitability of the expression data 
sets for inclusion in the analysis and the overall relationship between and within 
the biological replicates is assessed using principle components analysis (PCA). 
Comparing the signature of the mdx and mdx-ERRγ muscles showed clear 
difference between the two groups, demonstrating that they have distinctive 
profiles (figure 3.4). From this data set one cannot be unequivacol that the mdx-
ERRγ muscles are ‘tending towards’ the wild type muscle, just simple stating that 
mdx-ERRγ muscles are distinct from mdx muscles.  
 
 
Figure 3.3. Scatter plot analysis of wild type, mdx and mdx-ERRγ following IM-
AAV8-ERRγ into 6 week-old mdx 
Scatter plot showing the log ratios of the means of differentially regulated transcripts 
between (A) mdx and control, (B) mdx-ERRγ and control and (C) mdx-ERRγ and mdx. 
All genes are represented in these plots. (Red dots represent upregulation, blue dots 
downregulation; n=3, male mdx.  
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Figure 3.4. Principle components analysis of individual experimental samples 
Principal component analysis (PCA) scores plots comparing wild type, mdx and mdx-
ERRγ. Each dot represent a muscle sample from the respective groups (% variance in 
the parenthesis; n=3).  
3.2.3. Alterations in gene ontogeny following ERRγ over-expression in 
mdx 
To verify the biological meaning of observed changes in the expression of many 
genes, statistically different genes can be functionally classified using a 
combination of Gene Ontology (GO) criteria and other molecular descriptions. 
GO biological processes were grouped into general categories, like metabolic 
process, cell proliferation, biological regulation and cell communication. The 
analysis showed that the most significant enriched pathways are related to 
metabolic process. The distributions of these categories are represented in pie 
charts (figure 3.5 A). These genes were also classified into different categories 
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according to their contribution in different molecular functions. Accordingly, 
analysis showed that the most enriched genes are involved in protein binding. 
The distributions of these categories are represented in pie charts (figure 3.5 B). 
Although, using an identical approach we found that 1429 transcripts significantly 
changed their expression greater than 2-fold between mdx and mdx-ERRγ. For 
example; CoA4 gene (cytochrome c oxidase assembly factor 4) showed 29 fold 
increase in the treated muscles, which is an enzyme involve in the maturation of 
mitochondrial complex IV. Acadl, acyl-CoA dehydrogenase, involves in β-
oxidation of fatty acid and increased by 19 fold increase. Another example is 
Fabp1 that increase by 6 fold. 
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Figure 3.5. Gene ontology following ERRγ over-expression in mdx 
A) Changes of biological processes associated with over-expression of ERRγ. The red 
colour represents the up-regulated functions and green colour shows the down-
regulated functions. B) Changes of molecular functions associated with over-expression 
of ERRγ. The red colour represents the up-regulated functions and green colour shows 
the down-regulated functions. 
 
3.2.4. Expression level of ERRγ in the TA of mdx muscles following AAV8-
ERRγ gene transfer: 
To assess the change in the expression of ERRγ following AAV8-ERRγ gene transfer 
into TA muscles of mdx mice, quantitative real time PCR (qRT-PCR) was performed 
using specific primers for each gene of interest and the relative expression was 
normalized to the house keeping genes; Csnk2a2 and Htatsf1. ERRγ mRNA was over-
expressed 3 fold in the treated muscles compared to the control (n=5, p=0.02) (figure 3.6 
A). However, despite the increase in the mRNA level, no increase in the levels of ERRγ 
protein was detectable (figure 3.6 C), although the quality of ERRγ antibodies are 
notoriously poor. 
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Figure 3.6. Quantitative analysis of ERRγ using qRT-PCR and western blot 
A) Data were generated from samples of both cohorts; 6 and 12 week old mice and were 
recovered 4 weeks post administration. 3 fold increase in the expression of mRNA 
relative transcript of ERRγ in in treated TAs muscles compared to TAs injected with 
saline (n=5, p=0.02, paired student’s t-test). The level of ERRγ was expressed relative 
to the housekeeping genes; Htatsf1 and Csnk2a2. The levels of ERRγ protein in TA 
muscles were determined by western blot analysis using 25 μg of protein and Ponceau 
stain was used for normalization. The total ERRγ was determined using ERRγ antibody. 
B) The intensity of the bands was quantified using ImageJ software. C) The values 
showed no difference in the protein level of ERRγ between the treated and control TAs, 
(n=5 male mdx, p=0.429, paired student’s t-test). 
 
3.2.5. Expression of ERRγ in transgenic muscle: 
To compare the level of ERRγ over-expression between the transgenic TA muscles from 
transgenic mice specifically express ERRγ and TA muscles from our experiment, qRT-
PCR was performed using ERRγ primer and the relative expression was normalized to 
the house keeping genes; Csnk2a2 and Htatsf1. Analysis showed 170 fold over-
expression of ERRγ in transgenic TA muscles compared to mdx-ERRγ muscles from this 
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experiment (figure 3.7). This supraphysiological over-expression is relevant with respect 
to how the data from this study, that demonstrated a modest 3 fold over-expression, is 
interpreted 
Figure 3.7. Relative mRNA expression of ERRγ in transgenic TA muscles 
Expression of mRNA relative transcript of ERRγ in tibialis anterior muscles (TA) of the 
transgenic mice compared to TA muscles from gene transfer experiment and wild type. 
170 fold increase in the expression of ERRγ in mdx-ERRγ TA muscles (n=5 male mdx, 
One way Anova, p=0.0001).   
   
3.2.6. Impact of ERRγ over-expression on markers of oxidative 
metabolism: 
Succinate dehydrogenase staining (SDH) was performed to assess whether 
overexpressing ERRγ influenced the oxidative capacity of the myofibres within 
the TA muscles. We differentiate between oxidative and glycolytic fibres based 
on the intensity of the SDH stain, those fibres with a strong dark stain were 
accounted as oxidative fibres and the fibres with weak or faint stain were called 
 
 
130 
 
glycolytic fibres. The percentage of oxidative fibres was expressed by the number 
of oxidative fibres related to the total fibres per muscle. Following ERRγ over-
expression, the percentage of oxidative fibres increased in the treated TA 
muscles compared to those injected with saline only. This shift in oxidative 
capacity was found in all experimental groups with 100% increase in SDH 
positive fibres in 6 week-old mdx (p=0.0002) and 58% increase in 12 weeks old 
mdx (p=0.001) (figure 3.8 A-B).  
In order to assess whether overexpressing ERRγ has an impact on mitochondrial 
oxidative metabolism and biogenesis, we quantified the expression of a panel of 
genes related to these processes. However, all genes related to mitochondrial 
oxidative metabolism, mitochondrial biogenesis and fatty acid oxidation were 
unaffected between two groups (figure 3.8 C). 
 
 
131 
 
 
Figure 3.8. Oxidative metabolism of TA muscles and qRT-PCR analysis of genes 
related to Oxidative metabolism, mitochondrial biogenesis and fatty acid genes 
into TA muscles following ERRγ expression 
A) The relative abundance of oxidative fibres in mdx mice treated either at 6 (p=0.002) 
or 12 weeks (p=0.001) and samples were recovered 4 weeks later, based on 
quantification of an entire TA section. Data are expressed as a percentage (%) of total 
fibres, (n=6 per group, male mdx). B) Representative images of cross sections of mdx 
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and mdx-ERRγ TA muscles stained for SDH activity. Scale bar, 200 μm. C) Relative 
mRNA expression of genes involved in mitochondrial oxidative metabolism, 
mitochondrial biogenesis and fatty acid metabolism were unchanged with the over-
expression of ERRγ. The level of the test genes were expressed relative to the 
housekeeping genes; Htatsf1 and Csnk2a2. PERM1 (p=0.08), ND2 (p=0.499), TFAM 
(p=0.211), ERRα (p=0.455) and PGC-1α (p=0.696), PPARγ (p=0.757), PPARα 
(p=0.888), PPARδ (p=0.493), CPT1α (p=0.543), CPTβ (p=0.993), CAT (p=0.416) and 
utrophin (p=0.407), (n=5, paired student’s t-test). 
 
3.2.7. Moderate over-expression of ERRγ does not affect fibre typing  
Tibialis anterior muscle is a mixture of type IIA, IIB and IIX myofibres. To assess 
whether ERRγ gene delivery has any impact on the distribution of muscle fibre 
types, we stained muscle cross sections with antibodies against different MHC 
isoforms to quantify the relative fibre type content. Based on this approach, ERRγ 
has no effect on fibre type composition either in mdx mice treated at 6 week or 
at 12 weeks old (figure 3.9).  
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Figure 3.9. Myosin heavy chain analysis in TA muscles following IM of AAV8-ERRγ 
A) The relative abundance of different fibre types in TA, based on quantification of an 
entire TA section. Myosin heavy chain (MHC) analysis in mdx and mdx-ERRγ shows no 
difference in the number of fibre types in mdx mice treated at 6 weeks IIA (p=0.52), IIB 
(p=0.25) and IIX (p=0.35) or 12 weeks cohort IIA (p=0.10), IIB (p=0.25) and IIX 
(p=0.617), (n=6 per group, male mdx paired student’s t-test). B) Representative images 
of cross sections show the midportion of mdx and mdx-ERRγ TA muscles stained with 
antibodies against MHC isoforms, as indicated. Scale bar, 200 μm.  
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3.2.8. Moderate over-expression of ERRγ does not affect fibre size 
Laminin was used to assess the cross sectional area (CSA) of individual fibres. 
Individual fibre size was determined in the entire muscle cross section. Although, 
mdx mice have a high distribution of type IIB fibres which exhibit the largest CSA, 
however, the administration of the AAV8-ERRγ in all experimental groups did not 
result in any change in fibre size compared to control muscles. Analysis did not 
show any significant shift in the CSA of the fibres in all groups (figure 3.10). 
 
Figure 3.10. Cross sectional area of TA muscles following IM of AAV8-ERRγ 
A and B) Distribution of fibre cross-sectional area of mdx and mdx-ERRγ TA muscles 
treated at 6 (p=0.323) and 12 weeks of age (p=0.15), respectively with no shift in fibre 
size, (n=6 per group, male mdx, Chi square). C) Representative images of cross sections 
of mdx and mdx-ERRγ TA muscles immunostained with anti-laminin antibody. Scale bar, 
200 μm. 
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3.2.9. Effect of ERRγ over-expression on angiogenesis: 
The impact of ERRγ over-expression on angiogenesis markers and capillary 
density was investigated by assessing angiogenic factors and CD31 staining. 
VEGF-165 isoform is one of the angiogenic factors, increased by 1.6 fold in the 
mdx-ERRγ compared to the control mdx (p=0.018). Moreover, CD31 is a vascular 
endothelial marker was used to assess the capillary number. However, 
Intramuscular administration of the virus into TA muscles does not increase the 
capillary number neither in mice treated at 6 nor in 12-week old (figure 3.11).  
 
 
136 
 
 
Figure 3.11. Effect of ERRγ over-expression on angiogenesis in TA muscles 
following IM of AAV8-ERRγ 
A) VEGF-165 mRNA levels were determined by qRT-PCR, normalized to Htatsf1 and 
Csnk2a2. VEGF-165 expression was increased by 1.6 fold compared to untreated 
muscle, (n=5, male mdx, p=0.018, paired student’s t-test). B) Capillary density of mdx 
and mdx-ERRγ TA muscles, quantified by CD31-stained muscles, using ImageJ 
software shows no increase in the number of capillary number per fibre either in mdx 
mice treated at 6 weeks (p=0.233) or 12-weeks of age (p=0.983), (n=6 per group, male 
mdx, paired student’s t-test). C) Representative images of cross section of mdx and mdx-
ERRγ TA muscles stained with anti-CD31 antibody. Scale bar, 100 μm. 
 
 
137 
 
3.2.10. Haematoxylin and Eosin analysis: 
The percentage of centrally nucleated fibres was calculated using ImageJ 
software. It was found that administration of AAV8-ERRγ in the treated muscle 
was able to decrease the level of central nucleation from 81% to 73% in the mice 
treated at 6-weeks of age (p=0.006). However, there was no reduction in the 
number of central nuclei in the 12-week cohort as shown in (figure 3.12).   
 
 
Figure 3.12. H&E stain of centrally nucleated fibres in TA muscles following IM of 
AAV8-ERRγ 
A) Percentage of centrally nucleated fibres in mdx and mdx-ERRγ TA muscles of mdx 
mice treated at 6 or 12 weeks of age shows 10% decrease in centrally nucleated fibres 
in 6 week old mdx-ERRγ compared to mdx (p=0.006) but no change in the 12 weeks old 
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mice cohort (p=0.935), (n=6 per group, paired student’s t-test). B) Representative 
images of cross sections of mdx and mdx-ERRγ TA muscles stained with H&E. Scale 
bar, 50 μm.  
3.2.11. Embryonic myosin analysis (MYH-3): 
Myofibre regeneration was assessed by assessing expression of embryonic 
myosin heavy chain (MYH-3) within the muscles (Haslett et al., 2002). MYH-3 is 
expressed mainly during the embryonic stage of skeletal muscle development 
and is re-expressed during muscle regeneration. However, over-expression of 
ERRγ resulted in 2% significant reduction in the percentage of regenerating fibres 
in 6 week old cohort (p=0.001) but was not significant in 12 week old cohort 
(p=0.092) (figure 3.13).  
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Figure 3.13. Embryonic myosin heavy chain (MYH-3) analysis in TA muscles 
following IM of AAV8-ERRγ 
A) Percentage of positive fibres expressing MYH-3 in the entire TA from mdx and mdx-
ERRγ shows significant reduction in the MYH-3 positive fibres in TA of mdx-ERRγ from 
the group treated at 6 weeks old compared to mdx (p=0.001) but not in 12 weeks cohort 
(p=0.092), (n=6 per group, paired student’s t-test). B) Representative images of cross 
section of mdx and mdx-ERRγ TA muscles immunostained with anti-MYH-3 antibody. 
Scale bar, 100 μm.  
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3.2.12. Moderate over-expression of ERRγ is not sufficient to reduce 
necrotic muscle fibres  
Muscle fibre necrosis was assessed by scoring for IgG positive fibres to assess 
the sarcolemma integrity. However, the percentage of necrotic fibres was not 
different between mdx and mdx-ERRγ neither in 6 weeks nor in 12-weeks cohorts 
(figure 3.14). 
 
Figure 3.14. IgG staining of damaged fibres in TA muscles following IM of AAV8-
ERRγ 
A) The percentage of IgG positive fibres in the entire TA from mdx and mdx-ERRγ shows 
no reduction in the percentage of damaged fibres in the mdx mice treated at 6 (p=0.529) 
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or 12-weeks old (p=0.401), (n=6 per group, male mdx paired student’s t-test). B) 
Representative images of cross section of mdx and mdx-ERRγ TA muscles 
immunostained with anti-IgG antibody. Scale bar, 200 µm. 
3.2.13. The impact of AAV8-ERRγ gene transfer in 6 weeks old mdx on 
oxidative capacity, angiogenesis and inflammation in the second 
study: 
From the histological observations, intramuscular administration at 6 weeks of 
age showed reduced pathology associated with an increase in the percentage of 
oxidative capacity by SDH staining, reduced central nucleated fibres and the level 
of regeneration by embryonic myosin MYH-3. Therefore, we carried out similar 
experiment at 6 week-old male mdx in order to analyse genes at molecular level 
in a larger number of samples because the previous data of qRT-PCR were 
based on pooled samples of 6 and 12 weeks. SDH staining activity showed a 
significant increase in the TA muscles treated with AAV8-ERRγ as shown 
previously (figure 3.15).  
However, microarray data showed less than 2 fold difference in some genes of 
interest, the only gene that showed significant difference was IL-6 (inflammatory 
cytokine). Therefore, we analysed the key genes of interest related to oxidative 
angiogenesis and inflammation markers using qRT-PCR. Analysis was 
performed on TA muscle obtained from mdx mice treated at 6 weeks of age, 
(n=6) and run to assess the effect of ERRγ over-expression on genes related to 
oxidative metabolism, angiogenesis and inflammation. Relative transcript mRNA 
level of ERRγ showed significant increase following intramuscular administration 
of AAV8-ERRγ by 5 fold (figure 3.16 A; p=0.01). However, genes related to 
oxidative metabolism or angiogenesis showed no difference between the treated 
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and the contralateral TAs as observed previously. Pro-inflammatory markers; IL-
1β and TNF-α were significantly reduced in the treated TAs (p=0.039), (p=0.046) 
respectively, but not with IL-6 (figure 3.16 D).  
 
 
Figure 3.15. SDH staining activity of TA muscles following over-expression of 
ERRγ at mdx mice treated at 6 weeks-old  
The relative abundance of oxidative fibres in mdx and mdx-ERRγ in mdx mice treated at 
6 weeks old, based on quantification of an entire TA section. Data are expressed as a 
percentage (%) of total fibres, (n=6, male mdx, paired student’s t-test, p=0.003). 
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Figure 3.16. Real time PCR analysis of genes involved in oxidative metabolism, 
angiogenesis and inflammation 
RNA levels for the indicated genes were determined by qRT-PCR, normalized to 
housekeeping genes; Htatasf1 and Csnk2a2 levels mdx, (n=6, male mdx, paired 
student’s t-test). A) 5 fold increase in the expression of ERRγ (p=0.01). B) Relative 
expression of oxidative metabolism markers revealed no significant difference to control; 
Sdha (p=0.671), Sdhc (p=0.417), NduFp (p=0.288), Cox5 (p=0.711), Atp5 (p=0.214) and 
PERM1 (p=0.915). C) Expression of VEGF-165 angiogenesis marker was unaffected 
following ERRγ over-expression (p=0.892). D) Inflammatory markers; IL-1β and TNF-α 
were significantly decreased by 5.5 fold (p=0.039) and 1.9 fold (p=0.046) respectively, 
IL-6 was unaffected (p=0.468)  
 
3.2.14. Connectivity map (cMap): 
The gene expression core signature was uploaded to cMap in order to identify 
substances that cause either similar or opposite effects on the expression of the 
core signature genes. In other words, we screened for compounds that result in 
a similar (agonistic) or dissimilar (antagonistic) expression profile. The resulting 
compounds were ranked based on their enrichment score. This value is a 
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measure for the strength of the correlation of the gene expression profile provided 
and the profile of the substances deposited in the database. This resulted in 94 
drugs with a highly positively correlated and 35 substances with a highly 
negatively correlated gene expression profile (Appendix). The list showed drugs 
with anti-inflammatory, anti-apoptotic properties that positively correlated the 
genomic profiles of ERRγ over-expression. However, the screening approach 
successfully identified substances that 1) have already been shown to be useful 
in human diseases; diflorason and pancuronium bromide 2) under current 
investigation; benfotiamin and ebselen and 3) are so far unknown but promising 
candidates; eucatropine. 
3.3. Discussion: 
The data has shown here represent the first evidence of the effect of post-natal 
over-expression of ERRγ in mdx mice. Data has shown an increase in SDH 
activity, a decrease in centrally nucleated fibres and a reduction in the 
inflammation markers in the 6 week-old mdx. 
Initially, C2C12 myoblast cells were transfected with murine p-AAV8-ERRγ 
plasmid and C2C12 myotubes cells were transduced with AAV8-ERRγ virus. The 
MTS assay results suggested a role of ERRγ in increasing the metabolic activity 
of the cells and is further confirmed by cell counts, where no change in the 
number of cells was observed. Rangwala et al., showed upregulation of 
mitochondrial function in response to over-expression of ERRγ in primary mouse 
myotubes represented by induced expression of fatty acid metabolism genes 
(Cpt1b and fabp3) and citrate synthase activity. Moreover, genes of mitochondrial 
ETC, fatty acid oxidation and TAC were increased  (Rangwala et al., 2010). 
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Therefore, since number of the cells unchanged and MTS assay increased in 
myoblast and myotubes, therefore MTS assay has to be due to increased activity 
per cell not more cells.  
Scatter plots of the transcriptomic data demonstrates that mdx TA muscle 
overexpressing ERRγ has different distribution of genes expression compared to 
the mdx-control. Following over-expression of ERRγ, 1429 transcripts 
significantly changed their expression greater than 2-fold between mdx and mdx-
ERRγ. Based on global gene expression, the range of spread following ERRγ 
over-expression has been narrowed down by 1% compared to the mdx. Principal 
component analysis (PCA) was run to study the relationship within and between 
biological replicates and to study the overall distribution of gene expression. PCA 
has demonstrated a clear difference between the wild type and mdx as expected. 
More importantly, treated TA muscles are distinct from mdx, such that these 
muscles are moved away from diseased phenotype. This shift means that treated 
muscles do not exhibit the same gene expression pattern as mdx and therefore 
over-expression of ERRγ may play a role in rescuing the disease pathology. PCA 
analysis provides further support that over-expression of ERRγ at 6 weeks of age 
may improve the pathology associated with the disease. The distinct difference 
between the expression patterns of mdx and mdx-ERRγ does not imply the 
differences are positive per se, however other data, disclosed herein, and the 
gene ontology data give confirmatory evidence that this shift is positive.  
As mentioned earlier, the loss of dystrophin in both mdx and DMD, ultimately 
results in impaired oxidative phosphorylation and reduced expression of 
mitochondrial genes, leading to defects in ATP production, which is hypothetically 
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involved in disease pathogenicity (Kuznetsov et al., 1998, Even et al., 1994, 
Timpani et al., 2015). Previously, it has been shown that a selective over-
expression of ERRγ in transgenic mdx mouse muscle, reprogram defects in mdx 
mice by restoring the metabolic and angiogenic program through upregulation of 
mitochondrial oxidative capacity (SDH activity) angiogenesis factors (VEGF-165 
and VEGF-189) as they are downregulated compared to wild type (Matsakas et 
al., 2013). Further, ERRγ induced a shift towards slow-oxidative fibres, improved 
vasculature and blood flow which ameliorated muscle damage in mdx. A 
limitation to that work, however, is that the beneficial effects of ERRγ were 
demonstrated in transgenic animals and perform at supraphysiological levels and 
in the context of disease prevention rather than treatment. Although using 
genetically modified mouse model is a powerful tool in understanding the 
molecular mechanism underlying specific gene, however, there are significant 
limitations of genetically modified mouse. The presence of a phenotypic outcome 
does not always reflect the function of the modified genes and can be influence 
by other environmental and genetic factors for example; the potential functional 
alteration of neighbouring genes and therefore the interpretation of the findings 
is not always straightforward. In addition, the transgenic mice allow stable 
expression of the transgene from the embryonic life (Lin, 2008, Babinet, 2000). 
In this chapter, we assessed the short term effect of postnatal over-expression 
of ERRγ on two ages of mdx mice; active degeneration/regeneration period at 6 
weeks and the period after crisis at 12 weeks of age.  
Subsequent to the in vitro analysis, we assessed the impact of over expression 
of ERRγ on mitochondrial function and angiogenesis in mdx mice. Mice treated 
with AAV8-ERRγ via intramuscular administration route lead to a 3 fold increase 
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in the transcript level of ERRγ and increased muscle oxidative capacity as 
showed by SDH staining in all treated groups either at 6 or 12 weeks of age. 
Despite the increase in the oxidative capacity of the fibres which is represented 
by SDH staining, none of the genes related to oxidative metabolism and 
mitochondrial biogenesis (PERM1, ND2, TFAM1, ERRα, PGC-1α, utrophin) or 
fatty acid oxidation (PPARα, PPARγ, PPARδ, CTP1α, CTP1β, CAT) were 
affected at the transcript level. Similarly, in the second study on 6-week old mdx, 
SDH activity was increased. Further, expression of ETC genes (Sdha, Sdhb, 
NduFp, Cox5, Atp5) and down stream target of ERRγ (PERM1) were not affected 
with the 5 fold over-expression of ERRγ. Compared to our results, transgenic 
mice which specifically overexpress ERRγ in mdx mice, resulted in remodelling 
the oxidative capacity of the fibres as shown by increasing the number of 
oxidative fibres represented by SDH staining. Moreover, transgenic over-
expression of ERRγ in wild type mice showed an increase in PPARα and δ, the 
latter is a metabolic regulator known to involve in a shift towards slow-oxidative 
fibres and is downregulated in mdx mice. Further, the genome wide expression 
showed upregulation in the genes of fatty acid metabolism (CTP1α, CTP1β, CAT) 
and ETC (Sdha, Sdhb, NduFp, Cox5, Atp5) (Narkar et al., 2011), however, 
sarcolemmal utrophin expression was not different (Matsakas et al., 2013, 
Rangwala et al., 2010, Narkar et al., 2011). These results suggest the 
tremendous difference in the supraphysiological over-expression of ERRγ in 
transgenic mice with 170 fold compared to the modest over-expression we 
achieved in this study could be one of the factors that result in unchanged level 
of the expression of the genes examined in our study. Moreover, treatment of 
mouse myoblasts with GSK4716, an agonist for ERRβ/γ resulted in over-
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expression of oxidative metabolism genes; ERR α, β, γ, PGC-1α, β and key 
genes of mitochondrial pathways; Cpt1b, fatty acid metabolism gene, Atp5b, ETC 
genes and Idh3, function in Krebs cycle (Rangwala et al., 2010). These results 
could be time dependent since the effect of agonist in tissue culture was 
assessed 48 hours following treatment only. It is important to consider that the 
response may changed following different lengths of treatments. In the same 
way, effect of adiponectin of fatty acid utilization was shown to be time-dependent 
as the expression of PPARα target genes; CPT1 and AcO peaked at 3 hours 
following treatment of adiponectin and then slowly reduced to basal level after 24 
hours (Yoon et al., 2006). Therefore, it would be better to investigate the effect 
at different time points to give better understanding if the response is time 
dependent. Another comparison to our results is the upregulation of 
transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-γ 
coactivator-1α (PGC-1α) that ameliorated DMD pathology, promoted fast to slow 
fibre type transition and increased mitochondrial genes using transgenic model 
(Handschin et al., 2007) and gene transfer approach (Selsby et al., 2012). The 
results of the previous two studies are different to the outcomes presented in this 
chapter following over-expression of ERRγ, possibly due to different time of 
intervention and exposure time as they inject neonatal mice in order to prevent 
disease, whereas, the injection here take place at 6 weeks as a strategy to protect 
muscle from further decline. PGC-1α was downregulated in primary mouse 
myotubes transduced with adenovirus (AD) mediated expression of ERRγ 
(Rangwala et al., 2010) and was not affected in the mdx transgenic muscle of 
ERRγ (Matsakas et al., 2013), despite being a coactivator of ERRs (Godin et al., 
2012), which suggest that ERRγ works independent of PGC-1α. Moreover, in 
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contrast to our result, induced expression of peroxisome proliferator-activated 
receptor γ coactivator 1 and estrogen-related receptor induced regulator in 
muscle-1 (PERM1) via AAV approach in cultured C2C12 myotubes and in 
C57BL/6J mice regulate mitochondrial biogenesis and oxidative capacity as well 
as angiogenesis via the transcriptional induction of VEGF (Cho et al., 2016, Cho 
et al., 2013). These results are different possibly due to the use of wild type mice 
rather than mdx, in which fibrosis may interfere with the virus delivery and hence 
limit the amount of available tissue to target with gene therapy (Bernasconi et al., 
1999), as well as the amount of oxidative and metabolic stress may influence the 
outcomes. In addition, active cycle of degeneration/regeneration at 6 weeks of 
age may result in virus cargo loss. Previously, it has been shown that AAV 
mediated expression of U7 for dystrophin exon skipping were lost from mdx mice 
within 3 weeks after intramuscular injection (Le Hir et al., 2013). It is possible the 
virus has been lost in this study as another reason of unchanged protein level of 
ERRγ. Herein, unaffected expression of the previous tested genes in this study 
may be due to the modest over-expression of ERRγ compared to transgenic 
muscle or the time of intervention where the active cycle of regeneration and 
degeneration at 6 weeks of age diminishes the activation of ERRγ pathway due 
to AAV loss. However, the increase in the SDH activity could be due to the fact 
that protein level is not a representation of the transcript level. Therefore, it is 
important to consider that all genes were measured at one time point only, which 
suggest the need to check other time points in which the genes may showed a 
difference. In the same pattern, ND2 gene in H2K dystrophic cells showed no 
effect following 24 hours CBD treatment. However, assessing its expression at 
different time points (1-24) hours showed a peak of over-expression at 12 hours 
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and then it returns back to normal (Foster et al., personal communication). 
Therefore, we could speculate that all of these genes were upregulated at some 
point during (4 weeks) of expressing ERRγ and resulted in adaptive responses 
in terms of enhancement of SDH activity and then reverse back to their basal 
level.  
In DMD, more oxidative slow skeletal muscle fibres are known to be more 
resistant to the dystrophic pathology compared with faster, glycolytic fibres (Head 
et al., 1992). An abundance of recent evidence shows that induction of slow 
myofibre program, whether via transgenic (Matsakas et al., 2013), 
pharmacological (Ljubicic et al., 2014), physiological (Ljubicic et al., 2011) or 
gene therapy (Selsby et al., 2012) methods ameliorates the dystrophic pathology 
in mdx mice possibly due to their capability to generate more ATP as they are 
rich in mitochondria. Generally, loss of dystrophin leads to progressive increase 
in oxidative fibre content because of a selective loss of fast fibres; IIB and IIx 
(Webster et al., 1988, Petrof et al., 1993b). In contrast to the previous works 
where mdx mice specifically transgenically overexpress ERRγ in skeletal 
muscles (Matsakas et al., 2013, Rangwala et al., 2010), gene delivery of ERRγ 
into TA muscles does not result in an increase in type IIA and IIX myofibres and 
no change between the treated and the control in type IIB myofibres within all 
cohorts. In transgenic mice, the development of the myosin heavy chain isoform 
takes place during embryogenesis while in this experiment specifically the 
administration was delivered postnatally. On the other hand, over-expression of 
PGC-1α using an AAV approach, induced a shift towards slow twitch type I fibres 
in soleus muscle when PGC-1α was over-expressed prior to the initial onset of 
myofibre damage when they were injected as neonates (Selsby et al., 2012), 
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whereas in this work we sought to determine the impact of ERRγ in TA muscles 
during the early regenerative phase, which follows the first wave of necrosis. This 
difference could be due to the use of different muscles in which soleus muscle 
contained predominantly slow twitch (type I) fibres (Gollnick et al., 1974). In 
contrast, TA muscle is considered glycolytic with type IIB fibres being 
predominant (Kammoun et al., 2014). In turn, over-expression of ERRγ either at 
6 or 12 weeks has no effect on fibre type distribution.  
Rangwala et al., showed a decrease in the size of fast twitch muscle parallel to 
the shift towards slow twitch muscles which have smaller size in transgenic mice 
specifically overexpressing ERRγ (Rangwala et al., 2010). However, our data 
demonstrated no difference in the fibre size in all aged animal which is consistent 
with the MHC data. However, it is important to note that there was no increase in 
the total number of the fibres in the treated muscles compared to the control, thus 
confirming that the postnatal shift in the oxidative capacity was due to increase 
in oxidative potential of the muscles not the number of the fibres.    
We then evaluated the potential of vascular differences in mdx muscles following 
the over-expression of ERRγ. Compared to wild type muscle, vascular density 
has been shown to be reduced in mdx mice as a result of reduced availability of 
NO in the muscle cells due to miss-localization of nNOS and leads to muscle 
ischemia and impaired blood flow (Loufrani et al., 2004, Messina et al., 2007). 
Also, satellite cells isolated from mdx mice exhibit decreased expression of 
hypoxia inducible factor 1 α (HIF-1α), VEGF and a decreased ability to induce 
angiogenesis (Rhoads et al., 2013). Previously, it was shown that adenovirus 
mediated expression of ERRγ increased the expression of VEGF gene and 
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induced the secretion of VEGF in C2C12 myotubes. Further, incubating human 
umbilical vein endothelial cells (HUVECs) with the condition medium from ERRγ-
overexpressing C2C12 myotubes, increased proliferation, migration and tube 
formation of HUVECs (Liang et al., 2013). These results propose that VEGF is a 
downstream target of ERRγ over-expression and hence, proliferation, migration 
and tube formation of endothelial cells were mediated by VEGF. Furthermore, 
transgenic over-expression of ERRγ in mdx mice upregulate angiogenic factors; 
VEGF-165 and VEGF-189 (Matsakas et al., 2013). Our results showed different 
outcomes on VEGF-165 expression. For example; when muscles from the two 
groups were combined, the expression of VEGF-165 increased. Thereafter, the 
moderate upregulation of VEGF-165 was not supported by an increase in the 
number of capillary per fibre in both groups possibly due to the fact the data of 
qRT-PCR was generated from pooled samples of two different ages and does 
not represent the direct effect of overexpressing ERRγ on each cohort, as it 
mentioned earlier that samples were mounted on the same cork for each group 
which then require large number of samples to perform proper statistical analysis, 
therefore pooled samples were used. It is important to consider that single 4 
weeks timepoint in this study is possibly not sufficient to detect these changes 
and adaptive responses may still be ongoing. Nevertheless, assessing over-
expression of VEGF-165 on higher number of muscles from 6 weeks old mdx 
demonstrated unchanged expression following 5 fold over-expression of ERRγ. 
Therefore, over-expression of ERRγ has no effect on the level of angiogenesis 
when administered at the stage of active cycle of regeneration and degeneration 
(6 weeks). Previous studies conducted in wild type mice with transgenic over-
expression of PGC-1α, PGC-1β or ERRγ (Arany et al., 2008, Chinsomboon et 
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al., 2009, Narkar et al., 2011) and in mdx mice with transgenic over-expression 
of ERRγ (Matsakas et al., 2013) showed upregulation in the expression level of 
angiogenic markers in contrast to postnatal over-expression of ERRγ in mdx. 
Possibly, the expression of ERRγ here is much more moderate comparing to 
transgenic models and the virus only expressed for short length of time, hence is 
not enough to increase expression of VEGF-165 and capillary number in mdx 
fibres. Furthermore, in comparison to our result, intramuscular administration of 
AAV mediated expression of VEGF into 4 week old mdx mice induced the 
capillary number per fibre following 3 fold increase in the VEGF protein level 
(Messina et al., 2007). Since the length of VEGF expression in that study was 4 
weeks, similar to the length of expressing ERRγ in our study, the different time 
of intervention is the main difference between the two studies.  
A cumulative index of pathology that measures muscle damage and regeneration 
over the life of the mouse is reflected in the presence of centrally nucleated fibres 
(Deasy et al., 2009). Non-centrally nucleated fibres are an indicator of those 
spared from damage. Between 3-4 weeks of age, mdx mice start the first wave 
of fibre necrosis followed by a regeneration process, featured by a centrally 
nucleated fibres and results in replacement of a large proportion of the damaged 
fibres by 5-6 weeks of age (Gillis, 1999). In our study, the reduction in the number 
of fibres with central nucleation suggest that degeneration/regeneration has been 
slowed by the over-expression of ERRγ at 6 weeks of age but not at 12 weeks 
whereby the over-expression has no effect on reducing the centrally nucleated 
fibres. It has been reported that between 12-24 weeks of age, the cycle of 
degeneration/regeneration reaches a steady state level (Gillis, 1999). Previous 
study on treating mdx of 12 weeks with GW501516 and AICAR agonists of 
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PPARγ and AMPK separately or in combination, for 4 weeks, reduced centrally 
nucleated fibres which is opposite to our result (Jahnke et al., 2012). The 
difference to our study was possibly due to the level of activation of PPARγ and 
AMPK, as the GW501516 and AICAR agents were injected more than once per 
week and as a consequence induced the reduction in central nucleated fibres 
compared to the modest over-expression of ERRγ with a single injection only. 
This reduction in centrally nucleated fibres was further supported by the reduction 
of embryonic myosin heavy chain involved in muscle regeneration.  
Expression of MYH-3 is a hallmark of muscle regeneration dystrophy (Haslett et 
al., 2002) and regeneration was assessed because it is an indicator of damage 
previously experienced by the muscle. Regenerative fibres were significantly 
lower in the 6 weeks treated muscles but not in12-week in consistent with central 
nucleation results. In general, decreased number of embryonic myosin heavy 
chain positive fibres could be explained as an indicator of decreased capacity for 
repair or decreased damage (Hollinger and Selsby, 2015). As centrally nucleated 
fibres were less following ERRγ over-expression in 6 weeks treated mice, MYH-
3 data supported the idea that over-expression of ERRγ decreased muscle 
degeneration. Possibly, the over-expression of ERRγ drive an impact on 
membrane integrity and hence the reduction in central nucleation and MYH-3 is 
an indication of less muscle turnover and less damage. Increased expression of 
PGC-1α in 12 month old mdx mice using AAV approach showed functional 
improvements and an increase of MYH-3 positive fibres with no change in the 
expression of the genes examined (Hollinger and Selsby, 2015). Therefore, we 
could argue that reduced level of MYH-3 and a reduction in the percentage of 
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central nucleation in this study is an example of an initial adaptive response to 
the AAV8-ERRγ, despite no change was observed in the protein level of ERRγ.    
In this study, necrotic muscle fibres were observed in larger groups of fibres in 
muscle tissue, whereas in the treated mice, the necrotic fibres were observed as 
scattered small groups or individual fibres within the muscle tissue, however, 
there was no significant reduction in the IgG uptake by muscle fibres following 
the over-expression of ERRγ neither in 6 nor in 12 week old treated mdx, which 
is inconsistent with the observed reduction in the central nucleation and MYH-3 
positive fibres. We anticipated that a reduction in central nucleation and 
regenerated fibres as an adaptive response to the presence of the vector before 
being lost due to active degeneration/regeneration, which cannot be definitive as 
has not assessed. However, the integrity of the membrane was not maintained 
due to loss of dystrophin, which highlight the need to recue dystrophin for any 
gene therapy for DMD (Le Hir et al., 2013). It has been demonstrated that optimal 
restoration of dystrophin is required to protect against pathology. If not, the loss 
of the therapeutic gene will, at best, establish transient improvement. Compared 
to our study, over-expression of PGC-1α at 3 weeks of age reduced the necrotic 
area in soleus muscle with no difference in the centrally nucleated fibres 
(Hollinger et al., 2013), possibly because different muscles exhibit different 
degree of damage and that soleus-oxidative muscle is less prone to damage than 
TA, glycolytic muscle (Webster et al., 1988, Pedemonte et al., 1999). However, 
multiple factors are involved in muscle fibre necrosis, where disruption of Ca+2 
homeostasis activates proteases such as calpain which are involved in protein 
degradation, including cytoskeletal and membrane proteins that lead to necrosis. 
Previous studies on treating mdx with GW501516 and AICAR agonists of PPARγ 
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and AMPK separately or in combination reduced levels of central nucleation, the 
number of regenerated fibres and gene involved in degeneration, e.g. miRNA-
31. That reduction was combined with decreased expression of FOXO-1, 
involved in muscle atrophy and IgM uptake by the fibre (Jahnke et al., 2012). 
Therefore, it is possible that a reduction in regeneration fibres (MYH-3) in this 
study is due to reduced expression of genes involved in atrophy. However, further 
investigation on genes related to repair process such as; paired box 7, myocyte 
enhancer factor 2c and myogenic factor 5 will give better understanding on the 
role of ERRγ on muscle repair.   
It has been reported that levels of TNF-α and IL-1β are upregulated in DMD 
serum compared to healthy muscles (Kumar and Boriek, 2003, De Paepe and 
De Bleecker, 2013, Barros Maranhao et al., 2015). Matsakas et al., showed 
increased expression of pro inflammatory cytokines; TNF-α, IL-1β and IL-6 in the 
mdx muscles compared to C57 wild type muscles (Matsakas et al., 2013). Here 
we demonstrated that over-expression of ERRγ in TA muscles of mdx mice at 6 
weeks of age resulted in a reduction in the expression level of pro-inflammatory 
cytokines; IL-1β and TNF-α. Previously, it has been demonstrated that 
downregulation of TNF-α and IL-1β pathways improves the dystrophic phenotype 
in mdx mice (Hodgetts et al., 2006). For example; partial blocking of IL-1β in mdx 
mice via Kineret, which is a recombinant IL-1 receptor antagonist approved by 
the FDA for treating rheumatoid arthritis, has improved forelimb grip strength 
(Benny Klimek et al., 2016). In contrast to our study, over-expression of PGC-1α 
in 12 month old mdx mice showed increased expression of IL-1β (Hollinger and 
Selsby, 2015). On the other hand, TNF-α is known to inhibit contractile function 
of skeletal muscle, induce muscle wasting and increase production of ROS via 
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NF-κB signaling pathway, which in turn can influence catabolic processes in 
dystrophic muscles (Morrison et al., 2000). Further, TNF-α and IL-1β cytokines 
are required for muscle repair as demonstrated in multiple literatures (Chen et 
al., 2007). In chronic obstructive pulmonary disease (COPD) which is 
characterized by muscle wasting, TNF-α mRNA expression is elevated and 
shown to have a direct negative effect on muscle fibre oxidative phenotype by 
inducing a shift from type I to type IIB. In addition, mitochondrial biogenesis 
markers such as TFAM and NRF-1 were down regulated in response to elevated 
level of TNF-α (Remels et al., 2010). These detrimental effects of increasing 
expression of TNF-α on mitochondrial respiration suggest a link between a 
reduction in the inflammation marker observed following over-expression of 
ERRγ and the increase in the percentage of oxidative fibres. Speculatively, 
decreased expression of pro-inflammatory cytokines in this study is possibly 
linked to increased SDH activity of the fibres.  
Reduced expression of these cytokines may suggest that muscles under less 
stress that means less infiltration of inflammatory cytokines. This point could 
support, in part, the unchanged expression of IL-6, which is known to involve in 
muscle repair (Pedersen, 2007, Fujimori et al., 2002, Serrano et al., 2008, 
Scheller et al., 2011). Interestingly, IL-6 was shown to induce expression of 
VEGF (Cohen et al., 1996). Our results supported this interaction as there is no 
difference on VEGF expression. Further, we could suggest that over-expression 
of ERRγ improves the inflamed environment by decreasing the pro-inflammatory 
cytokines. Therefore, decreased expression of pro-inflammatory cytokines in this 
study highlights again the importance of the time of intervention and how that 
may change the experimental outcomes. In DMD, muscles have a complex 
 
 
158 
 
immune environment, where the muscles are under constant damage and that 
eventually prevent the transition from M1 to M2 macrophage phenotype. 
Therefore, despite the reduction in pro-inflammatory cytokines, the transition 
from M1 to M2 will never happen as the muscle will start overexpressing pro-
inflammatory cytokines when the second cycle of degeneration is initiated. 
However, the drawback of the second experiment, when we assessed the effect 
of overexpressing ERRγ in 6 week-old mdx in large number of samples, is that 
we do not have a conclusion on the level of ERRγ protein as the samples have 
been lost. 
Based on the global gene expression and scatter blot generated from microarray 
in this study, over-expression of ERRγ shows alterations in the gene ontogeny 
profiles. Analysis of the cMap data shows that many of the drugs that gives the 
greatest correlation with ERRγ over-expression are steroid based, which is 
known to have anti-inflammation properties. Noteworthy, an increase in oxidative 
stress drives inflammation response, whereas a reduction in oxidative stress 
drives anti-inflammation properties, therefore, drugs that are naturally anti-
inflammatory fully expect to be in the top of the list. This finding highlight the pro-
oxidative and anti-inflammatory properties of ERRγ upregulation. In the cMap list, 
diflorason and pancuronium bromide, which has been used for neuromuscular 
diseases (Giostra et al., 1994) and epitiostanol that has been used for breast 
cancer (Dembitsky et al., 2017) are examples of steroid-based drugs. However, 
we would not prioritize them due to side effects of steroid. Numerous clinical trials 
have recognized both the effect of steroids in DMD and the recognized risk of side effects 
associated with their daily use, such as weight gain and decreased bone mineral density 
(Angelini and Peterle, 2012). We highlighted some of the compounds with non-
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steroid, anti-inflammatory application to emphasize the presence of other drugs 
with clinical applications that possibly mimics ERRγ over-expression. For 
example; benfotiamin, is one of the most effective treatment for preventing 
diabetes. It is known as a chemical derivative of thiamine nutrient (vitamin B1), 
which is known to regulate level of glucose metabolism (Arora et al., 2006). Type 
2 diabetic (T2D) patients are characterized by oxidative stress, an impaired 
glucose tolerance, a reduced skeletal muscle oxidative capacity and 
mitochondrial dysfunction (Phielix and Mensink, 2008). Emerging evidence 
suggested that boosting oxidative capacity through improving mitochondrial 
function might be beneficial to patients. A study on patients of type II diabetic 
showed that two weeks treatment with benfotiamine has an ability to reduce heart 
failure, decreased oxidative stress and restore heart cell function (Ceylan-Isik et 
al., 2006). Moreover, we identified compounds with high scores as Heat shock 
protein 90 (Hsp90) inhibitor, for example; tanespimycin, monorden, 
geldanamycin and alvespimycin. Therapeutic Hsp90 inhibitors have been 
developed as anti-inflammatory therapy. In cancer, for example; Hsp90 is a 
molecular chaperon responsible for folding many proteins directly involved in 
progression of cancer and therefore, inhibition of Hsp90 protein folding 
mechanism leads to attack numerous oncogenic pathway (Liu et al., 2018).  
Binding of these compounds to Hsp90, leads to degradation and reduction of the 
target proteins. Specifically, alvespimycin is an analogue to geldanamycin and 
tanespimycin, with high affinity to Hsp90 and Phase I clinical trial using 
alvespimycin in acute myeloid leukemia (AML) showed that alvespimycin is well 
tolerated and showed signs of clinical activity (Lancet et al., 2010). In parallel, 
Hsp proteins are also important factors in skeletal muscle physiology and 
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adaption to stress and exercise. They involve in maturation and activation of 
inflammatory cells and regulate expression of pro-inflammatory factors (Paepe 
et al., 2012). For example; overexpression of Hsp72 in dystrophic muscles, 
through administration of a pharmacological inducer (BGP-15), preserve muscle 
strength and ameliorates the dystrophic pathology (Gehrig et al., 2012).  
In addition, compounds with antioxidant and anti-inflammatory properties were 
identified from the cMap, such as ebselen, known to mimic glutathione 
peroxidase (GPx1). Ebselen has anti-inflammatory and antioxidant properties 
(Muller et al., 1984). Historically, it has been evaluated pre-clinically for diabetes, 
ischemic stroke and hearing loss. It is well characterized to reduce oxidative 
stress in noise-related hearing loss. In preclinical study of the hearing loss, 
treatment with ebselen has been shown to stimulate protein expression of GPx1 
and the phase I clinical trial approved safety for the prevention of noise-induced 
hearing loss (Kil et al., 2007). Based on this outcomes, Ebselen could be used in 
the prevention and management of oxidative stress-linked to DMD and 
importantly, it highlight the beneficial effect of ERRγ over-expression in regulating 
oxidative stress associated with DMD. Among the list, GW8510 is another 
compound that has highly significant correlation with gene expression profile. 
GW8510 is a 3′-substituted indolone and is known to inhibit cyclin-dependent 
kinases 2 and 5 (CKD2 and 5), which regulate the cell cycle (Johnson et al., 
2005). GW8510 has been shown as a neuroprotective agent for Parkinson 
disease. The neuroprotective properties has been evaluated in human neuronal 
cells treated with neurotoxin (MPP), in the presence of different concentration of 
GW8510. The results showed protection against cell death and the exact 
mechanism remains to be elucidated (Wimalasena et al., 2016). MPP is known 
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to target mitochondrial function and to induce endoplasmic reticulum stress 
response in neurons (Kim-Han et al., 2011). These effects are parallel to the 
effects induced by transgenic over-expression of ERRγ, where it showed 
remodeling of oxidative metabolism in mdx mice to the normal level (Matsakas 
et al., 2013). 
Based on these data, we should take into account that overexpression of ERRγ 
by AAV gene transfer is a valid approach, but conscious that it is not the only 
approach; cross correlation of pharamaceuticals can lead to the identification and 
repurposing of approved drugs, with a faster timeline to clinic.   
In conclusion, this first study has provided histological analysis of TA muscles 4 
weeks post administration of AAV8-ERRγ into 6 and 12 week old mdx mice. We 
have shown improvement in the SDH activity of the muscle fibres in both groups. 
The increase in the SDH activity of the muscles treated at 6 weeks of age was 
supported by a reduction in the centrally nucleated fibres and regenerative fibres. 
Despite these changes, none of the genes related to oxidative metabolism, 
mitochondrial biogenesis were affected when the samples of both groups were 
analyzed together. The second study was run to check the expression of genes 
on larger number of samples and hence we demonstrated no effect of ERRγ 
over-expression on the tested genes. Although, the data from qRT-PCR does not 
showed any difference between the treated and control TA muscles. The data 
from histology analysis, GO and PCA analysis give an arguments for exploring 
the effect of ERRγ over-expression in different ages of mdx mice and at different 
doses.   
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4. Chapter Four 
 
Systemic administration of AAV8-ERRγ into 3 and 6 
week-old mdx 
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4.1. Introduction: 
In the previous chapter, we showed an intramuscular administration of AAV8-
ERRγ in 6 week-old mdx led to an improvement in the succinate dehydrogenase 
activity (SDH) and a reduction in the centrally nucleated fibres. In addition, PCA 
analysis showed a distinct profile expression of treated samples from the control.  
CMap was further support that overexpression of ERRγ in 6-week old mdx is an 
encouraging strategy in dystrophic tissues. Here, to assess the potential for 
achieving systemic transduction of skeletal muscle with AAV8-ERRγ, we studied 
the short-term effect of systemic administration of AAV8-ERRγ into 6 weeks old 
mdx male mice.  
It has been suggested that mdx gender influenced physiological and pathological 
outcomes. Assessing histopathology demonstrated male to be severely more 
affected than female at 6 weeks of age by quantifying damaged fibres using 
Evans blue dye (EBD). At 24 weeks of age, females tended to have more 
damaged fibres (Salimena et al., 2004). Two studies have suggested that skeletal 
muscles of male mdx are more severely affected at younger age (4-12 weeks of 
age), where they showed more inflammation, increased sarcolemmal 
permeability and higher deposition of extracellular matrix, whereas age matched 
females showed more regenerating fibres. These differences are possibly due to 
the accepted fact that both innate and adaptive immune responses of females 
are more robust than in males (Verthelyi, 2006) and also attributed to female 
estrogen level and the regulation of nitric oxide by estrogen (Verthelyi, 2006). 
Later, at 6 months of age, female mdx showed greater specific force compared 
to aged match male. After 6 months, female become more affected and at 20 
months, they showed lower tetanic force (Salimena et al., 2004, Yoshida et al., 
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2006). Evidence of different innate and adaptive immune responses in post-
pubertal male and female mice influence these striking difference in 
dystropathology between male and female (Yoshida et al., 2006). Further, later 
in adult life, hormonal changes during the estrus cycle affect stress, motor activity 
and immune status (Hakim and Duan, 2012). Therefore, female hormones play 
a role in the pattern of myogenesis and repair since adult female mdx performed 
better than males, but aged females performed worse than males. While such 
gender issues appear to be important in the mdx mouse and since DMD affect 
boys, it might be more appropriate to use male mice for DMD research. All 
experiments in this study were performed on young male mdx mice at a range of 
ages to assess the effect of systemically overexpressing ERRγ on active 
pathology of mdx.    
In DMD, gene based therapy was developed as an efficient, safe systemic 
approach to deliver dystrophin to the muscle fibres with a viral vector. Systemic 
administration of viral vector mediated expression of a gene of interest should 
achieve efficient and widespread expression of the transgene in vast majority of 
skeletal muscles, where they represent around 40% of body weight. Adeno 
associated viruses (AAV) represent one of the viral vectors with attractive 
advantages, for example; no known pathogenicity, ability to transduce a wide 
variety of tissues including dividing and non-dividing cells, presence of serotypes 
that exhibit tropism for striated muscles, such as 1, 2, 8 and 9 and a lower ability 
to elicit immune response than adenoviral vectors (Hareendran et al., 2013). The 
main challenge in gene therapy is the selection of an appropriate serotype, which 
require knowledge of performance in the target species of interest and cells type. 
Although, small number of serotypes have been evaluated in small and large 
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animals, the knowledge of tissue and target cell tropism is limited (Lisowski et al., 
2015). To date, there are 12 different serotypes (1-12), with more than 100 AAV 
variants have been described in the literature, although most gene transfer 
experiments are performed with AAV1-9 (Hareendran et al., 2013). In skeletal 
muscle and liver, AAV2 showed therapeutic efficacy, but other comparative 
studies using AAV1 and AAV8 support improved gene delivery to skeletal muscle 
and liver, respectively (Lisowski et al., 2015). Also, AAV2, AAV4, AAV9 and 
AAVrh10 have been delivered to target eye (Boye et al., 2013) and AAV1, 6, 8 
and 9 show strong cardiac transduction, with AAV9 to be the most cardiotropic in 
rodents (Tilemann et al., 2012). 
Currently, rAAV capsid serotype selection for a specific clinical trial is based on 
effectiveness in animal models. However, there are still significant concerns of the 
translatability to humans because pre-clinical results have been proved to be poorly 
predictive in humans (Manno et al., 2006, Nietupski et al., 2011, Naso et al., 
2017). AAV8 which transduce many animal models very effectively, showed low 
transduction efficiency in human (Jiang et al., 2006). For example; using AAV8 
targeting IX deficiency in mice achieved about 100% transduction in liver (Nakai 
et al., 2005), but clinical trial in human using the same vector showed low level 
of transduction efficiency (Nathwani et al., 2014). To date, there are more than 
70 approved clinical trials, for example; AAV8 has been shown to transduce liver 
of rodents and non-human primates and is now being explored in clinical trials to 
deliver genes for hemoglobinopathies and other disease (Kattenhorn et al., 
2016).  Engineered AAV1 is now being explored in clinical trails for heart failure 
(Naso et al., 2017).  
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Skeletal muscle exhibits several advantages, such as, stability and susceptibility 
to transfection, which make it an attractive target tissue for gene therapy (Lu et 
al., 2003b). However, there are several obstacles for rAAV delivery that may limit 
the potential of the vector. The major barriers are 1) Limited capacity of rAAV of 
4.7 kb, excluding delivery of large genes such as dystrophin. However, this is not 
an issue in the studies included in this thesis as ERRγ fits into AAV. The 
observations of mildly affected BMD patients with very large dystrophin deletions, 
led to understanding that truncated dystrophin is functional and shown to 
completely prevent disease in mdx mice. Such findings encourage researchers 
to develop mini and micro dystrophin genes based on the deletion of non-
essential regions and keeping the essential regions of the gene, resulting in short 
but functional dystrophin that overcome the limited capacity issue of AAV 
(Gregorevic et al., 2004, Gregorevic et al., 2006, Harper et al., 2002), which 
suggest the requirement of re-administration strategies. 2) Unexpected immune 
response, which represent the main challenge facing AAV gene delivery. Immune 
response can be developed against the AAV capsid or the transgene product 
and can prevent prolonged transgene expression (Daya and Berns, 2008). 
Immune response directed against AAV can be divided into; innate and adaptive 
immunity (Hareendran et al., 2013). Innate immunity is the first non-specific 
defence mechanism, involves limited response of cytokines and chemokines. 
Innate immune response can cause local or systemic toxicity with higher dose of 
AAV, whereas adaptive immune response can be divided into humoral and cell-
based immune response. Humoral response is mediated by neutralizing 
antibodies, preventing the re-administration of vector and limiting AAV 
transduction. Cells-mediated response functions at the cellular level, eliminating 
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the transduced cells using cytotoxic T cells (Nayak and Herzog, 2010, Kay, 
2011).  
To avoid immune response, immunosuppression regime or modifying AAV 
vectors have been used with different levels of efficiency. The advantage in the 
context of gene therapy is that, the duration of the intervention is relatively short. 
Using a combination of anti-CD4 antibodies and cyclosporine prevent 
neutralizing antibodies formation and allow vector re-administration (McIntosh et 
al., 2012). Repeated administration of AAV1 in mdx mice combined with 
immunosuppression using two specific agents (CTLA-4/Fc and anti-mouse 
CD40L monoclonal antibody) to block B-T cells interaction, results in preventing 
formation of neutralizing antibodies against AAV1 (Lorain et al., 2008). However, 
the main limitation is the absence of antigen specificity, which raises concerns 
over the risk of serious infection by hypogammaglobulinemia (Ginzler et al., 
2012). Modification of AAV capsid is another strategy to improve transduction 
and prevent immune response. It is based on shielding AAV from recognition by 
antibodies or T cells by masking their immunogenic epitopes. Genetic 
modification of the capsid works by mutating neutralizing antibodies epitopes. It 
was done by scanning for the peptides to map neutralizing epitopes for antibodies 
present in human or mice. Then, AAV variant libraries were generated by either 
insertion of peptides at specific positions to disrupt the antibody binding site of 
viral capsid or by site directed mutagenesis of specific residues of immunogenic 
peptides on AAV capsid (Hareendran et al., 2013). The main advantage of this 
strategy is that no need for immunosuppression to reduce antibody titres, 
however, the novel AAV may reduce transduction efficiency of the target tissue 
and may alter tissue tropism (Masat et al., 2013).  
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Dystrophic muscles are characterized by increased susceptibility to damage, 
impaired Ca+2 homeostasis, increased ROS production and oxidative stress 
(Whitehead et al., 2010, Gervásio et al., 2008, Allen et al., 2016). ROS are potent 
pro-inflammatory mediators which activate NF-κB leading to activation of TNF-α 
activity and derive fibrosis (Figari et al., 1987, Kim et al., 2007). Moreover, 
impaired mitochondria and ATP production have also been reported (Rybalka et 
al., 2014, Kuznetsov et al., 1998, Percival et al., 2013, Timpani et al., 2015). In 
addition, dystrophic deficiency is characterized by accumulation of damaged 
proteins/organelles such as dysfunctional mitochondria, further contribute to 
muscle pathology (De Palma et al., 2012), impaired vasculature and blood flow 
(Loufrani et al., 2004, Ennen et al., 2013, Matsakas et al., 2013). Further, in the 
absence of dystrophin, normal localization of nNOSµ is prevented, which is 
required for NO production, leads to defective nNOS signalling, resulting in 
impaired muscle contraction due to excessive muscle ischemia damage that 
possibly impair recovery from muscle fatigue (Thomas et al., 1998, Percival et 
al., 2010). These deficiencies contribute to pathology and excessive 
accumulation of fibrotic tissues that drastically reduce the motility and contractile 
function of dystrophic muscle and ultimately decreases the amount of muscle 
tissue that can be targeted by gene therapy (Mann et al., 2011).  
As a consequence, targeting energy producing pathways by therapeutic 
intervention seems logical. In the absence of efficient therapeutic strategies that  
address the primary genetic defect, treatments which target the mitochondrial 
dysfunction and muscle perfusion could ameliorate disease progression. To 
stimulate respiratory capacity in muscle tissues, inducing expression of different 
mitochondrial biogenesis regulators has been addressed previously. For 
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example; transgenic over-expression of PGC-1α increased utrophin expression 
(Handschin et al., 2007) and the post-natal over-expression of PGC-1α induced 
a fast to slow fibre type shift and an increase in mitochondrial proteins in the mdx 
mouse (Selsby et al., 2012). Moreover, PGC-1α has been shown as an angiokine 
in ischemic skeletal muscle (Arany et al., 2008). In addition, induction of PERM1 
in cultured C2C12 myotubes and in C57BL/6J mice regulated mitochondrial 
biogenesis and oxidative capacity as well as angiogenesis via the transcriptional 
induction of VEGF (Cho et al., 2013, Cho et al., 2016). 
Moreover, increasing expression of the angiogenic factor (VEGF) via AAV gene 
transfer, enhances muscle function in mdx mice and induces muscle 
regeneration (Messina et al., 2007). AMPK is known as a regulator of cellular 
metabolism in response to cellular stress in muscles. Further, activation of AMPK 
pharmacologically with AMP analogue (AICAR) increases VEGF transcription 
and protein and capillarization in skeletal muscle in vitro (Ouchi et al., 2005) and 
in wild type mice (Zwetsloot et al., 2008). Inhibiting expression of AMPK using 
dominant negative mutant of the α2-subunit of AMPK lead to inhibiting 
vascularisation in vitro by inhibiting endothelial cell migration towards VEGF 
(Nagata et al., 2003).  
Estrogen-related receptors (ERRs) are orphan nuclear receptors of which ERRα 
and γ are highly expressed in tissues associated with metabolic activity such as 
brain, liver, kidney, placenta, adipose tissues and skeletal muscle (Pearen and 
Muscat, 2012). However, in skeletal muscle, ERRγ is found to be expressed 
exclusively in highly vascularized aerobic muscles, specifically in type I fibres 
(Narkar et al., 2011). Moreover, ERRγ controls the induction of genes associated 
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with oxidative metabolism, fatty acid oxidation pathway, oxidative respiratory 
chain, angiogenic genes and contractile genes especially those associated with 
slow fibres which raises the possibility of fibre type transition from fast to slow 
linked to metabolic demands (Narkar et al., 2011, Huss et al., 2004, Huss et al., 
2002). More interestingly, transgenic over-expression of ERRγ in a murine model 
of hind limb vascular occlusion shows enhancement in re-vascularisation and 
neo-angiogenesis which assists the repair damage of ischemic skeletal muscle 
and maximizes the restoration of blood perfusion (Matsakas et al., 2012).  
Based on this background and the results obtained from previous chapter, we 
aim to assess the effect of post-natal over-expression of ERRγ on skeletal 
muscle pathology of mdx mice systemically. Here, we investigate the effect of 
post-natal over-expression of ERRγ in mdx using AAV8 to determine the extent 
to which systemic ERRγ gene transfer can rescue dystrophic muscle from 
disease-related decline. We assess the effect systemic administration of AAV8-
ERRγ under the control of spc5-12 promoter into 6 weeks of age (during the 
active regenerative cycles). Six week-old mdx mice were injected with 1x1012 vg 
delivered in 100 µl to the tail vein, while the control mdx mice were injected 
similarly with an equal volume of saline (n=7), samples were collected post-
mortem at 4 weeks post administration. A summary of all tabulated data will be 
provided at the end of the results.  
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4.2. Results: 
4.2.1. Evaluation of ERRγ over-expression in different muscles following 
ERRγ gene transfer into 6 week-old mdx: 
Following intravenous administration of AAV8-ERRγ into 6 week-old mdx, the 
expression of ERRγ was assessed by quantitative real time PCR (Q-PCR) in 
different muscles using specific primer for ERRγ. EDL, gastrocnemius, TA, 
diaphragm and quadriceps showed over-expression of ERRγ mRNA by 3, 10, 6, 
5 and 3 fold respectively with no change in the soleus expression of ERRγ (figure 
4.1 A-F). However, the protein analysis showed no increase in the relative protein 
level of ERRγ in EDL muscle and 2 fold increase in gastrocnemius (figure 4.1 G-
I).  
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Figure 4.1. ERRγ gene transfer increases expression of ERRγ in mdx mice treated 
at 6 weeks old 
Intravenous administration of 1X1012 vg AAV8-ERRγ into 6 week old mdx and samples 
were collected 4 weeks later increased expression of ERRγ in some assessed muscles. 
Total RNA was harvested from mdx and mdx-ERRγ muscles. (A-F) Relative mRNA 
levels of ERRγ for the indicated muscles were determined by qRT-PCR, normalized to 
the indicated housekeeping genes levels. EDL muscles show 3 fold increase (p=0.001), 
gastrocnemius muscles show 10 fold (p=0.001), TA muscles show 6 fold (P=0.001), 
diaphragm muscles show 5 fold (p=0.011), quadriceps muscles show 3 fold (p=0.006) 
and no difference in soleus muscles (p=0.437). The levels of ERRγ protein in 
gastrocnemius and EDL muscles respectively were determined by western blot analysis, 
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using 30 µg of protein and Ponceau stain was used for normalization. The total ERRγ 
protein was determined using ERRγ antibody. G) The intensity of the bands in EDL 
muscles from 6 week old mdx study was quantified using ImageJ software. H) The 
intensity of the bands in gastrocnemius muscles from 6 week old mdx study was 
quantified using ImageJ software. I) ERRγ gene transfer increases ERRγ protein levels 
in gastrocnemius muscle by 2 fold (p=0.04) with no increase in EDL muscle (p=0.239), 
(n=7, un-paired student’s t-test).  
 
4.2.2. Gene transfer of AAV8-ERRγ has no effect on muscle function in 
EDL muscles of mdx mice treated at 6 weeks old: 
To test the effect of ERRγ gene transfer on physiological function of freshly 
recovered EDL muscles, tetanic force, specific force and specific force following 
lengthening contractions were assessed. EDL muscles were used due to its ideal 
size and geometry, including definitive tendons (Brooks and Faulkner, 1988). In 
the experiment of mdx mice treated at 6 weeks of age and recovered 4 weeks 
post administration, there was no difference in the EDL muscle mass (figure 4.2 
A). Neither the tetanic force of the AAV8-ERRγ EDL muscles nor the specific 
forces differed from those of the control (figure 4.2 B-C). In order to assess to 
which extent ERRγ gene transfer improve resistance to eccentric contraction, 
muscles underwent a series of 10 lengthening contractions. ERRγ failed to 
improve resistance to contraction induced injury (figure 4.2 D). 
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Figure 4.2. Gene transfer of ERRγ into 6 week old mdx has no effect on muscle 
force 
Intravenous injection of 6 week old mdx mice with 1X1012 vg of AAV8-ERRγ and 
recovered 4 weeks later has no impact on A) EDL muscle mass (p=0.539). Muscles were 
stimulated according to standard techniques in order to assess tetanic force and specific 
force. B) Tetanic force was unaffected with ERRγ gene transfer (p=0.449). C) Tetanic 
force normalized by muscle cross sectional area is specific force. Cross sectional area 
(mm2)= mass (mg)/ [(Lo mm)* (L/Lo)* (1.06 mg/mm3)], where L/Lo is the fibre to muscle 
length ratio (0.45 for EDL) and 1.06 is the density of muscle. However, specific force is 
not different between mdx and mdx-ERRγ (P =0.541), (n=7 for mdx and mdx-ERRγ, un-
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paired student’s t-test). D) EDL muscles were given a series of 10 lengthening 
contractions (150 Hz for 500 msec, followed by 200 msec at a 110% Lo). Eccentric 
contraction shows no difference between the two groups of muscle, (n=7 for mdx and 
mdx-ERRγ, p=0.320, two-way Anova).  
 
4.2.3. Impact of ERRγ over-expression on oxidative metabolism in 
muscles of mdx mice treated at 6 weeks old: 
In the experiment of 6 week-old mdx, gastrocnemius was chosen to assess the 
effect of over-expression of ERRγ on histology as these muscles showed the 
highest over-expression of ERRγ by 10 fold. An enzymatic succinate 
dehydrogenase (SDH) stain was used to assess whether over-expression of 
ERRγ has an effect on the percentage of oxidative fibres as a representation of 
oxidative activity. Based on counting the fibres in the entire muscle cross section, 
over-expression of ERRγ in gastrocnemius muscles from 6 weeks experiment 
showed a 14% increase in the percentage of oxidative fibres (p=0.001) (figure 
4.3 A). In order to assess the effect of ERRγ over-expression on genes related 
to oxidative metabolism and mitochondrial biogenesis, specific primers were 
used to evaluate the relative expression of these genes. Gastrocnemius muscle 
from 6 week old mdx study was analysed for some parameters as it showed a 
higher level of ERRγ over-expression. In addition, EDL muscles since it is used 
for functional assessment. However, none of the examined genes related to 
oxidative metabolism or mitochondrial biogenesis showed any difference 
between mdx and mdx-ERRγ in the 6 week-old mice of either gastrocnemius or 
EDL muscles (figure 4.3 B-C). 
 
 
177 
 
 
 
 
178 
 
Figure 4.3. Effect of ERRγ over-expression on oxidative capacity 
Over-expression of ERRγ in gastrocnemius muscles from 6 week study showed 
increased SDH activity. A) The relative abundance of oxidative fibres in mdx and mdx-
ERRγ in 6 weeks study based on quantification of an entire cross section of 
gastrocnemius. Data are expressed as a percentage (%) of total fibres. SDH activity is 
increased by 14% in gastrocnemius muscles (p=0.001). B) ERRγ over-expression in 
gastrocnemius muscle from 6 week-old mdx shows no difference in the relative mRNA 
level of oxidative metabolism genes; ND2 (p=0.830), SIRT1 (p=0.928), ERRα (p=0.137), 
PERM1 (p=0.274), PPARα (p=0.532), PPARγ (p=0.059), PPARδ (p=0.07) and PGC-1α 
(p=0.1). C) Relative mRNA expression of the indicated genes related to oxidative 
metabolism and mitochondrial biogenesis in EDL muscles from 6 week study. No 
difference in the expression level of any indicated genes Atp5 (p=0.181), Cox5 
(p=0.063), NduFp (p=0.1), sdhc (p=0.675), sdha (p=0.475), PERM1 (p=0.416), SIRT1 
(p=0.165), NRF2 (p=0.305), ND2 (p=0.191), TFAM (p=0.535), PGC-1α (p=0.121), (n=7, 
un-paired student’s t-test). 
 
4.2.4. Increasing expression of ERRγ does not significantly alter myosin 
isoforms in gastrocnemius muscle of mdx mice treated at 6-weeks 
old: 
We asked whether postnatal over-expression of ERRγ shift the muscle fibre type. 
We used staining of muscle cross section with antibodies against the different 
MHC isoforms to quantify the fibre type content. However, we found that over-
expression of ERRγ has no effect on fibre type composition in gastrocnemius 
from 6 weeks experiment (figure 4.4). 
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Figure 4.4. Over-expression of ERRγ in gastrocnemius muscles has no impact on 
muscle fibre typing 
A) The relative abundance of different fibre types in gastrocnemius from 6 week old mdx 
based on quantification of an entire muscle sections. Myosin heavy chain (MHC) 
analysis in mdx and mdx-ERRγ shows no difference in the number of fibre types in 
gastrocnemius, type I (p=0.10), IIA (p=0.212), IIB (p=0.161) and IIX (p=0.844). B) 
Representative images of cross sections show the mid-portion of mdx and mdx-ERRγ 
muscles stained with antibodies against MHC isoforms, as indicated. Scale bar, 200 μm, 
(n=7, un-paired student’s t-test). 
 
4.2.5. Impact of ERRγ over-expression on angiogenesis in mdx mice 
treated at 6 weeks-old: 
In order to assess the effect of ERRγ over-expression on genes related to 
angiogenesis, specific primers were used to evaluate the relative expression of 
these genes. Over-expression of ERRγ in 6 week old mdx shows no difference 
in the transcript levels of angiogenesis markers neither in gastrocnemius nor in 
EDL muscles (figure 4.5 A-B). 
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Figure 4.5. Over-expression of ERRγ has no effect on angiogenesis in mdx mice 
treated at 6-weeks old: 
Relative mRNA levels of angiogenic markers shows no difference in the expression of 
A) VEGF-165 (p=0.519) and VEGF-189 (p=0.396) in gastrocnemius muscles or B) 
VEGF-165 (p=0.259) and VEGF-189 (p=0.10) in EDL muscles between mdx and mdx-
ERRγ from 6 weeks study, (n=7 for mdx and mdx-ERRγ, un-paired student’s t-test). 
 
4.2.6. Effect of ERRγ over-expression on myofibre central nucleation in 
gastrocnemius muscle of mdx mice treated at 6-weeks old: 
Haematoxylin and eosin staining was used to assess whether over-expression 
of ERRγ decreased central nucleation. Gastrocnemius muscles from mice 
treated at 6 weeks of age showed 8% reduction in the percentage of centrally 
nucleated fibres (p=0.007) (figure 4.6).  
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Figure 4.6. Over-expression of ERRγ reduces central nucleation in gastrocnemius 
muscle of mdx mice treated at 6-weeks old  
A) Percentage of centrally nucleated fibres in mdx and mdx-ERRγ of gastrocnemius from 
6 weeks study shows 8% reduction of centrally nucleated fibres (p=0.007). B) 
Representative images of cross sections of mdx and mdx-ERRγ gastrocnemius stained 
with H&E. Scale bar, 50 μm, (n=7, un-paired student’s t-test). 
 
4.2.7. Effect of ERRγ over-expression on muscle damage of mdx mice 
treated at 6-weeks old: 
To determine the effect of ERRγ over-expression on muscle damage, serum CK 
level was assessed. The level of CK in the blood serum was higher in mdx serum 
compared to WT serum as demonstrated previously (Matsakas et al., 2013). 
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However, the over-expression of ERRγ does not reduce the serum CK in 6 week 
old mice (figure 4.7 A). In addition, muscle damage was assessed by scoring for 
IgG positive fibres as an indicator of sarcolemmal integrity. In the 6 week study, 
over-expression of ERRγ in gastrocnemius had no effect on the number of IgG 
infiltrated fibres (figure 4.7 B). To further assess the level of regeneration, the 
number of fibres expressing embryonic myosin (MYH-3) was assessed in an 
entire muscle cross section, the percentage of fibres expressing MYH3 was not 
different between the mdx and mdx-ERRγ in gastrocnemius from the 6 weeks 
study (figure 4.7 D).  
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Figure 4.7. ERRγ gene transfer has no effect in CK levels, IgG infiltration or MYH-
3 positive fibres in mdx mice treated at 6 weeks old  
A) Creatine kinase assay measurement shows no difference in the blood serum of mdx 
and mdx-ERRγ in 6 weeks (p=0.495). B, D) The percentage of IgG and MYH-3 positive 
fibres in the entire gastrocnemius muscles of mdx and mdx-ERRγ show no difference of 
the damaged fibres in 6 week study (p=0.262) or MYH-3 positive fibres (p=0.685). C, E) 
Representative images of cross section of mdx and mdx-ERRγ gastrocnemius muscles 
immunostained with anti-IgG antibody, anti-MYH-3 antibody, respectively. Scale bar, 
200 μm, (n=7, un-paired student’s t-test). 
 
4.2.8. Impact of ERRγ over-expression on inflammation, degradation, 
translation, ubiquitination calcium and antioxidant markers in EDL 
muscle of mdx mice treated at 6-weeks old:  
To find out whether increasing expression of ERRγ affects the expression levels 
of markers related to pro and anti-inflammatory pathways, degradation, 
translation, ubiquitination, calcium and antioxidant markers, specific primers 
were used. EDL muscle was used for these assessments. 3 fold over-expression 
of ERRγ in EDL from the 6 week study has no effect on the expression of genes 
related to inflammation (TNF-α, IL-1β, IL-6 and IL-10) except a 1.6 fold increase 
of NF-κB which is expected to increase in the dystrophic muscles (p=0.006) 
(figure 4.8 A). In addition, none of the autophagy related genes (P62, Beclin-1, 
Bnip3) or apoptotic marker; chathespin-L or atrophy gene; FOXO-1 were affected 
(figure 4.8 B). Furthermore, to determine if the over-expression of ERRγ had any 
impact in the calcium handling, two markers were assessed. However, over-
expression of ERRγ in the 6 weeks old mdx did not change expression of RYR-
1 Ca+2 release channel or SERCA-1, a Ca+2 pump channels (figure 4.8 C). Genes 
involved in the translation pathways (Gadd34 and 4EBP-1) were unchanged 
(figure 4.8 D), ubiquitination genes; Atrogin-1 was reduced by 1.4 fold (p=0.026) 
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and MuRF-1 was unaffected (figure 4.8 E). Finally, SOD2 was used as an 
antioxidant marker and showed no change (figure 4.8 F).  
 
Figure 4.8. Impact of ERRγ over-expression on inflammation, degradation, 
translation, ubiquitination calcium and antioxidant markers in EDL muscle of mdx 
mice treated at 6-weeks old  
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Relative mRNA levels for the indicated genes in the EDL muscles of of mdx and mdx-
ERRγ from 6 weeks study A) Relative mRNA levels for the indicated inflammatory 
markers; TNF-α (p=0.552), IL-1β (p=0.628), IL- 6 (p=0.902) and 1.6 fold increase of NF-
κB (p=0.006) IL-10 (p=0.535). B) Relative mRNA levels for the indicated autophagy 
markers; P62 (p=0.383), Beclin-1 (p=0.710), Bnip3 (p=0.824), chathepsin-L (p=0.07), 
FOXO-1 (p=0.877). C) Over-expression of ERRγ in EDL muscle of 6 week-old mdx has 
no effect on the expression of calcium receptors; RYR-1 calcium channel (p=0.629), 
SERCA-1 (p=0.678). D) Relative mRNA levels for the indicated translation markers; 
4EBP-1 (p=0.788) and Gadd34 (p=0.624). E) Relative mRNA levels for the indicated 
ubiquitination markers; 1.4 fold decrease of Atrogin-1 (p=0.026) and MuRF1 (p=0.78). 
F) Relative mRNA levels for the antioxidant marker; SOD2 (p=0.183), (n=7, un-paired 
student’s t-test). 
 
4.3. Evaluation of administration of AAV8-ERRγ at earlier (pre-crisis) 
timepoint in mdx mice: 
Observation from earlier study on 6 week-old mdx showed modest output 
following over-expression of ERRγ. These results were particularly surprising as 
it was an age/sex matched study consistent with the transcriptomic study in which 
the PCA and gene ontology data was particularly encouraging. Therefore, we 
thought to determine if a similar protocol, but delivered to an earlier age and for 
a longer timepoint would have a better impact on the dystrophic pathology. In 
fact, the onset of pathology begins at 3 weeks of age where mdx undergo severe 
myofibre necrosis and subsequent regeneration in limb muscles (Grounds et al., 
2008). The timing of the age of onset of muscular dystrophy corresponds to the 
disappearance of utrophin around the sarcolemma (Clerk et al., 1993). Also, it 
could be the result of huge disruptions in intracellular signalling and excessive 
inflammation (Evans et al., 2009a), or a result of an increase in motor activity at 
the time of weaning (Mokhtarian et al., 1995). The high level of necrosis between 
21 and 28 days provides an excellent model to assess therapeutic interventions 
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aimed at preventing or decreasing muscle necrosis (Grounds and Torrisi, 2004, 
Radley et al., 2008, Radley and Grounds, 2006, Hollinger et al., 2013). Muscle 
necrosis peaks at 4 weeks of age and then becomes stable, where low level of 
damage was observed as approximately 6% of each skeletal muscle being 
actively necrotic. However, discrepancies in the literatures have been reported 
about the stable period of necrosis. Some have reported 8-12 weeks (McGeachie 
et al., 1993, Heier et al., 2014), others reported 10-12 weeks of age (Godfrey et 
al., 2015, Muntoni et al., 1993, Dangain and Vrbova, 1984). Following 12 weeks 
of age, muscles exhibit a low level of muscle necrosis and reduced creatine 
kinase levels. After 20 months of age, they exhibit a more severe pathology with 
the general replacement of skeletal muscle with fibrous connective tissue, 
diminished cardiac and respiratory function and reduced life span (Chamberlain 
et al., 2007). In mdx mice, the major wave of necrosis occurs between 3-4 weeks 
of age and is followed by a regenerative process between 5-6 weeks of age, 
which results in the replacement of a large proportion of the damaged fibres 
(Gillis, 1999). This study was carried out in 3 week-old mdx and recovered 6 
weeks post administration to better evaluate the over-expression of ERRγ in 
dystrophic tissue. Intraperitoneal administration with 1x1012 vg administered in 
50 μl just off the midline in the lower left quadrants, while the control mice were 
injected with an equal volume of saline solution, n=12 (mdx control) and n=10 
(mdx-ERRγ). The number of animals herein was changed to improve the power 
of this study. In both studies; 6 and 3 weeks of age, samples were collected 
around the stable period of degeneration/ regeneration process (9-10 weeks of 
age). 
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4.3.1. Evaluation of ERRγ over-expression in different muscles following 
ERRγ gene transfer into 3 week-old mdx: 
Following IP AAV8-ERRγ gene transfer, assessing the over-expression of ERRγ 
mRNA in different muscles showed increased expression in EDL muscle by 2 
fold (p=0.002) and TA muscle by 3 fold (p=0.02) respectively, with no change in 
the expression of ERRγ in the other examined muscles (figure 4.9 A-E). Protein 
level was found to increase by 2 fold in EDL muscle (p=0.013) (figure 4.9 F-G). 
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Figure 4.9. ERRγ gene transfer increases over-expression of ERRγ mRNA in EDL 
and TA muscles of mdx mice treated at 3 weeks-old  
Intraperitoneal administration of 2X1012 vg AAV8-ERRγ into 3 week old mdx and 
samples were collected 6 weeks later increased levels of ERRγ mRNA in some 
assessed muscles. Total RNA was harvested from the mdx and mdx- ERRγ muscles. 
(A-E) Relative mRNA levels of ERRγ for the indicated muscles were determined by qRT-
PCR, normalized to the indicated housekeeping gene levels. Results show 3 fold 
increase of ERRγ mRNA in EDL (p=0.002), 2 fold increase in TA (p=0.02) and no change 
in gastrocnemius (p=0.467), diaphragm (p=0.446) and quadriceps (p=0.321), (n=12 for 
mdx, n=10 for mdx-ERRγ, un-paired student’s t-test). The levels of ERRγ protein in EDL 
muscles were determined by western blot analysis, using 30 μg of protein and Ponceau 
stain was used for normalization. The total ERRγ protein was determined using ERRγ 
antibody. F) The intensity of the bands was quantified using ImageJ software. G) ERRγ 
gene transfer increases ERRγ protein levels in EDL muscle by 2 fold (p=0.013), (n=10 
for mdx and mdx-ERRγ, un-paired student’s t-test), samples were run in two blots. 
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4.3.2. Gene transfer of AAV8-ERRγ improves specific force in EDL 
muscles of mdx mice treated at 3-weeks old: 
In order to assess the functional benefits of ERRγ over-expression in dystrophic 
mice at 3 weeks of age and recovered at 9 weeks, EDL was examined for muscle 
function. EDL muscles treated at 3 weeks of age showed no difference in the 
mass following treatment (figure 4.10 A). The tetanic isometric force generated 
from EDL muscles of treated mdx was unaffected compared to the control, 
however the specific force was significantly greater than that of the control by 
14% (p=0.043) (figure 4.10 B-C). Similar to 6 weeks experiment, ERRγ has failed 
to improve resistance to contraction induced injury (figure 4.10 D). Cross 
sectional area showed no difference between the two groups (figure 4.11 A). 
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Figure 4.10. Gene transfer of ERRγ improves specific force in dystrophic muscle 
treated at 3 weeks of age by 14% 
Intraperitoneal administration of 2X1012 vg of AAV8-ERRγ into 3 week old mdx mice and 
recovered 6 weeks later has no impact on A) EDL muscle mass (p=0.991). Muscles were 
stimulated according to standard techniques in order to assess tetanic force and specific 
force as described in (figure 4.1). B) Tetanic force is unaffected with ERRγ gene transfer 
(p=0.112). C) ERRγ gene transfer into 3 week old-mdx led to a 14% improvement of 
specific tension in EDL muscles (p=0.043). D) EDL muscles were given a series of 10 
lengthening contractions (150 Hz for 500 msec, followed by 200 msec at a 110% Lo), 
eccentric contraction shows no difference between the two groups, (n=12 for mdx and 
n=10 for mdx-ERRγ, p=0.211, two-way Anova).  
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Figure 4.11. Cross sectional area of EDL muscle treated at 3 weeks of age. 
A) Distribution of fibre cross sectional area of mdx and mdx-ERRγ EDL muscles, 
calculated from laminin stained images and shows no difference between the two groups 
of muscles, chi square (p=0.242), B) Representative images of cross sections of mdx 
and mdx-ERRγ immuno-stained with anti-laminin antibody, scale bar, 200 µm, (n=12 for 
mdx and n=10 for mdx-ERRγ, un-paired student’s t-test). 
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4.3.3. Impact of ERRγ over-expression on oxidative metabolism in EDL 
muscles of 3 week old mdx mice: 
In this experiment, EDL muscle was chosen as it showed the highest over-
expression of ERRγ. An enzymatic succinate dehydrogenase (SDH) stain was 
used to assess whether over-expression of ERRγ has an effect on the 
percentage of oxidative fibres as a representation of oxidative activity. EDL 
muscles from mice treated at 3 weeks of age which exhibited a 3 fold over-
expression of ERRγ resulted in a 60% increase in the percentage of oxidative 
fibres (p=0.008) (figure 4.12 A). In order to assess the effect of ERRγ over-
expression on genes related to oxidative metabolism and mitochondrial 
biogenesis, specific primers were used to evaluate the relative expression of 
these genes. Sdha gene was upregulated by 2 fold (p=0.006) and PGC-1α, which 
is the upstream inducer of mitochondrial biogenesis genes was upregulated by 2 
fold (p=0.006) at the mRNA level following over-expression of ERRγ. However 
none of the other analysed genes related to oxidative metabolism showed a 
difference at the transcript level (figure 4.12 C).  
We then determined the relative expression levels of mitochondrial complex I, II, 
III and V using antibodies specific to protein subunits of each complex in EDL 
muscle lysates from mdx mice treated at 3 weeks old. Relative protein level of 
complex I was increased by 2.7 fold (p=0.006), II was increased by 1.3 fold 
(p=0.013) and III was increased by 1.7 fold (p=0.019) following ERRγ over-
expression. In contrast, complex V was unaffected (figure 4.12 D-E). However 
protein analysis of PGC-1α resulted in insignificant difference between the 
treated EDL and the control (figure 4.12 F-G). Moreover, the relative protein level 
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of the induced regulator of PGC-1α and ERR, muscle 1 gene (PERM1) was not 
different between the two groups (figure 4.12 H-I).  
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Figure 4.12. The potential of ERRγ over-expression to increase oxidative capacity 
in mdx mice treated at 3 weeks of age  
A) The relative abundance of oxidative fibres in mdx and mdx-ERRγ in 3 weeks study 
based on quantification of an entire cross section of EDL muscles. Data are expressed 
as a percentage (%) of total fibres. SDH activity is increased by 60% (p=0.008). B) 
Relative mRNA expression of the indicated genes related to oxidative metabolism and 
mitochondrial biogenesis in EDL muscles from 3 weeks study. Atp5 (p=0.07), Cox5 (P-
0.903), NduFp (p=0.067), sdhc (p=0.059), sdha (p=0.006), PERM1 (p=0.418), SIRT1 
(p=0.249), NRF2 (p=0.621), ND2 (p=0.751), TFAM (p=805), PGC-1α (p=0.006) and 
utrophin (p=0.155). RNA levels for the indicated genes were determined by qRT-PCR, 
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normalized to the house-keeping genes; Htatsf1 and Csnk2a2. 30 μg of protein was 
loaded per lane and Ponceau stain was used for normalization. C) The total OxPhos 
complex protein was determined using OxPhos complex antibodies. D) The intensity of 
the bands was quantified using ImageJ software; Atp5, a maker of complex V (p=0.214), 
complex I (p=0.006), complex II (p=0.013), complex III (p=0.019). E) The total PGC-1α 
protein was determined by PGC-1α antibody. F) Analysis of PGC-1α bands shows no 
difference between mdx and mdx-ERRγ (p=0.07). G) The total PERM1 protein was 
determined by PERM1 antibody. H) Analysis of PERM1 bands shows no difference 
between mdx and mdx-ERRγ (p=0.10), (n=10 mdx and mdx-ERRγ, un-paired student’s 
t-test). 
 
4.3.4. Increasing expression of ERRγ does not significantly alter myosin 
isoforms EDL muscles of mdx mice treated at 3 weeks old: 
To assess the effect of ERRγ over-expression in EDL muscles treated at 3 weeks 
of age on the fibre type distribution, we used staining of muscle cross section 
with antibodies against the different MHC isoforms. We found that over-
expression of ERRγ has no effect on fibre type composition (figure 4.13). 
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Figure 4.13. Over-expression of ERRγ in 3 week-old mdx has no impact on muscle   
                     fibre typing 
A) The relative abundance of different fibre types in EDL muscles from mdx mice treated 
at 3 weeks old, based on quantification of an entire muscle sections. Myosin heavy chain 
(MHC) analysis in mdx and mdx-ERRγ shows no difference in the number of fibre types; 
type I (p=0.838), IIA (p=0.658), IIB (p=0.388) and IIX (p=0.843). B) Representative 
images of cross sections show the mid-portion of mdx and mdx-ERRγ muscles stained 
with antibodies against MHC isoforms, as indicated. Scale bar, 200 μm, (n=10 for mdx 
and mdx–ERRγ, un-paired student’s t-test). 
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4.3.5. Impact of ERRγ over-expression on angiogenesis in mdx mice 
treated at 3 weeks-old: 
To evaluate the effect of ERRγ over-expression in angiogenesis, specific primers 
were used to check the transcript level of genes involved in angiogenesis using 
qRT-PCR. In addition, muscle capillary density was assessed on muscle sections 
using the vascular endothelial marker CD31. Interestingly, moderate over-
expression of ERRγ in 3 week old treated EDL resulted in 1.6 fold and 2 fold 
increase in the transcript levels of vascular endothelial growth factors VEGF-165 
(p=0.02) and VEGF-189 (p=0.0008), respectively (figure 4.14 A) and a significant 
increase in the number of capillaries per fibre by 46% increase (p=0.005) (figure 
4.14 B-C).  
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Figure 4.14. Over-expression of ERRγ improves angiogenesis in mdx mice treated 
at 3-weeks old  
A) In EDL muscles from mdx mice treated at  3 weeks old, expression of VEGF-165 and 
VEGF-189 increases by 1.8 fold (p=0.02) and 2 fold (p=0.0008), respectively. B) CD31 
analysis of capillary number per fibre based on quantification the whole EDL muscle 
shows 46% increase (p=0.005). C) Representative images of mdx and mdx-ERRγ EDL 
stained with CD31 antibody, scale bar, 100 μm, (n=12 for mdx, n=10 for mdx-ERRγ, un-
paired student’s t-test). 
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4.3.6. Reduction in central nucleation following ERRγ over-expression in 
EDL muscles treated at 3 weeks of age: 
Haematoxylin and eosin staining was used to assess whether over-expression 
of ERRγ has an effect on central nucleation. EDL muscles from mice treated at 
3 weeks of age exhibited a 17% reduction in central nucleation following ERRγ 
over-expression (p=0.006) (figure 4.15).  
 
 
Figure 4.15. Over-expression of ERRγ in mdx mice treated at 3 weeks-old reduces 
central nucleation 
A) Percentage of centrally nucleated fibres in mdx and mdx-ERRγ of EDL muscles from 
3 weeks study shows 17% reduction (p=0.006). B) Representative images of cross 
sections of mdx and mdx-ERRγ EDL muscles stained with H&E, scale bar, 50 μm. (n=12 
for mdx, n=10 for mdx-ERRγ, un-paired student’s t-test). 
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4.3.7. Effect of ERRγ over-expression on muscle damage in mdx mice 
treated at 3-weeks old: 
To determine the effect of ERRγ over-expression on muscle damage, serum CK 
level was assessed. Similar to the previous study, no difference was found in CK 
level, IgG or MYH-3 positive fibres in EDL treated at 3 weeks of age (figure 4.16). 
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Figure 4.16. ERRγ gene transfer has no effect in CK levels, IgG infiltration or MYH-
3 positive fibres in mdx mice treated at 3-weeks old  
A) Creatine kinase assay measurement shows no difference in the blood serum between 
mdx and mdx-ERRγ (p=0.161). B, D) The percentage of IgG and MYH-3 positive fibres 
in the entire EDL muscles of mdx and mdx-ERRγ show no difference of the damaged 
fibres (p=0.228) or MYH-3 positive fibres (p=0.831). C, E) Representative images of 
cross section of mdx and mdx-ERRγ EDL muscles immunostained with anti-IgG 
antibody, anti-MYH-3 antibody, respectively. Scale bar, 50 μm, (n=12 for mdx, n=10 for 
mdx-ERRγ, un-paired student’s t-test). 
 
4.3.8. Impact of ERRγ over-expression on inflammation, degradation, 
translation, ubiquitination calcium and antioxidant markers in EDL 
muscle of mdx mice treated at 3-weeks old  
EDL muscle was used to assess the relative mRNA expression of inflammatory 
markers, degradation, translation, ubiquitination, calcium and antioxidant 
markers using specific primers for qRT-PCR for inflammatory markers; TNF-α 
(p=0.02), and IL-1β (p=0.04), were increased by 2 fold, whereas IL-6 was 
increased by 3 fold (p=0.03) and NF-κB was increased by 1.6 fold (p=0.01) with 
no difference in the expression of IL-10 (figure 4.17 A). None of the autophagy 
related genes; P62, Beclin-1, Bnip3, apoptotic marker; chathespin-L or atrophy 
gene; FOXO-1 were affected in the 3 week-old mdx (figure 4.17 B). Interestingly, 
there was a difference found in calcium receptor RYR-1 with 2 fold increase 
(p=0.03), with no difference in SERCA-1 expression following over-expression of 
ERRγ (figure 4.17 C). Genes involved in translation showed a decreased 
expression following ERRγ over-expression. Gadd34 was decreased by 0.26 fold 
(p=0.025) and 4EBP-1 was decreased by 0.69 fold (p=0.006) (figure 4.17 D). In 
addition, ubiquitination markers; Atrogin-1 and MuRf-1 were assessed and the 
transcript level of the latter was increased by 2 fold (p=0.045) (figure 4.17 E). The 
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expression of antioxidant gene SOD2 in the 3 weeks old mdx, tended to be 
increased but failed to reach significant (p=0.051) (figure 4.17 F). 
 
Figure 4.17. Impact of ERRγ over-expression on inflammation, degradation, 
translation, ubiquitination calcium and antioxidant markers in EDL muscle of mdx 
mice treated at 3-weeks old  
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Relative mRNA levels in the EDL muscles of mdx and mdx -ERRγ from 3 weeks study 
A) Inflammatory markers; 2 fold increase of TNF-α (p=0.02), 2 fold increase of IL-1β 
(p=0.04), IL-10 (P=0.348), 3 fold increase of IL-6 (p=0.03) and 1.6 fold increase of NF-
κB (p=0.01). B) Autophagy markers; P62 (p=0.342), Beclin-1 (p=0.08), Bnip3 (p=0.170), 
chathepsin-L (p=0.379), FOXO-1 (p=0.807). C) Indicated calcium markers; 2 fold 
increase in RYR-1 calcium channel (p=0.03), SERCA-1 (p=0.08). D) Relative mRNA 
levels for the indicated translation markers showed a 0.69 fold decrease of 4EBP-1 
(p=0.006) and 0.26 fold decrease of Gadd34 (p=0.025). E) Relative mRNA levels for the 
indicated ubiquitination markers, Atrogin-1 (p=0.383) and 1.5 fold increase of MuRF1 
(p=0.045). F) Relative mRNA levels for the antioxidant marker SOD2 (p=0.051), (n=12 
for mdx, n=10 for mdx-ERRγ, un-paired student’s t-test). 
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Table 4.1. Summary of the data for 3 and 6 week-old mdx experiments 
 
Colour guide: Red=increase, green=decrease, *p<0.01, **p<0.001, ***p<0.0001 
3 week-old Experiment
EDL muscle EDL muscle Gastrocnemius muscle
Muscle mass No difference No difference
specific force * No difference
maximum force No difference No difference
CSA No difference No difference
ERRγ ** ** **
VEGF-165 * No difference No difference
VEGF-189 *** No difference No difference
IL-10 No difference No difference
1L-1β * No difference
IL-6 * No difference
TNF-α * No difference
NF-κB ** **
PGC-1α ** No difference No difference
TFAM No difference No difference
ND2 No difference No difference No difference
NRF2 No difference No difference
PERM1 No difference No difference No difference
SIRT-1 No difference No difference No difference
Atp5 No difference No difference
cox5 No difference No difference
NduFp No difference No difference
Sdhc No difference No difference
FOXO-1 No difference No difference
P62 No difference No difference No difference
Cathepsin-l No difference No difference
Beclin-1 No difference No difference
Bnip3 No difference No difference
Atrogin No difference * No difference
murf-1 * No difference No difference
4EBP-1 ** No difference No difference
Gadd34 * No difference
RYR-1 * No difference
SERCA-1 No difference No difference
Antioxidant SOD2 No difference No difference
SDH **  **
H&E 17% reduction ** 8% reduction **
MYH-3 No difference No difference
IgG No difference No difference
MHC No difference No difference
CD31 **
ERRγ * No difference *
PGC-1α No difference
PERM-1 No difference
Complex I ** No difference
Complex II * No difference
Complex III * No difference
Complex IV No difference No difference
6 week-old Experiment
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4.4. Discussion 
The only published work on the impact of ERRγ on mdx pathology was 
addressed in transgenic mice, which showed 170 fold over-expression of ERRγ, 
however, did not permit determination of whether this approach has beneficial 
effects when initiated after the onset of muscle necrosis (Matsakas et al., 2013). 
In this chapter, we investigated the effect of postnatal over-expression of ERRγ 
in skeletal muscle of mdx mice and whether the gene delivery helps improving 
the defects in oxidative metabolism and angiogenesis and thereafter will help in 
delaying the disease pathology and improving muscle function. Two different 
ages of mdx mice were used in different studies; 6 week old, where mice 
experience cycles of degeneration and regeneration, consistent with previous 
work and earlier when mice start to exhibit early signs of muscle injury, at 3 week 
old, but for longer time.  
Over-expression of ERRγ in transgenic muscles of 170 fold is massively high 
comparing to the modest increase in all examined muscles in these two studies. 
However, the soleus muscles from 6 week-old mdx study, showed no change in 
the expression of ERRγ. Unchanged expression may be due to low transduction 
of AAV in soleus muscles which is composed by type 1 and type IIA fibres. A 
study using AAV8/lacZ in utero showed rare transduction of slow-twitch fibres 
(Koppanati et al., 2009); this demonstrate preferential transduction of AAV8 into 
fast-twitch muscle fibres.  
Muscle from mdx mice has been shown previously to experience force deficit due 
to loss of dystrophin (Brooks and Faulkner, 1988). Here we demonstrated that, 
EDL muscles from mdx mice treated with AAV8-ERRγ at 3 weeks of age showed 
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an increase in specific force in addition to an increase in oxidative capacity, 
angiogenesis markers and increased number of capillary density. They also have 
shown upregulation of inflammatory markers and down regulation of genes 
involved in translation. On the other hand, although EDL muscles from mdx mice 
treated with AAV8-ERRγ at 6 weeks of age showed similar over-expression of 
ERRγ, however, no improvement in specific force or any of the other parameters 
were observed. It is important to mention that gastrocnemius muscles showed 
the highest level of ERRγ over-expression in the 6 weeks study, therefore, we 
used it to assess pathology and some of the genes.  
It is important to consider that skeletal muscle represents about 40% of body 
mass. Therefore, under the condition of dystrophic pathology, metabolic rate is 
decreased compared to the control and varies during mice life. For example, 
different studies have assessed the effect of mdx age on energy requirement. 
Two studies on 6-12 months old mdx showed no difference in energy 
expenditures (Dupont-Versteegden et al., 1994, Mokhtarian et al., 1996). In 
contrast, at 4-6 weeks of age, the metabolic rate was less compared to the 
control, which was attributed indirectly to the increased rate of muscle 
degeneration and regeneration, disturbance of Ca+2 homeostasis, ultimately 
decreased physical activity. Interestingly, effect of time of intervention on the 
outcomes of gene therapy was addressed by different studies using AAV 
mediated expression of PGC-1α. Administration of AAV6-PGC-1α into neonatal 
or 3 weeks or 12 months old mdx resulted into different outcomes, which highlight 
the effect of time as an essential parameter to account for when discussing the 
results of gene therapy. For example; AAV-PGC-1α into neonatal mdx showed 
an increased expression of mitochondrial genes and an improvement in muscle 
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function. On the other hand, no effect on histology or gene expression were 
observed when the virus administered at 12 months of age. In addition, treated 
mdx at 3 weeks of age with the same vector showed an increase in the genes 
related to inflammation, metabolism, sarcomere, but no change in the number of 
fibres with central nucleation. The results of these studies will be discussed 
throughout this chapter as a comparison to our results and to emphasize the 
effect of time of intervention on the outcomes obtained in this chapter (Hollinger 
and Selsby, 2015, Hollinger et al., 2013, Selsby et al., 2012). Further, 
administration of quercetin into 3 months old mdx for 6 months decreased 
histopathological injury in the heart and diaphragm and decreased inflammation 
(Hollinger et al., 2015), however, administration for long term showed different 
outcomes. In a study of 2 months old mdx, respiratory function was protected for 
the first 4-6 months of treatment, but later become insensitive. These results 
again highlight the importance to consider factors such as age and length of 
treatment on the outcomes (Selsby et al., 2016).    
In dystrophic muscle, oxidative stress leads to mitochondrial dysfunction and to 
50% reduction in ATP availability (Kuznetsov et al., 1998, Even et al., 1994). Loss 
of NO disturb glucose metabolism, as there is a reduced expression of Glut4, 
responsible for glucose uptake, therefore, represents one of the causes of energy 
deficit in dystrophy (Olichon-Berthe et al., 1993, Schneider et al., 2018). Reduced 
ATP production in mdx mice has been demonstrated previously to disturb Ca+2 
buffering and diminish satellite cell repair mechanisms (Onopiuk et al., 2009). It 
is also associated with a reduction in the ability of a muscle to produce force and 
altered cross bridge mechanics (Fitts, 1994). Dystrophic mitochondria are more 
susceptible to damage as they are more fragile at both the inner and outer 
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mitochondrial membranes (Scholte and Busch, 1980). It is though that 
mitochondrial dysfunction results from 1) Ca+2 overload which lead to inhibition 
of ATP synthesis and continued permeability of transition pore (PTP) (Ascah et 
al., 2011). 2) Mitochondrial mis-localization is another reason, as proper 
mitochondrial localization is important to function. Mitochondrial pool work in a 
system that allows them to translocate to the sites of increased metabolic 
demand and they are extremely responsive to changes in regions of intracellular 
environment. However, loss of dystrophin has negatively impact the localization 
and density of sub-sarcolemmal mitochondria (Percival et al., 2013). 3) Impaired 
mitophagy and accumulation of damaged mitochondria that are not perform 
properly in energy production and have increased chance to undergo opening of 
PTP complex which leads to mitochondrial swelling, collapse of mitochondrial 
membrane potential that induce apoptosis (Grumati et al., 2010). All of this leads 
to further elevation of ROS, which then further impacts on calcium dysregulation 
and mitochondrial function.     
It is well established that mitochondrial ATP synthesis depends on normal 
respiratory chain function, which is known as the oxidative phosphorylation 
system that coordinates electron transfer with the proton gradient to generate 
ATP. Defects in mitochondrial respiratory chain by mean of impaired function of 
mitochondrial enzymes can cause skeletal muscle weakness in mdx muscle 
(DiMauro, 2006). Here, specific force produced from muscle of 3 week-old mdx 
overexpressing ERRγ was greater than the control. Accordingly, protein levels of 
mitochondrial protein complex, OXPHOS enzymes as complex (I, II and III) were 
increased in 3 week-old mdx, as well as expression of sdha, which is the active 
subunit of the SDH enzyme that links two important pathways within 
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mitochondria; the Krebs cycle and oxidative phosphorylation. As part of the Krebs 
cycle, sdha converts succinate to fumarate and transfers electron to oxidative 
phosphorylation (Comim et al., 2016). Succinate dehydrogenase (SDH) enzyme 
activity in the muscle cross sections were increased in mdx mice treated at 3 and 
6 weeks of age following 3 and 10 fold over-expression of ERRγ in EDL and 
gastrocnemius muscles, respectively. Interestingly, lower over-expression of 
ERRγ in EDL muscles resulted in higher improvement in SDH. The difference in 
the distribution of muscle fibre types between EDL and gastrocnemius muscles 
is potentially the reason for this difference, which may affect the response of 
these fibres to ERRγ over-expression. Using mATPase method, EDL muscles 
shows predominance with type IIB fibres and a lower proportion of type I fibres. 
Gastrocnemius muscle has higher proportion of IID fibres and less with type IIB 
fibres (Cornachione et al., 2011).   
Recently, it has been demonstrated that dystrophic muscles exhibit deficiency in 
the capacity of mitochondrial oxidative phosphorylation, specifically, a deficiency 
in mitochondrial complex I function, which limit the ATP producing capacity of 
mitochondrial. The problem was with NADH influx into ETC, whereby NADH is 
unable to be oxidized by complex I or is being sequestered away from complex I 
to establish proton motive force (Rybalka et al., 2014, Godin et al., 2012). In 
addition, mdx mitochondrial encountered decreased mitochondrial biomass 
which underscores loss of ETC function (Rybalka et al., 2014, Percival et al., 
2013, Godin et al., 2012). Transgenic over-expression of ERRγ in skeletal 
muscles of mdx mice increase mitochondrial enzyme activity and enhance 
expression of genes involved in electron transport chain (Narkar et al., 2011, 
Matsakas et al., 2013). Phenotypic characterization revealed that ERRγ whole 
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body knockout demonstrated reduced expression of tricarboxylic acid cycle 
(TCA) and electron transport chain (ETC) complex I enzymes (Alaynick et al., 
2007). These results were based on gain-and-loss of function, therefore, we 
hypothesize that over-expression of ERRγ postnatally will improve expression of 
defective genes in mdx mice. In the study of 3 week-old, mRNA expression of 
the other nuclear encoded genes NduFp, Atp5, sdhc subunits showed a trend of 
increase, however, failed to reach significant difference. Moreover, expression of 
the cytochrome c oxidase Cox5, complex IV, was not different between the two 
groups in this study. However, discrepancy in the literature about Cox expression 
has been reported. Kuznetsoz et al., has reported that activity of Cox was 
reduced in mdx quadriceps muscles compared to the control (Kuznetsov et al., 
1998). Alternatively, others have reported unchanged activity of Cox in mdx and 
DMD patients (Percival et al., 2013, Sperl et al., 1997, Rezvani et al., 1995). We 
could speculate that the time for increased Cox expression is not yet to respond 
to the ERRγ over-expression, or, perhaps the increased expression has peaked 
earlier, exerted its effect and then reduced to basal level once again. Literatures 
have reported this type of effect in different fields, for example; AchE expression 
is time dependent in co-culture of cell line that resemble motor neuron (NG108-
15) cells with chick myotubes. The induction reached maximum after 2 days of 
transfection of luciferase-tagged mouse AchE promoter and then plateau (Jiang 
et al., 2003). Similarly, C2C12 myoblast treatment with serum shock showed time 
dependent manner of over-expression of MyoD (myogenic marker), reached 
maximum over-expression after 16 hours and then lowered to basal level, then 
upregulated again after 32 hours (Chatterjee et al., 2013). Further, following 
skeletal muscle injury, markers of immune and satellite cells, factors for muscle 
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regeneration increased in the early stage of recovery and then all genes returned 
to normal at 14 days post injury (Xiao et al., 2016). Therefore, we could speculate 
that similar pattern of expression has occurred in the genes including in this 
study, where they were overexpressed as a transient adaptation to the over-
expression of ERRγ and then return back to basal level.  
Furthermore, athletes who stop training after extensive exercise, their muscles 
show adaptation that maintain the mass and strength of the muscles for some 
time before complete loss. By assessing SDH activity, analysis showed stabilized 
SDH activity for the next 12 days of inactivity and then started to reduce (Coyle 
et al., 1984). In our study, given the improved specific force by 14% and 
increased protein activity of mitochondrial proteins, it is likely to suggest that the 
cells are more capable of ATP production and may indicate an increased 
mitochondrial number or volume. We could also anticipate that over-expression 
of ERRγ results in the early adaptive responses that have benefits over a more 
protected time period, which is the increase in specific force. Although, with active 
cycles of regeneration, the virus has been lost, however, some benefits remains 
at endpoint. With loss of virus, we can overcome this by the use of the mimetics 
that overexpress ERRγ, as described in the previous chapter. The virus loss has 
been addressed previously as one of the major issue encountered with AAV 
based gene therapy due to the cycles of degeneration and regeneration (Le Hir 
et al., 2013, Peccate et al., 2016). However, this could be overcome with 
repeated administration or combined therapy with dystrophin rescue (Peccate et 
al., 2016, Majowicz et al., 2017). The extent of the metabolic improvements were 
not seen in 6 week-old mdx and so the lack of force improvements. Speculatively, 
in 3 week-old mdx, which showed an increase in specific force, metabolic 
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improvements increased platform to produce ATP, which possibly match the 
demand at cross-bridge level and then result in the specific force improvement. 
Further, increased mitochondrial volume limits the contribution of free radicals 
and calpain to disease-related muscle injury (Spencer and Mellgren, 2002).  
We also assessed the level PGC-1α, co-activator of ERRγ (Sever and Glass, 
2013). Interestingly, similar of what has been shown for PGC-1α and other 
regulators (MEF-2 factors) in skeletal muscle (Hock and Kralli, 2009, Handschin 
et al., 2003), PGC-1α expression was increased in treated muscles compared to 
the control in the young treated mdx, suggesting the presence of a positive 
feedback regulatory loop. Despite the increase in the PGC-1α mRNA expression 
following over-expression of ERRγ in 3 week-old mdx, the corresponding protein 
level was unchanged. This is reminiscent of changes seen in mice fed with 
resveratrol (Gordon et al., 2013). In contrast to our study, the transgenic mice 
with 170 fold over-expression of ERRγ has no effect on the expression of PGC-
1α (Matsakas et al., 2013). Moreover, this is opposite to what has been shown in 
myotubes obtained from primary cell line of transgenic muscle of ERRγ, where 
induction of ERRγ resulted in down regulation of PGC-1α (Rangwala et al., 2010, 
Matsakas et al., 2013). Hence, these difference between our study and data 
based on transgenic muscles are possibly due to different level of ERRγ over-
expression between transgenic and gene transfer approach. Alternatively, it 
could be one of these parameter that respond to ERRγ in the first instance and 
then turn down due to vector loss (Peccate et al., 2016, Majowicz et al., 2017).  
As mentioned earlier, there may be a consequence to turn off the expression of 
these genes that showed no difference, after they did their function (Wan et al., 
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2012). Furthermore, massive over-expression does not always lead to an 
increase in the other family members or genes in the same pathway. They may 
work in an independent or dependent manner as shown in the family of orphan 
receptors. For example; ERRs are shown to work in a compensatory manner in 
heart, where ERRγ is upregulated in ERRα-null mice. Also, a complete inhibition 
of individual ERR isoform does not prevent mitochondrial biogenesis or activity 
due to presence of a compensatory mechanism through increased expression of 
other isoforms (Murray et al., 2013, LaBarge et al., 2014).  
In addition to measuring oxidative gene expression, we also assessed PGC-1α 
pathway change because of increased expression of PGC-1α. However, 
expression of genes involved in mitochondrial biogenesis (SIRT1, NRF2, ND2 
and TFAM) were not affected with the over-expression of ERRγ in our study, 
possibly due to the fact that ERRγ over-expression is not sufficient to induce such 
changes or alternatively, these genes were overexpressed at some point, 
establish an effects and then return back to basal levels. For example; ND2 was 
shown to increase after 2 hours of CBD treatment. However, at a 24 hour 
timepoint, its expression return back to control levels (Foster et al, personal 
communication).  
SIRT1 is working upstream of PGC-1α, and its expression has been shown to 
increase following over-expression of PGC-1α by AAV gene transfer in neonatal 
mdx (Selsby et al., 2012). It is generally thought that induction of mitochondrial 
biogenesis is under the control of transcriptional coactivators PGC-1α and PGC-
1β which control the binding of their downstream factors (nuclear respiratory 
factor); NRF-1, NRF2 (GABP) and ERRα to the promoter of nuclear genes 
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encoding regulators of oxidative phosphorylation and mitochondrial replication 
and transcription (TFAM) (Hock and Kralli, 2009, Scarpulla et al., 2012). To test 
the general changes in mitochondrial biogenesis we measured expression of 
NRF-2, which was unchanged, may explain unchanged expression of TFAM. In 
muscle, NRF-2 is believed to control transcription of utrophin gene (Angus et al., 
2005). Consistent with this, expression of utrophin was unchanged. Similar to 
what has been shown in transgenic muscle of ERRγ, where no increase in the 
localization of utrophin in the sarcolemma (Matsakas et al., 2013). However, 
activity of PGC-1α is not controlled by increased in protein level only but also 
through post translational modification (PTM), acetylation, therefore, the 
expression of PGC-1α target TFAM was unchanged as the activity of PGC-1α 
protein was not changed. As there is no increase in the mitochondrial biogenesis 
related genes; ND2, NRF2 and TFAM, in the presence of an increase in the 
activity of mitochondrial proteins involved in electron transport chain, we could 
speculatively suggest there is no difference in the mitochondrial number but the 
function or performance of mitochondria was improved and therefore cause 
ability to meet cellular ATP demand; given that muscle oxidative capacity not only 
relies on mitochondrial density but also on mitochondrial function.   
Skeletal muscle has mitochondria located beneath the sarcolemmal membrane 
(subsarcolemmal, SSM) or between the myofibrils (intermyofibrillar, IMF) 
(Hoppeler and Flueck, 2003). It was demonstrated that despite the reduction in 
the density of the SSM content, there is no significant difference in the total 
mitochondrial content between dystrophic muscles and the control. Moreover, 
the disruption in SSM localization promotes mitochondrial inefficiency and reduce 
mitochondrial ATP-generating capacity. Therefore, the reduction in energy 
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available was not due to a reduction in mitochondrial number, per se (Percival et 
al., 2013, Even et al., 1994, Rybalka et al., 2014, Kuznetsov et al., 1998). 
Generally, it was demonstrated that mitochondrial performance depends on 
number, activity and energetic efficiency (Crescenzo et al., 2015). Therefore, 
unchanged expression of genes associated with mitochondrial biogenesis does 
not conflict with the improvement of mitochondrial efficiency as it is possible that 
specific population of mitochondria may be more responsive to ERRγ over-
expression. In further studies, the use of mitochondrial fraction rather than the 
total mitochondria will address this question as whether ERRγ over-expression 
has specific effect on each population of mitochondria in term of number and 
performance.   
PERM1 has been shown to act as a downstream effector of PGC-1α and ERRs 
and it is required for maximal oxidative capacity by upregulating genes related to 
mitochondrial biogenesis (Cho et al., 2013). Unexpectedly, over-expression of 
ERRγ did not increase the transcript or protein level of PERM1, possibly because 
the effect of ERRγ over-expression is not sufficient or its expression in mdx mice 
was not decreased to the level that require an upregulation by ERRγ. Further 
analysis including wild type mice will add more clarity on the level of this gene in 
dystrophic muscle.  
In many transgenic mouse models, an increase in muscle oxidative capacity is 
closely associated with a shift towards more oxidative muscle fibre type. For 
example; muscle specific over-expression of ERRγ, PGC-1α, PGC1-β and 
PPARδ showed increased number of type I, IIA, IIX and a decrease in type IIB 
(Matsakas et al., 2013, Rangwala et al., 2010, Lin et al., 2002, Arany et al., 2007, 
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Wang et al., 2004). In addition, rescue of dystrophic muscle by AAV-PGC-1α 
over-expression in neonatal mdx involves fast to slow fibre shift (Selsby et al., 
2012). In contrast, postnatal over-expression of ERRγ at 3 weeks of age in mdx 
mice showed enhanced oxidative capacity but no changes in fibre type 
composition. The lack of change is expected as other studies were performed on 
transgenic mice; for example transgenic overexpression of PGC-1α, which is 
known to promote expression of type I and IIa fibres (Lin et al., 2002). As there 
was no shift towards slow oxidative fibres, we did not observe an increased 
expression of utrophin which is highly expressed in slow oxidative fibres 
(Chakkalakal et al., 2003). Since the increase in ERRγ in the current studies are 
moderate and postnatally compared to other transgenic models where the 
increase of different transcription factors take place throughout development, 
possibly the effect of ERRγ is restricted to specific target genes for example; 
mitochondrial protein to improve energy production, angiogenesis genes but not 
towards the genes controlling fibre typing.  
Besides enhancing oxidative capacity, over-expression of ERRγ in 3 week-old 
mdx showed enhanced vascularisation, which has been seen previously as a 
muscle adaptation in response to endurance exercise (Chinsomboon et al., 
2009). ERRγ increased expression of VEGF-165 and VEGF-189, factors 
important for angiogenesis (Tammela et al., 2005b). This change suggests that 
ERRγ promotes angiogenesis to meet the increased muscle oxidative capacity. 
Alternatively, the oxidative stress in these cells is reduced so metabolic stress is 
reduced. We could suggest that over-expression of ERRγ has similar effect in 
vascularisation as seen in mice with transgenic over-expression of PGC-1α, 
PGC1-β or ERRγ (Arany et al., 2008, Chinsomboon et al., 2009, Narkar et al., 
 
 
222 
 
2011). VEGF over-expression-induced angiogenesis has been show to promote 
regeneration which is possibly helps in delaying the disease progression 
(Messina et al., 2007).   
In the context of force production, it has been demonstrated that in vivo over-
expression of VEGF-165 in wild type mice following ischemia decreased skeletal 
muscle cell apoptosis suggesting a role in muscle cell survival. In addition, in vitro 
over-expression of VEGF-165 in C2C12 cells induced myoblast cell migration 
possibly by activating signalling which modulate migration (Germani et al., 2003). 
Messina et al., has demonstrated that over-expression of VEGF has a powerful 
effect on muscle from mdx mice, in which increased number of myogenic positive 
satellite cells and developmental myosin heavy chain cells suggested a 
regenerative effect of VEGF. Importantly, VEGF over-expression enhanced 
forelimb strength (Messina et al., 2007). The question is how increasing 
angiogenesis marker following ERRγ over-expression may contribute to 
increased specific force in 3 week-old mdx. The fact that studies have 
demonstrated an association between angiogenesis and myogenesis by an 
interaction between vascular cells and myogenic progenitor cells and there is a 
correlation between number of capillary and the number of stem cells (SC) 
associated with the same myofibre (Latroche et al., 2017). We could anticipate 
that the angiogenesis markers improve the capacity of SC to activate and 
proliferate through its regenerative effects. However, because no difference in 
the percentage of MYH-3 was observed in these mice, we excluded the increase 
in the repair. Therefore, the increase in the angiogenesis marker could be a 
response of increased metabolic demand. Alternatively, these stem cells will 
possibly give rise to myogenic precursor cells (MPCs) that express Pax7 and 
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then Myf5 and MyoD. These MPS will differentiate and fuse to form new myofibre 
or fuse to existing damaged fibres (Yin et al., 2013). Later, it is possible these 
newly formed myofibres exhibit increased expression of sarcomeric protein that 
maintain muscle contraction. Therefore, increasing expression of angiogenic 
markers in this study following over-expression of ERRγ may play a role in 
enhancing muscle function. Interventions that increase vascular density such as 
exercise is beneficial in the management of muscle ischemia to recruit more 
blood vessels and enhance the reparative re-vascularisation and reperfusion 
(Ding et al., 2004, Cheng et al., 2010). ERRγ has been demonstrated previously 
to reverse muscle ischemia by remodelling the myofibres to be more oxidative, 
which express high levels of angiogenic factors and increased blood flow 
(Matsakas et al., 2012). In this study, we showed an increase in the capillary 
density, which is a measure of neoangiogenesis (Al Haj Zen et al., 2010). 
Therefore, it is likely to reduce ischemia, which is considered one of the causes 
of muscle weakness in dystrophic muscles as it impairs recovery from fatigue 
(Allen et al., 2016). The fact that increased ischemia is associated with reduced 
activity of electron transport chain complex that impair the ETC, resulting in 
decreased ATP production,  reduction of oxygen, that affect antioxidant system 
and increase ROS, all make cells more susceptible to oxidative stress (Rouslin, 
1983). Speculatively, improved ischemia following increased capillary density 
and increase activity of mitochondrial complex in 3 week-old mdx will reduce 
metabolic stress, increase the level of ATP available for excitation-contraction-
coupling and increase force production. 
Defect in vasoconstriction response triggered by muscle-derived NO due to miss-
localization of nNOS is observed in mdx during muscle contraction resulting in 
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muscle ischemia (Froehner et al., 2014). In this respect, sildenafil, a 
phosphodiesterase type 5 inhibitor (PDE-5) was shown to improve blood flow in 
muscle and improve diaphragm force production by enhancing the NO-cGMP 
signalling pathway (Percival et al., 2012). NO is known to directly involve in 
modulation of excitation-contraction coupling and nNOS is the main source of NO 
in skeletal muscle. Targeting nNOS was shown to be remarkable effective in 
improving muscle function by using modulated form of nNOS in mdx mice 
(Rebolledo et al., 2016) and clinical trial on inducing NO signalling resulted in 
improving muscle function in DMD patients (Hafner et al., 2016). In consistence 
to our finding, transgenic over-expression of nNOS in mdx reduce central 
nucleation without restoring utrophin expression (Wehling et al., 2001). We could 
speculate that improving muscle function following over-expression of ERRγ 
occurs in part via restoration of nNOS and NO signalling. Improving angiogenesis 
and its impact on myogenesis is a new player and a potential therapeutic target 
in DMD research that should be considered in the future studies.  
In mdx mice, centrally nucleated fibres are considered an index of muscle fibre 
regeneration (Ferrari et al., 1998). Our results showed fewer centrally nucleated 
fibres in 3 week and 6 week old treated mdx which suggested less regeneration 
and hence less damage in these muscles overexpressing ERRγ. However, fibres 
infiltrated with IgG, embryonic myosin positive fibre and CK level were not 
decreased in the treated muscles likely due to the high variability between the 
muscles and possibly due to unchanged level of utrophin expression. Intensive 
studies were targeted to rescue muscle damage either by dystrophin or utrophin 
replacement (Rafael et al., 1994, Hirst et al., 2005, Rafael et al., 1998, Tinsley et 
al., 1998, Phelps et al., 1995). In contrast to our study of young mice, over-
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expression of PGC-1α in 3 week-old mdx induced utrophin expression with no 
change in central nucleation (Hollinger et al., 2013). Here, the reduction in central 
nucleation in both studies following over-expression of ERRγ could indicate a 
beneficial reduction in muscle cell degeneration or damage or a reduction in 
muscle regeneration. Previous nNOS-null mice studies showed that CK level 
were unaffected even though central nucleation was reduced (Froehner et al., 
2014), being consistence with both studies discussed in this chapter. The fact 
that ERRγ carried out at different ages complicates the interpretation of these 
data. The possible explanation here is that reduced central nucleation in 6 week-
old mdx results from reduced regeneration. However, in 3 week-old mdx, the 
reduction is possibly results from reduced degeneration, which is supported by 
the increase in angiogenesis and inflammation markers, known to involve in 
regeneration and repair (Palladino et al., 2013, Arsic et al., 2004, Li et al., 2005, 
Karin and Clevers, 2016, Wynn and Vannella, 2016).  
Inflammation plays a critical role in the development of pathology of DMD. 
Disruption of DGC components results in activation of innate immune system and 
inflammatory signalling pathway that ultimately lead to degeneration and 
progressive muscle weakness (Evans et al., 2009b). In the study of 3 week-old 
mdx but not in 6 week, over-expression of ERRγ resulted in an increase in the 
transcript levels of NF-κB, TNF-α, IL-1β and IL-6 with no effect on IL-10. We 
anticipated the unchanged expression of IL-10 to the effect of intervention time. 
It is possible that with upregulation of other pro-inflammatory cytokines, it is not 
the time for this anti-inflammatory cytokine to upregulate. Although, TNF-α is 
known as pro-inflammatory cytokine, it is thought to have a maintenance role in 
the muscle fibre where the level of TNF-α was found to be higher in regenerating 
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muscle fibres. It was hypothesized that generation of double knock out mouse 
for TNF-α (TNF-mdx), would improve pathology associated with dystrophin 
mutation. However, the results obtained from that model was unexpected as the 
body weight was reduced and serum CK level and whole body strength was 
unaffected, suggesting that depletion of TNF-α would be compensated by 
upregulation of other inflammatory cytokines (Spencer et al., 2000). 
Speculatively, depletion of TNF- will minimize the level of regeneration which 
emphasize that at certain point in mdx mice life, there is a need to upregulate the 
level of pro-inflammatory cytokines in order to repair the muscle damage. 
Moreover, eliminating total TNF-α expression contributed to pathological 
progression in mdx diaphragm muscles (Grounds and Torrisi, 2004). Since 
differentiating myoblast was shown to increase the release of TNF-α that is 
correlated with regenerating activity (Chen et al., 2007) and ERRγ is essential in 
regulating myogenesis (Murray et al., 2013), it is potentially possible to suggest 
that myogenesis promoted by over-expression of ERRγ is associated with 
increased level of TNF-α.  
IL-6 has both pro and anti-inflammatory properties, involves in inflammation, 
regulation of regeneration and anti-inflammatory processes by acting through two 
signalling pathways (Scheller et al., 2011). In one hand, blocking IL-6 with a 
monoclonal antibody in mdx mice led to an increase in muscle inflammation 
suggesting IL-6 has an anti-inflammatory effect possibly by mediating muscle 
repair, however, without improving muscle function (Kostek et al., 2012). Further, 
blockade of IL-6 attenuated the dystrophic pathology of mdx mice (Pelosi et al., 
2015). In support to anti-inflammatory role of IL-6, it has also been reported to 
involve in muscle regeneration by inducing myoblast differentiation (Serrano et 
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al., 2008). Treating various cells for 48 hours with IL-6 results in a significant 
induction of VEGF, which highlight a role of IL-6 in angiogenesis pathway (Cohen 
et al., 1996). Therefore, we could suggest a link between increasing mRNA 
expression of VEGF-165 and VEGF-189 and increased capillary density in 3 
week-old mdx study, as these changes are a consequence to the increased level 
of IL-6.  
Then, increasing expression of IL-1β has been shown to stimulate hypoxia-
inducible factor 1α (HIF-1α), resulting in increased expression of VEGF (Silvestre 
et al., 2000). Therefore, we may suggest a link between increased expression of 
IL-1β in 3 weeks study and improved angiogenesis markers. However, all of 
these interactions require further investigation via assessing HIF-1α to elucidate 
any direct link between them. Further, growing body of evidence suggested that 
IL-6 is regulated, in part, by IL-1β through MAP kinase activity as shown in C2C12 
cells, treated with IL-1β (Luo et al., 2003a), which may suggest a link between 
IL-1β and IL-6 over-expression in EDL muscles of 3 weeks study.  
IL-10 works as anti-inflammatory cytokine through deactivating M1 macrophages 
and activating M2 macrophages, which promote angiogenesis and repair, 
whereas M1 macrophages produce pro-inflammatory cytokines. IL-10 null 
mutation causes severe reduction of muscle strength possibly due to imbalance 
between M1 and M2 that may affect muscle repair process (Arnold et al., 2007, 
Villalta et al., 2010). However, its expression was unaffected by the over-
expression of ERRγ, possibly because other cytokines were upregulated and 
compensate for its role in regeneration. Noteworthy, immune pathology in 
dystrophic muscle is complex in which full immunological repair, the transition 
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from M1 to M2 phenotype, is never achieved due to on going asynchronous 
damage.  
A PCR array on muscles from transgenic mice overexpressing ERRγ showed 
increased expression of IL-6 and IL-1β (Matsakas et al., 2013). Similarly, over-
expression of PGC-1α in mdx mice via gene transfer approach resulted in 
increased expression of the same cytokines; TNF-α, IL-6 and IL-1β (Hollinger et 
al., 2013, Selsby et al., 2012). Likewise, we are reporting similar results following 
over-expression of ERRγ. These results suggest the possibility that increased 
inflammation pathway is a direct result of increased these two genes (ERRγ and 
PGC-1α). All studies of AAV-PGC-1α were recovered 3 weeks post 
administration, which means the upregulation of inflammatory cytokines was not 
due to the virus infection per se. Therefore, despite using saline as a control in 
our studies, the upregulation in the pro-inflammatory cytokines here could not be 
a result of virus infection because the recovery time in our study was 6 weeks 
post administration. Also, reports have showed that PGC-1α over-expression 
activate NF-κB by phosphorylation (Olesen et al., 2012). Whether ERRγ has 
same effect since they share same target genes, it is for future work to 
investigate.  
Moreover, accumulative evidence suggests an association between 
inflammation and angiogenesis as a protection against exacerbated pathology. 
In mdx mice; ischemia, hypoxia and inflammation are considered as stimuli of 
angiogenesis (Shweiki et al., 1992, Silvestre et al., 2000). We could suggest a 
link between increasing angiogenesis and inflammation markers reported in the 
same study of overexpressing ERRγ at 3 weeks of age, where these 
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inflammatory cytokines (TNF-α, IL-1β and IL-6) stimulate expression of 
angiogenesis following over-expression of ERRγ. Oriana del Rocío Cruz-
Guzmán et al., has reported an association between the level of inflammatory 
cytokines and muscle function in DMD patients. Patients with improved muscle 
function, they showed increased level of inflammatory cytokines (TNF-α, IL-1β 
and IL-6) (Cruz-Guzmán et al., 2015). Speculatively, increasing expression of 
(TNF-α, IL-1β and IL-6) in young mice study could be associated with improved 
specific force.  
However, none of these changes were observed in the study started at 6 weeks 
of age, in which force was not changed, except the increase of NF-κB, which is 
expected in dystrophic environment. Since the early life of the mdx mouse (3-12) 
weeks of age is considered the period of highest level of necrosis and 
inflammation (Grounds et al., 2008), assessing the potential of ERRγ to remodel 
the cytokines level is appropriate. As we determine the effect at one time point is 
a limitation in each study, further studies by cell sorting on fresh tissues to 
quantify inflammation precisely could address the direct effect of ERRγ on 
inflammation.   
The rapid release of Ca+2 from the sarcoplasmic reticulum through the ryanodine 
receptors induces the contraction of myofibrils and the re uptake of Ca+2 by the 
Ca+2ATPase (SERCA pump) induces relaxation. Precise balance between Ca+2 
release and uptake is required to maintain the functioning of contraction/ 
relaxation process (Berchtold et al., 2000). In mdx mice, a functional defect was 
identified in the RYR-1 receptor, which contributes to altered Ca+2 homeostasis 
in dystrophic muscle. S-nitrosylation of RYR-1 in dystrophic muscles lead to 
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depletion of calstabin-1 (FKBP12) from RYR-1. Calstabin-1 is a calcium channel 
stabilizing binding protein. Deletion of calstabin-1 specifically in skeletal muscle 
has been shown to cause a loss of depolarization-induced contraction and 
impaired excitation-contraction coupling because of reduced maximal voltage-
gated SR Ca+2 release (Tang et al., 2004).   
Moreover, in mdx mice there is evidence of reduced levels of SERCA-1 
expression and impaired capacity of Ca+2 pumping by SERCA-1 which leads to 
impaired Ca+2 removal from the sarcoplasm (Divet and Huchet-Cadiou, 2002, 
Kargacin and Kargacin, 1996). Over-expression of SERCA-1 has been shown to 
mitigate the dystrophic disease pathology in mdx mice as well as the muscle 
damage induced by contraction (Quinlan et al., 1992, Goonasekera et al., 2011). 
In our study there is a trend of increased expression of SERCA-1 in mdx mice 
treated with AAV8-ERRγ at 3 weeks of age, however, did not reach a significant 
difference. In contrary to our results, transgenic over-expression of PGC-1α 
showed decreased expression of SERCA-1 and RYR-1, which resulted in 
reduced maximal force production following chronic exercise (Summermatter et 
al., 2012). Speculatively, we could suggest that the increase in specific force in 3 
week-old mdx following over-expression of ERRγ may be due to the alteration in 
the expression of RYR-1 which then involve in the correction of Ca+2 handling 
and reduce the level of ROS. As a result, the stress of reactive nitrogen species 
(RNS) is reduced and muscle force is subsequently increased. On the other 
hand, there was no change in the expression of these calcium receptors in 6 
week-old mdx treated with AAV8-ERRγ, which in away correlated with 
unchanged muscle function. Further investigation on the effect of ERRγ over-
expression on Ca+2 handling mechanism is required.  
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Antioxidant gene expression such as catalase, superoxide dismutase 1 (SOD1), 
superoxide dismutase 2 (Sod2) (Hollinger and Selsby, 2015) and glutathione (Lu, 
2013) were decreased in dystrophic muscle compared to healthy muscle. We 
demonstrated that expression of (SOD2), a mitochondrial antioxidant enzyme 
showed a trend of increased expression following over-expression of ERRγ, 
however, failed to reach significance in 3 week-old mdx. Comparable to our 
result, inducing expression of PGC-1α in mdx muscle via AAV at 12 months 
showed no effect on SOD2 expression (Hollinger and Selsby, 2015). It is possible 
that level of oxidative stress in the 3 week treated mice has already been reduced 
through reducing metabolic stress, reducing central nucleation fibres and 
increasing expression of calcium release channel (RYR-1), hence, no need to 
increase expression of antioxidant, SOD2 at the same time. In response to 
oxidative stress, NRF-2 is activated as a general regulator of antioxidant genes 
(Zhang et al., 2015). Since the expression of NRF-2 was unaffected following 
over-expression of ERRγ in 3 weeks study, it supports this argument of reduced 
oxidative stress in these mice. Interestingly, resveratrol induced upregulation of 
SOD1 but not SOD2 in mdx mice when treated at 9 weeks of age (Hori et al., 
2011), which attract the attention of investigating other antioxidants to clarify the 
direct effect of ERRγ over-expression on ROS and detoxifying enzymes and 
highlight the importance of intervention time and length of studies as these 
factors lead to different outcomes. 
In the past few years, studies have started to emerge on impaired autophagy in 
DMD as evidenced by the presence of swollen mitochondrial, protein aggregation 
and distension of sarcoplasmic reticulum (Culligan et al., 2002) and activation of 
Akt signalling in mdx muscles (Dogra et al., 2006) and DMD patients (Peter and 
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Crosbie, 2006). Activation of Akt-mTOR pathway resulted in inhibition of related 
autophagy pathways (Dogra et al., 2006, Peter and Crosbie, 2006). Other studies 
based on pharmacological treatment of mdx with AICAR, an agonist of the energy 
sensor AMPK, resulted in activation of autophagy through inducing activity of LC3 
that further impact on improving mitochondrial integrity via increased resistance 
to PTP opening and improve muscle structure and function (Pauly et al., 2012). 
Moreover, PGC-1α over-expression through gene transfer into 3 week-old mdx 
enhanced expression of LC3 and Atg12 (Hollinger et al., 2013). As ERRγ share 
similar target genes with PGC-1α, it was expected that over-expression of ERRγ 
gene transfer may perform a similar function. Conversely, assessing the 
expression of genes involved in autophagy showed no effect of ERRγ over-
expression on any of these genes. However, a debate exists as Spitali et al., has 
reported that protein levels of autophagy marker in mdx are similar to wild type 
mice and the regulation of autophagy in mdx mice is dependent on the muscle 
type, where glycolytic muscles exhibit greater autophagy process in terms of 
vesicles formation than the oxidative muscles (Spitali et al., 2013). Therefore, 
further investigation of other muscles is required to elucidate the role of ERRγ in 
autophagy. On other hand, a low protein diet was shown to reactivate autophagy 
and normalize the level of Akt and mTOR signalling and resulted in recovery of 
muscle function in mdx (De Palma et al., 2012).  
Forkhead box O (FOXO-1) transcription factor has been shown to regulate 
oxidative stress by promoting cellular antioxidant defence. Evidence has shown 
a role of FOXO-1 in the induction of autophagy process (Zhao et al., 2010). 
Deletion of FOXO-1 led to defective stem cell number and activity that was 
associated with increased accumulation of ROS (Tothova et al., 2007). Our 
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results in both studies showed no change the transcript level of FOXO-1. 
Similarly, following over-expression of PGC-1α into 12 months old mdx, the 
transcript level of FOXO-1 remain unchanged (Hollinger et al., 2013). Matsakas 
et al., showed the expression of FOXO-1 in mdx mice is less than C57BL and 
increased in the transgenic mice of ERRγ (Matsakas et al., 2013). Compared 
with the 3 fold modest increase of ERRγ in EDL muscles of both studies including 
in this chapter, 170 fold increase in the ERRγ over-expression in transgenic 
muscle compared to the control is possibly the reason of this different change. 
Therefore, it is necessary to assess the activity of these signalling pathways in 
order to draw a clear conclusion on the effect of ERRγ on autophagy and muscle 
function.  
Atrogin-1 (F-box only protein 32, FBXO32) and Muscle RING finger-1 (MuRF1) 
are two main markers of muscle atrophy and mice which lack either of them are 
considered resistance to atrophy (Sandri et al., 2013). They are both upregulated 
in muscular dystrophy where they are negatively regulated by AKT kinase (Sandri 
et al., 2004). MuRF1 is a muscle specific ubiquitin ligase which ubiquitinates and 
targets damaged proteins for degradation by the 26S proteasome, showed an 
increased expression in the study of 3 week old mdx but not in 6 weeks study. 
Previously, MuRF1 was found to increase following exercise suggesting 
increased proteasome-mediated proteolysis and increase in unfold protein 
response (UPR) flux (Pasiakos et al., 2010). Therefore, it is possible that 
transcript increase in the level of MuRF1 following ERRγ over-expression is an 
adaptive response for the increase in oxidative capacity which resulted in an 
increase in ROS as a normal result of enhanced oxidative capacity. In addition, 
NF-κB expression was enhanced in the same study, it might also explain the 
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increased expression of MuRF1, because it was found previously that NF-κB 
signalling upregulate MuRF1 expression (Cai et al., 2004). Atrogin-1, on the other 
hand is associated with muscle atrophy. Increased protein synthesis of Atrogin-
1 has been shown to accelerate protein degradation and suppress protein 
synthesis. We showed a reduction in the expression of Atrogin-1 in 6 weeks study 
but not in 3 weeks, which suggest the impact of age of these two different groups 
in the measured outcomes. However, it was found that Atrogin-1 level in mdx is 
lower than wild type (Whitehead et al., 2015). Compared to our results, postnatal 
over-expression of PGC-1α into 3 weeks old mdx mice showed increased 
expression of Atrogin-1 (Hollinger et al., 2013). Therefore, in our study, we could 
potentially suggest reduced protein turnover in 6 weeks ERRγ-treated EDL 
muscles compared with the control. However, further investigation of the 
signalling pathway involved in muscle atrophy would evaluate the difference in 
muscle atrophy between these two ages following over-expression of ERRγ.   
Eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) is a mRNA 
translation repressor protein that negatively regulates eukaryotic translation 
initiation factor 4E or eIF4E, which is a protein that forms a complex blocking 5’ 
ends mRNA cap structure, important for protein synthesis (Gingras et al., 1998). 
4EBP-1 is a downstream substrate of mTORC1, where phosphorylation of 4EBP-
1 resulted in inhibition of its ability to sequester eIF4E complex by repressing the 
cap-dependent mRNA translation initiation. Nutrient and deprivation of growth 
factors resulted in 4EBP-1 de-phosphorylation, increased binding to eIF4E and a 
parallel decrease in cap-dependent translation (Kleijn et al., 1998). In mdx, the 
phosphorylation level of 4EBP-1 was enhanced compared to wild type (De Palma 
et al., 2012), which led to its activation and inhibition of autophagy in muscles 
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(Mammucari et al., 2008). It has been demonstrated that enhanced 4EBP-1 
activity led to increased oxidative metabolism in skeletal muscle during aging and 
obesity (Tsai et al., 2015). Regulation of the cross talk between mTOR and AMPK 
was found to be regulated by resveratrol which was found to down regulate 
mTOR via AMPK activation to promote autophagy in cancer (Park et al., 2016). 
Following activation of AMPK, mTORC1 complex was inhibited by 
phosphorylation and at the same time the kinase was able to induce autophagy 
by phosphorylating ULK-1 during nutrient deprivation. The two crucial targets of 
mTOR; ribosomal protein S6 kinase (p70S6) and 4EBP-1 were 
dephosphorylated, and resulted in blocking protein synthesis (Hay and 
Sonenberg, 2004). Reduction in the transcript levels of 4EBP-1 is possibly a 
mechanism to conserve ATP under energy starvation and low metabolic 
condition (Horman et al., 2002). As we measure the expression at one time point, 
we could not draw a conclusion of why over-expression of ERRγ results in a 
reduced expression of these factors involving in pathways controlling protein 
synthesis. Assessment of AKt- mTOR pathway is required to understand the role 
of ERRγ in protein synthesis.  
Growth arrest and DNA damage inducible protein (GADD34) is a gene that 
reverse translational repression by de-phosphorylation of eIF2α (Novoa et al., 
2001). It has been shown previously that the DMD exhibit increased endoplasmic 
reticulum (ER) stress which cause apoptosis through different pathways and one 
of these is through C/EBP-homologous protein (CHOP) pathway. However, 
CHOP is regulated by activating transcription factors; ATF4 and ATF6. A 
mechanism of a pro-apoptotic activity of CHOP involves upregulation of Gadd34 
(Kim et al., 2014). The reduced expression of GADD34 following over-expression 
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of ERRγ is a marker of reduced cellular stress and speculatively would lead to 
less apoptosis. To better elucidate these pathways, it is required to investigate 
other regulators such as ATF4 and ATF6. However, the mechanism regulating 
translational control of 4EBP-1 and GADD34 gene expression is not fully 
understood and the role of these markers in the state of DMD require further 
investigation. 
In the 6 week study, neither gastrocnemius nor EDL muscles showed any results 
similar to what has been shown in EDL muscle treated at 3 weeks of age. The 
possible explanation is that, as the 6 weeks old muscle is well into the 
regenerative phase, the achieved ERRγ over-expression in gastrocnemius was 
not sufficient to induce change at the molecular level despite the reduction of 
central nucleation and SDH activity. The main drawback in both studies is that 
we do not have a conclusion of how many fibres are positive for ERRγ over-
expression. Therefore, it is helpful to develop a protocol in order to quantify the 
positive fibres of the ERRγ over-expression. Moreover, none of the positive 
changes have been observed in the 6 weeks treated EDL despite similar over-
expression of ERRγ to 3 week-old EDL muscles. We could speculate that the 
active cycle of regeneration during 6-weeks of age may lead to loss of vector 
(Peccate et al., 2016). Alternatively, different aged groups were treated for 
different lengths of time, which ultimately lead to different outcomes between 
them. Time of intervention between these two groups; early in necrotic phase at 
3 weeks of age vs regenerative phase at 6 weeks of age represent the main 
difference between these two studies. It is also possible to suggest that oxidative 
stress at 9 weeks of age (when these muscle are recovered) is already reduced 
by over-expression of ERRγ since we showed reduced pathology associated with 
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improving SDH activity and reducing central nucleation fibres in gastrocnemius 
muscles. Further, unchanged expression of inflammation markers could be a 
result of reduced stress because it was shown that pro-inflammatory cytokines 
are associated with muscle regeneration and repair (Serrano et al., 2008, 
Scheller et al., 2011). Speculatively, by definition, skeletal muscles 
overexpressing ERRγ are under less oxidative stress and therefore, do not need 
to upregulate these inflammatory markers.  
In conclusion, our investigation revealed several findings following over-
expression of ERRγ that are likely to have an effect on muscle function. Over-
expression of ERRγ increased expression of mitochondrial complexes; I, II and 
III, which possibly has an effect via improving level of ATP production that support 
the platform to improve excitation-contraction coupling and enhance muscle 
function. Further, increased expression of angiogenesis markers and vascular 
density could be another mechanism to explain the improved muscle force. As 
these factors have been shown to promote muscle regeneration and reduce force 
deficit in dystrophic muscle (Borselli et al., 2010, Messina et al., 2007, Deasy et 
al., 2009). Collectively, the exact mechanism by which ERRγ leads to the 
observed changes in specific force and gene expression is currently unclear.  
However, these data demonstrated that early intervention of ERRγ reduced 
metabolic stress by reducing oxidative stress and pathology leading to improved 
specific force and hence suggested ERRγ as a candidate therapeutic target in 
DMD.  
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5. Chapter Five 
Systemic administration of AAV9-ERRγ into 3 week-old 
mdx 
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5.1. Introduction: 
AAV is a small non-enveloped single-stranded DNA virus of 25 nm in diameter 
that has been detected in several tissues and different animal species (Horowitz 
et al., 2013). Initially, AAV was discovered as a contaminant of adenovirus 
preparations (Rose et al., 1966, Hastie and Samulski, 2015), further, Hermonat 
and Muzyczka run the first AAV gene transfer experiment. They used the virus 
to infect human Detroit 6 and KB cells, with antibiotic resistance tested with G418 
in the presence of a helper virus (adenovirus). The observed transduction 
efficacy was about 0.4-10% (Hermonat and Muzyczka, 1984). This experiment 
validate another milestone in vector development and the author highlighted 
areas that require further investigation and understanding in terms of studies of 
larger DNA fragments, host range mutants and gene therapy applications. The 
unique feature of AAV is that, the inverted terminal repeats (ITRs), cis-active 
sequences, of 145 base pairs are the only sequences required for AAV rescue 
and replication, therefore, most of AAV genome is available for substitution of 
foreign DNA (Hastie and Samulski, 2015). Therefore, these features of AAV 
make it an interesting tool for gene therapy. Nowadays, rAAV gene based 
therapy has been widely used for the potential to treat Duchenne muscular 
dystrophy (DMD) based on their safety profile, efficiency of transduction, ability 
to transduce dividing and non-dividing cells, stable expression and its low 
immunogenicity (Zincarelli et al., 2008, Kotterman and Schaffer, 2014, Wells and 
Wells, 2002, Calcedo and Wilson, 2013). However, the main difficulty has been 
found in the use of rAAV for DMD gene therapy is the high titers of rAAV required 
to transduce the enormous amount of tissue (40% of body mass) and the limited 
capacity of rAAV vector of 4.7 kb and the need to re-administer (Foster et al., 
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2008, McIntosh et al., 2012). It has been found that the therapeutic levels of 
transduction efficiency have been achieved using 1X1015 to 1X1016 vg/kg 
(Hinderer et al., 2018). Therefore, such systems are invaluable in a research and 
there is a need to develop rAAV vectors that can successfully attain efficient gene 
transfer and high expression at lowed viral titre.  
Different serotypes of rAAV have been described and those which show high 
tropism for skeletal and cardiac muscles, are more relevant to DMD due to their 
ability to transduce these tissues, for example; serotype 6, 8 and 9 (Inagaki et 
al., 2006). Among different AAV serotypes; 8 and 9 transduce tissues more 
ubiquitously than other serotypes and 9 showed the most robust tissue 
expression, highest protein level and the slowest clearance of viral genome from 
the blood  (Zincarelli et al., 2008). AAV9-mediated cardiac gene transfer resulted 
in high efficient and stable expression in mouse and rat (Bish et al., 2008, Moulay 
et al., 2015, Haihan and Tang, 2018). Despite the high level of gene transfer 
achieved following those particular serotypes, high titers of rAAV vector were 
required (Gregorevic et al., 2004). Therefore, finding a way to transduce the 
tissues efficiently and reduced viral dose is required for gene therapy.  
Increasing the transgene expression from a single virion has been an important 
development to help reduce the viral load required for translational programs; this 
can be achieved in a variety of ways for example; sequence optimization (Mauro 
and Chappell, 2014). A number of ways were used in sequence optimization in 
order to improve mRNA stability and translational efficiency. For example; codon 
optimization, inclusion of enhancer elements and WPRE sequence, sequence 
flanking the AUG start codon that can facilitate its recognition by eukaryotic 
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ribosomes as consensus Kozak sequence and increased GC content. These 
features have been shown to enhance transcription efficiencies, initiation of 
translation and improved translation efficiency.   
Codon optimization is resultant from the degenerative nature of the genetic 
codes, polypeptides chains of most proteins can be encoded by infinite numbers 
of mRNA sequences, for example; 4 different tRNA molecules encode the codon 
of valine amino acid. In gene therapy, optimization of cDNA sequence as an 
attempt to produce more proteins could be one way to reduce the viral dose 
required for efficient gene transfer. For example; in skeletal muscles, 
administration of codon optimized microdystrophin gene under the control of a 
muscle restrictive promoter (spc5-12) increased gene expression, improved 
muscle function and ameliorate disease pathology (Foster et al., 2008, Kornegay 
et al., 2010, Le Guiner et al., 2017). 
Codon usage and codon bias is observed in all species and for the purpose of 
codon optimization, it is suggested to select a codon, which correlates with high 
gene expression. The greatest deviation from random codon usage in organisms 
occurs in the highly expressed genes and results in a selection against the use 
of codons specifying tRNA with low proportions and selection of high frequency 
codons whose binding energy for interactions with anti-codon of the tRNA 
molecule is suboptimal, hence, maximize the level of expression (Makoff et al., 
1989, Bentele et al., 2013, Novoa and de Pouplana, 2012, Foster et al., 2008, 
Nguyen et al., 2004, Garmory et al., 2003, Ward et al., 2011, Nagata et al., 1999, 
Radcliffe et al., 2008, Qiao et al., 2011, Wang et al., 2012).   
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Enhancer elements and nuclear transport enhancers promote transport of 
genetic materials from cytoplasm to nucleus are also incorporated to enhance 
vector design. For example; simin virus 40 has been included in the expression 
cassettes to increase the efficiency of expression (Lu et al., 2003a). Further, to 
enhance transgene expression at the post-transcriptional and translational 
levels, the wood chuck post-transcriptional response element (WPRE) has been 
shown to enhance the levels of transgene expression from both plasmid and viral 
vectors. WPRE is a 600 bp, non-coding cis-acting element, promote RNA stability 
and transport of mRNA from the nucleus to the cytoplasm. WPRE is most 
effective when placed downstream of the transgene. Inclusion of WPRE 
elements into eGFP improved virus titre and transgene expression (Hlavaty et 
al., 2005). Furthermore, a consensus Kozak sequence has been shown to 
improve translation efficiency (Kozak, 2005). The mechanism of Kozak sequence 
recognition and function is not yet explored. However, the possible mechanism 
is that an interaction with consensus Kozak sequence (GCCACC) could reduce 
the rate of scanning and facilitate the recognition of AUG start codon by Met-
tRNA (Kozak, 1999). It is required for optimal translation of mammalian genes 
(Garmory et al., 2003). Increasing the percentage of C+G content, also, has 
resulted in enhanced gene expression in mammalian cells. Genes with high GC 
contents showed increased expression due to increased mRNA stability (Kudla 
et al., 2006).    
In this chapter we tested the hypothesis that optimization of ERRγ sequence 
within the ERRγ gene would result in increased level of transgene expression 
and hence increased protein levels. Two plasmids were modified to include the 
same optimized ERRγ sequences, 3-FLAG sequence, a consensus Kozak 
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sequence and WPRE. To include a Kozak consensus sequence at the translation 
start site, the sequence surrounding the initiation codon was modified to 
GCCACC. The two plasmids differ in the location of 3-FLAG sequence, one at 5’ 
end and the second at 3’ end instead, being conscious that sequence context 
may affect epitope recognition by antibodies. However, the native non-optimized 
plasmid expressing non-optimized sequence of ERRγ contained a human 
influenza hemagglutinin (Ha) tag at 3’ end. Plasmids expressing optimized 
sequence of ERRγ were prepared by (Eurofins Company), the sequences are 
included in the (Appendix). Then we sub-cloned sequences of sequence 
optimized ERRγ into pAAV. When that is completed, we assessed the 
proliferative response of mouse myoblast (C2C12) cells transfected with the two 
plasmids expressing sequence optimized ERRγ and compared their proliferative 
effects with the plasmid of non-optimized sequence of ERRγ. Next, we evaluated 
the protein level of ERRγ in human embryonic kidney cells (HEK-293T) 
transfected with the non-optimized pAAV-ERRγ and the plasmid expressing 
optimized ERRγ sequence. Finally, three week old, male mdx mice were injected 
intraperitoneally with 2X1012 vg of AAV9 expressing sequence optimized ERRγ 
in 100 μl of saline and the control mdx mice were injected with similar volume of 
saline. Muscles were obtained after 6 weeks post administration and EDL 
muscles were used to assess muscle function and ERRγ protein level. 
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5.2. Results: 
5.2.1. The sub-cloning of the sequence optimized sequences into the pAAV 
backbone:  
The two plasmids expressing sequence optimized ERRγ were prepared by 
(Eurofins Company) in a 5’Pex-k4 and 3’Pex-k4 backbones. To sub-clone each 
of the transgene of sequence optimized ERRγ into pAAV backbone, the non-
optimized pAAV-ERRγ plasmid was used as the backbone, with the native gene 
excised and the two optimized sequence variants of ERRγ was substituted to 
generate novel pAAV vectors. The PacI/AgeI double digestion of the non-
optimized pAAV-ERRγ (2, 3) showed two bands of the back bone (AAV) at 6155 
bp and the insert (ERRγ) at 1420 bp. The double restriction digestion of the 
plasmids; 5'F SO ERRγ and 3'F SO ERRγ using PacI and AgeI also showed 
bands at the expected sizes of 900 bp of the backbone and 1466 of the insert. 
The presence of ITRs in the non-optimized (pAAV-ERRγ); (MscI, XbaI, BssHII 
and SmaI) were confirmed; 10, 11, 12 and 13. The expected sizes for ITRs 
fragments are the following; MscI, (4223, 1324, 1221, 993, 685), Xbal, (2751, 
2391, 360), BssHII (3101, 3016, 85) and SmaI (3049, 2740, 2729, 298, 309) 
(figure 5.1). 
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Figure 5.1. Restriction digestion of non-optimized pAAV-ERRγ and plasmids 
expressing optimized sequence of ERRγ 
1, Undigested non-optimized pAAV-ERRγ 
2, Cut non-optimized pAAV-ERRγ (PacI/AgeI)-1 hr  
3, Cut non-optimized pAAV-ERRγ (PacI/AgeI)-24 hr 
4, Undigested Pex K4 So pAAV 5'F ERRγ 
5, Cut 5’Pex-k4 sequence optimized ERRγ (PacI/AgeI) (1 hr)  
6, Cut 5’Pex-k4 sequence optimized ERRγ (PacI/AgeI)- (24hr) 
7, Undigested 3’Pex-k4 sequence optimized ERRγ 
8, Cut 3’Pex-k4 sequence optimized ERRγ (PacI/AgeI)- (1hr) 
9, Cut 3’Pex-k4 sequence optimized ERRγ (PacI/AgeI)- (24hr) 
10, Single digest of non-optimized pAAV-ERRγ (MscI) 
11, Single digest of non-optimized pAAV-ERRγ (XbaI) 
12, Single digest of non-optimized pAAV-ERRγ (BssHII) 
13, Single digest of non-optimized pAAV-ERRγ (SmaI) 
5’Pex-k4= back bone of the plasmids from Europhin Company, (SO= Sequence 
optimized), (5'F= Flag at 5 end), (3'F= Flag at 3 end) 
 
Following ligation, transformation and mini-prep (Described in materials and 
methods, section 2.5.2 and 2.5.3), XhoI restriction enzyme was used to linearize 
the plasmids as a first confirmation step to check their sizes (figure 5.2).  
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Figure 5.2. Miniprep analysis of pAAV 5'F SO-ERRγ and pAAV 3'F SO-ERRγ 
A) Miniprep of the pAAV 5'F SO-ERRγ samples;  
1, Undigested non-optimized pAAV8-ERRγ 
2, Single digest of non-optimized pAAV8-ERRγ (XhoI)   
3, 5, 7, 9, 11, 13, 15, 17, Undigested samples of pAAV 5'F SO-ERRγ miniprep samples 
4, 6, 8, 10, 12, 14, 17, 18, Single digest of pAAV 5'F SO-ERRγ miniprep samples (XhoI).  
4, 10, 12, 18, Samples showed single band at the right size. 
B) Miniprep of the pAAV 3'F SO-ERRγ samples;  
1, Undigested non-optimized pAAV8-ERRγ 
2, Single digest of non-optimized pAAV8-ERRγ (XhoI)   
3, 5, 7, 9, 11, 13, 15, 17, Undigested samples of pAAV 3'F SO-ERRγ miniprep samples 
4, 6, 8, 10, 12, 14, 17, 18, Single digest of pAAV 3'F SO-ERRγ miniprep samples (XhoI). 
8, 10, 14, 16, 18, Samples showed single band at the right size. 
(SO= Sequence optimized), (5'F= Flag at 5 end), (3'F= Flag at 3 end) 
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Those samples which showed single band were digested with (BsrgI) to 
differentiate between the non-optimized pAAV8-ERRγ plasmid and the two 
plasmids expressing optimized sequence of ERRγ. Bsrg1 digestion of pAAV 3'F 
SO-ERRγ plasmid results in bands of 5587bp and 2030bp, whereas BsrgI 
digestion of the non-optimized pAAV8-ERRγ results in a single band (figure 5.3).  
 
Figure 5.3. Restriction digestion of pAAV 3'F SO-ERRγ plasmid using BsrgI 
1, Undigested non-optimized pAAV8-ERRγ 
2, Single digest of non-optimized pAAV8-ERRγ (BsrgI)   
3, 5, 7, 9, 11, 13, 15, 17, Undigested samples of pAAV 3'F SO-ERRγ samples 
4, 6, 8, 10, 12, 14, 16, 18, Single digest of pAAV 3'F SO-ERRγ miniprep samples (BsrgI). 
8, 12 samples, showed bands at the expected size (5587 and 2030 bp).   
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Also, to give more confidence for those samples of pAAV 3'F SO-ERRγ (8, 12), 
the samples were digested with the restriction enzyme (BstxI) to further 
differentiate them from non-optimized pAAV-ERRγ plasmid, which should result 
in 4117 bp and 3583 bp bands. Both plasmids expressing sequences of 
optimized ERRγ showed three bands; 4177 bp, 2592 bp and 908 bp, confirming 
their identity. Samples of pAAV 5'F SO-ERRγ were also digested with BsrgI and 
BstxI to confirm the sequence. The expected bands for the pAAV 5'F SO-ERRγ 
plasmid digested with BsrgI were 5656 and 1961 confirming the identity of these 
plasmids (figure 5.4).  
The integrity of the ITRs were checked with the following restriction enzymes; 
MscI, XbaI, SmaI and BsHII. All ITRs are present in both plasmids and therefore, 
we made a larger scale endotoxin free preparation for further tissue culture 
analysis and viral preparation (figure 5.5).  
 
Figure 5.4. Confirmation the sequence of the plasmids expressing optimized ERRγ 
with BstxI and ITR. 
1, Undigested non-optimized pAAV8-ERRγ 
2, Single digest of non-optimized pAAV8-ERRγ (BsrgI)   
3, Single digest of non-optimized pAAV8-ERRγ (BstxI)   
4, Single digest of non-optimized pAAV8-ERRγ (MscI)   
5, Single digest of non-optimized pAAV8-ERRγ (SmaI) 
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6, 10 Undigested samples of pAAV 3'F SO-ERRγ  
7, 11, Single digest of pAAV 3'F SO-ERRγ samples (BstxI). 
8, 12, Single digest of pAAV 3'F SO-ERRγ samples (MscI). 
9, 13, Single digest of pAAV 3'F SO-ERRγ samples (SmaI). 
14, Undigested samples of pAAV 5'F SO-ERRγ sample 
15, Single digest of pAAV 5'F SO-ERRγ sample (BsrgI). 
16, Single digest of pAAV 5'F SO-ERRγ sample (BstxI). 
(SO= Sequence optimized), (5'F= Flag at 5 end), (3'F= Flag at 3 end)  
 
 
Figure 5.5. Confirmation the ITRs sequence in the pAAV 5'F SO-ERRγ and pAAV 
3'F SO-ERRγ 
1, Undigested non-optimized pAAV8-ERRγ 
2, Single digest of non-optimized pAAV8-ERRγ (MscI)   
3, Single digest of non-optimized pAAV8-ERRγ (Xbal)   
4, Single digest of non-optimized pAAV8-ERRγ (SmaI)   
5, Single digest of non-optimized pAAV8-ERRγ (BsHII) 
6, Undigested samples of pAAV 5'F SO-ERRγ samples 
7, Single digest of pAAV 5'F SO-ERRγ samples (MscI). 
8, Single digest of pAAV 5'F SO-ERRγ samples (XbaI). 
9, Single digest of pAAV 5'F SO-ERRγ samples (SmaI). 
10, Single digest of pAAV 5'F SO-ERRγ samples (BsHII). 
11, 14, Undigested samples of pAAV 3'F SO-ERRγ samples 
12, 15, Single digest of pAAV 3'F SO-ERRγ samples (XbaI). 
13, 16, Single digest of pAAV 3'F SO-ERRγ samples (BsHII). 
(SO= Sequence optimized), (5'F= Flag at 5 end), (3'F= Flag at 3 end) 
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5.2.2. FLAG fusion protein was detected in pAAV 3'F SO-ERRγ but not 
pAAV SO 5'F-ERRγ:  
To evaluate the protein level of ERRγ in vitro, Human embryonic kidney cells 
(HEK-293T) cells were co-transfected with either non-optimized pAAV-ERRγ or 
pAAV SO 5'F-ERRγ or pAAV 3'F SO-ERRγ and pCAGGβ-Galactosidase (-gal) 
plasmid as a control to standardize amounts. A β-Gal ELISA was run on cell 
lysate to assess the transfection efficiency between all plasmids and showed no 
difference in transfection efficiency between them (figure 5.6 A). Then, in order 
to detect FLAG protein in the sequence optimized plasmids, we run western blot 
on the lysate of the transfected HEK-293T cells. Unexpectedly, we detected the 
band only on the 3'F optimized ERRγ and therefore we carried out the work on 
this plasmid only (figure 5.6 B).  
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Figure 5.6. β-gal assay and western blot of FLAG antibody in HEK-293T cells 
transfected with non-optimized pAAV-ERRγ, pAAV 5'F SO-ERRγ and pAAV 3'F 
SO-ERRγ 
A) β-gal assay showed no difference in the transfection efficiency between the HEK-
293T cells co-transfected with non-optimized ERRγ or sequence optimized 5'F ERRγ 
and sequence optimized 3'F ERRγ and β-gal plasmid. B) The presence of ERRγ-Flag in 
HEK-293T cells transfected with either non-optimized pAAV-ERRγ, pAAV 5'F SO ERRγ 
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and pAAV 3'F SO ERRγ was determined by western blot analysis using 20 μg of the 
protein and Flag antibody. ERRγ-Flag band was detected at the expected size of ERRγ 
(57 KDa) in the lysate of HEK-293T cells transfected with pAAV 3'F SO ERRγ. (SO= 
Sequence optimized), (5'F= Flag at 5 end), (3'F= Flag at 3 end) 
 
5.2.3. Sequence optimized pAAV 3’F SO ERRγ showed increased ERRγ 
protein level in transfected HEK-293T cells: 
To find out the level of ERRγ protein following sequence optimization of ERRγ, 
western blot has been run on HEK-293T cells lysate transfected with either non-
optimized pAAV-ERRγ or pAAV 3'F SO ERRγ. Densitometry analysis showed 20 
fold increase in the level of ERRγ protein as a result of optimizing ERRγ 
sequence (p=0.0001). Cells transfected with native, non-optimized pAAV-ERRγ 
showed weak signal (figure 5.7).  
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Figure 5.7. Western blot of ERRγ in HEK-293T cells transfected with non-optimized 
pAAV-ERRγ and pAAV 3'F SO-ERRγ 
A) The levels of ERRγ in HEK-293T cells transfected with non-optimized ERRγ or 
sequence optimized 3'F ERRγ were determined by western blot analysis using 20 μg of 
protein. The total ERRγ was determined using ERRγ antibody. β-actin was used for 
normalization using β-actin antibody. The intensity of the bands was quantified using 
ImageJ software. B) Western blot analysis showed 20 fold increase (n=4, unpaired 
student’s t-test, p=0.0001) in the ERRγ protein level in the HEK-293T cells transfected 
with sequence optimized 3'F ERRγ. (SO= Sequence optimized), (5'F= Flag at 5 end), 
(3'F= Flag at 3 end) 
 
5.2.4. NADPH assay showed no difference between non-optimized and 
sequence optimized plasmids: 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay was used to 
evaluate the effect of sequence optimized ERRγ on cell metabolic activity and 
comparing that effect with the non-optimized sequence following transient 
transfection of C2C12 cells with the three different plasmids. However, there was 
no difference in the metabolic activity of the cells transfected with either plasmids 
expressing sequence optimized of ERRγ and none of them showed metabolic 
difference compared to the plasmid expressing non-optimized sequence of 
ERRγ. However, there was an increase in the myoblast metabolic activity 
transfected with the sequence optimized plasmids compared to the control cells 
transfected with pAAV-eGFP plasmid and in the cells transfected with non-
optimized sequence ERRγ plasmid compared to the control as well (figure 5.8).  
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Figure 5.8. MTS assay of C2C12 cells transfected with non-optimized pAAV-ERRγ 
and pAAV 5'F SO-ERRγ and pAAV 3'F SO-ERRγ 
C2C12 cells transfected with either non-optimized pAAV-ERRγ (p=0.0001) or pAAV 5'F 
SO-ERRγ (p=0.001) and pAAV 3'F SO-ERRγ plasmids (p=0.001) showed significant 
difference in the proliferation activity of the cells when they are compared to the control 
(pAAV-eGFP plasmid). (SO= Sequence optimized), (5'F= Flag at 5 end), (3'F= Flag at 3 
end). 
 
5.2.5. Intraperitoneal administration of 2X1012 vg rAAV9 3'F SO-ERRγ into 
3 week old mdx mice improves muscle function: 
In order to assess if the over-expression of rAAV9 3'F SO-ERRγ improved 
muscle function in mdx mice, 2X1012 vg of a rAAV9 3'F SO-ERRγ under the 
control of spc5-12 promoter was administered via intraperitoneal route into 3 
week-old mdx. Muscle samples were recovered 6 weeks post virus 
administration. EDL muscles were examined for muscle function. There was no 
difference between treated and control EDL muscle mass (p=0.808). The 
injection of rAAV9 3'F SO-ERRγ had no effect on maximal tetanic force compared 
to untreated mdx injected with saline. However, specific force was significantly 
improved by 14% (p=0.021) following treatment with rAAV9 expressing sequence 
optimized ERRγ compared to mice injected with saline. In addition, we tested the 
ability of sequence optimized ERRγ to protect mdx EDL muscle from eccentric 
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contraction by assessing force production following a series of 10 eccentric 
contractions. Injection of AAV9 3'F SO-ERRγ was unable to protect mdx muscles 
from force deficit induced by the contraction induced injury (figure 5.9). 
 
Figure 5.9. Gene transfer of rAAV9 3'F SO-ERRγ improves specific force in the 
EDL muscle of mdx mice. 
A) ERRγ gene transfer of AAV9 3'F SO-ERRγ into 3 week-old mdx does not change 
muscle mass (p=0.808). Muscles were stimulated according to standard techniques in 
order to assess tetanic force and specific force. B) ERRγ gene transfer of AAV9 3'F SO-
ERRγ into 3 week-old mdx has no effect on maximal tetanic force (p=0.154). C) Tetanic 
force normalized by muscle cross sectional area is specific force. Cross sectional area 
(mm2) is calculated using the following equation; mass (mg)/ [(Lo mm)* (L/Lo)* (1.06 
mg/mm3)], where L/Lo is the ratio of fibre to muscle length (0.45 for EDL) and 1.06 is the 
density of muscle. ERRγ gene transfer of AAV9 3'F SO-ERRγ into 3 week-old mdx leads 
to 14% recovery of specific force in EDL muscles (p=0.021). D) EDL muscles were given 
a series of 10 lengthening contractions (150 Hz for 500 msec, followed by 200 msec at 
a 110% Lo) in order to evaluate sarcolemma stability. Force deficit induced by a series 
of eccentric contraction was not different between mdx control and mdx treated with 
AAV9 3'F SO-ERRγ (n=10 mdx, n=12 mdx-ERRγ, unpaired student’s t-test). (SO= 
Sequence optimized), (3'F= Flag at 3 end).  
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5.2.6. ERRγ protein level is not increased in the EDL muscle following gene 
transfer of rAAV9 3'F SO-ERRγ: 
To test the hypothesis that optimizing the sequence of ERRγ  would result in an 
increase in  ERRγ protein levels within the muscle, analysis of ERRγ protein in 
EDL muscles from mice injected with AAV9 3'F SO-ERRγ was assessed by 
western blot. No difference in ERRγ protein level was detectable between control 
and treated muscles (p=0.436) (figure 5.10). 
 
Figure 5.10. Western blot analysis of ERRγ in EDL muscles 
The level of ERRγ in EDL muscles was determined by western blot analysis using 40 μg 
of protein and Ponceau stain was used for normalization. A) The total ERRγ was 
determined using ERRγ antibody. B) The intensity of the bands was quantified using 
ImageJ software. Analysis showed no difference in the protein level of ERRγ between 
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mdx control and mdx injected with AAV9 3'F SO-ERRγ (n=10 mdx, n=12 mdx-ERRγ, 
unpaired student’s t-test, p=0.436).  
 
5.3. Discussion: 
The application of sequence optimization of a eukaryotic gene in an attempt to 
maximize transgene levels is a well trodden path. Here we seek to determine in 
the sequence optimization of ERRγ in muscle following rAAV gene transfer and 
to assess the impact on the muscle function of the mdx mouse.  
Foster et al., demonstrated that systemic delivery of an rAAV expressing a 
sequence optimised microdystrophin into mdx mice significantly improved mRNA 
up to 30 fold and improved protein expression and the physiological assessment 
showed improvements in specific force (Foster et al., 2008). Recently, systemic 
delivery of rAAV mediated sequence optimized β-sarcoglycan into a model of 
limb-girdle muscular dystrophy type 2 (sgcb-/-) improved diaphragm force, 
reduced the level of creatine kinase and increased protein expression of the 
transgene in all muscles which initially exhibited a complete loss of β-sarcoglycan 
protein (Pozsgai et al., 2017). Here the delivery of rAAV9 3'F SO-ERRγ into the 
mdx mouse has been assessed, to investigate its impact on ERRγ mRNA and 
protein levels in the muscle and its impact on dystrophic muscle function. 
ERRγ sequence was optimized to include a consensus kozak sequence 
(GCCACC), which has been shown to induce translation efficiency. It plays a role 
in the initiation of translation by influencing the recognition of AUG start codon by 
eukaryotic ribosomes (Garmory et al., 2003). In addition, codon usage within the 
ERRγ gene was modified based on optimal transfer RNA (tRNA) frequencies. 
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Codon usage is defined as a degeneracy of the genetic code. All amino acids 
can be encoded by more than one codon, however, not all synonymous codons 
are used with equal frequency and certain codons are used more frequently to 
encode any given amino acids especially with highly expressed genes. These 
frequencies are correlated with the corresponding tRNA levels in the cells and 
they are species specific (Ikemura, 1981). In addition, G-C% content was 
increased in the optimized sequence of ERRγ by 9%. Previously it was shown 
that increasing GC content increased mRNA synthesis, enhanced mRNA 
stability, induce nuclear export of mRNA and protein translation (Kudla et al., 
2006).  
The first aim of this study was to assess the mRNA and protein level of ERRγ in 
vitro following transient transfection of sequence optimisation of the ERRγ gene. 
Although sequence optimization should increase transcript stability and hence 
enhancing protein level, we do not have a conclusion on how much optimizing 
sequence of ERRγ increased mRNA transcript. Although, the cDNA was 
synthesized from RNA that was extracted from C2C12 cells transfected either with 
the plasmid of non-optimized or optimized sequence of ERRγ and specific 
primers were designed for the optimized sequence, however, we encountered a 
contamination on non-template control for a reason that could not be explained, 
and as a result it has not been possible to generate the data of relative RNA 
expression levels. Clearly, moving forward, it will be important to address this 
issue. Therefore, we carried out on assessing the protein level. Optimization of 
ERRγ gene resulted in a 20 fold increase in the protein level of ERRγ in the HEK-
293T cells following transfection of the pAAV 3’F SO ERRγ compared to the non-
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optimized sequence. We demonstrated here, that optimizing sequence of ERRγ 
gene induce significant protein level in vitro.  
To further assess the impact of using optimized sequence of ERRγ in vitro, we 
asses MTS assay, which is a colorimetric method for determining the metabolic 
activity of the cells. We showed here that sequence optimization of ERRγ, like 
the non-optimized sequence, promotes the metabolic activity of myoblast C2C12 
cells. No significant differences in the metabolic activity were observed between 
the cells transfected with the optimized and non-optimized sequence of ERRγ 
and no difference was observed between the two plasmid expressing the 
sequence optimized ERRγ. This was unexpected as the sequence optimized 
ERRγ resulted in 20 fold increase in ERRγ protein level compared to the non-
optimized, which suggested the effect of over-expression of ERRγ on metabolic 
activity should be more. As the metabolic activity appeared to be the same, 
therefore, it is not the sequence having the effect. The possible explanation is 
that, despite increasing protein level, the cells have limited capacity to respond 
to the increase in the protein level of ERRγ. Although, the two plasmids induced 
similar induction on metabolic activity of the myoblast cell. This highlighted the 
significant effect of ERRγ on improving muscle metabolism. As demonstrated 
previously by Rangwala et al., there was an increase in the mitochondrial function 
represented by the upregulation of fatty acid metabolism and citrate synthase 
activity genes following adeno virus mediated expression of ERRγ in primary 
mouse myotubes (Rangwala et al., 2010).     
Histological and morphological changes in skeletal muscles of the mdx mouse 
are a result of dystrophin loss has detrimental effects on muscle function (Capote 
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et al., 2010). The second aim of this study was to deliver the optimized transgene 
efficiently to skeletal muscles in order to produce strong level of ERRγ expression 
and evaluate the impact of its expression on function of the muscle. 
Administration of rAAV9 3'F SO-ERRγ into 3 week-old mdx muscle improved 
specific force compared to untreated mdx muscles by 14%. Previously, using 
codon optimization approach has been investigated in spinal muscular atrophy 
(SMA) and the survival analysis showed increased life expectancy from 27 to 
over 340 days. Also, it showed correction of motor function (by monitoring 
spontaneous activity) and rescue the weight loss phenotype in mice (Dominguez 
et al., 2011). Furthermore, administration of AAV8 expressing codon optimized 
sequence of ornithine transcarbamylase (OTC) for ornithine transcarbamylase 
deficiency (OTCD), which is the common urea cycle disorder, has improved the 
protein expression and achieved sustained correction of OTCD biomarker and 
clinical protection against an ammonia challenge (Wang et al., 2012)  
Using optimized sequences has been reported previously to induce protein level 
in skeletal muscle (Foster et al., 2008) and liver (Wang et al., 2012). Surprisingly, 
despite the increase in the protein level (20 fold) following HEK-293T cell 
transfection with the plasmid expressing optimized ERRγ, administration of 
rAAV9 3'F SO-ERRγ has no effect in the protein level of ERRγ in the treated EDL 
muscles compared to untreated, with reasons postulated herein.  
For our results here and similar to the previous chapter, we showed an 
improvement in specific force by 14% following administration of rAAV8-ERRγ 
using the same titre and the same age of mice. In the previous study, we showed 
that the increase in specific force was correlated with an increase in the level of 
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ERRγ protein and an increase in the protein level of mitochondrial complexes; I, 
II and III, and an increase in the expression of angiogenic factors; VEGF-165, 
VEGF-189 and capillary number per fibre. However, in the absence of any data 
to support the increase of muscle force following systemic administration AAV9 
mediated expression of optimized sequence of ERRγ, we speculatively refer the 
increase in specific force to the increased level of ATP production and may also 
indicate an increase in mitochondrial volume or number, which potentially reduce 
Ca+2 level per mitochondria that consequently help to maintain Ca+2 homeostasis 
and reduce mitochondrial dysfunction. Therefore, for future study, we may need 
to consider re–administration to make sustained change in the protein level.  
Further, based on the data from previous chapter in young mdx mice where we 
showed increased protein expression of mitochondrial complex, increased 
capillary number, increased RYR receptor, there is a potential decrease in the 
level of oxidative stress and ROS level, which is possibly another factor of 
improved force capacity. Alternatively, it is possible to suggest that the cargo 
makes adaptive response in terms of improving muscle function, before it is lost 
due to the cycles of degeneration/regeneration. For example; rAAV9 3'F SO-
ERRγ may be there for sufficient time to improve muscle force, however, due to 
the regenerative process, this lead to loss of vector and hence, no detection of 
any increase in the protein level, however, some benefits maintained as shown 
by the increase in specific force. Previously, it was shown that dystrophin 
restoration was declined following 6 months of AAV mediated exon skipping 
therapy (Peccate et al., 2016). It is possible that AAV mediated expression of 
sequence optimized ERRγ is lost from the muscle earlier than that of AAV 
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mediated exon skipping of dystrophin. Therefore, we could not detect any change 
at the protein level, while the effect on muscle function is still preserved.   
As all parameters are the same as the previous study, it is unclear why there is 
no increase in the protein level in the presence of increased specific force. It is 
possible that inability to detect any increase in the protein level is due to the 
antibody failure, which require investigating another antibodies. In conclusion, 
further evaluation of RNA and protein level is required to investigate this result. 
Moreover, as the sequence is Flag-tagged, it is possible to check the number of 
positive fibres in the muscle as a further evaluation of sequence optimized effect 
on protein level.  
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6. Chapter Six 
 
General discussion 
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6.1. General discussion: 
Dystrophic skeletal muscles undergo repeated bouts of myofibre necrosis, 
regeneration and growth, processes with a high metabolic cost. Moreover, the 
dystropathology is associated with inflammation, increased intracellular calcium, 
oxidative stress and metabolic abnormalities. Since muscle mass makes up such 
a high proportion, which is about 40% of total body mass, there must have been 
considerable selective pressure to minimize the cost of maintenance and to 
maximize the functionality of muscle tissue for all species. 
The broad aim of this project research was to demonstrate the potential of gene 
therapy approach implying AAV mediated expression of ERRγ to improve 
oxidative capacity and angiogenesis in mdx mice, a model of DMD. The collective 
studies presented in this thesis have investigated the potential of ERRγ over-
expression to improve force production and pathology associated with mdx mice, 
at different ages, with different doses. The main aim of this thesis was to assess 
the short-term effect of over-expression of ERRγ on function and pathology of 
mdx male mice. We hypothesized that over-expression of ERRγ on male mdx 
mice will improve the oxidative capacity and angiogenesis markers.  
The main outcomes of the research presented in this thesis are summarized as: 
1. Ontology data from IM of AAV8-ERRγ into TA muscles at 6 weeks of age 
showed that over-expression of ERRγ has changed gene expression pattern 
compared to the mdx. In addition, PCA analysis has demonstrated that treated 
samples are completely distinguishable from the untreated mdx phenotype.  
Principal component analysis (PCA) of transcriptomic data showed that following 
ERRγ over-expression, treated muscle could be distinguished from untreated 
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dystrophic muscle. Profiles of genes expressed in mdx-ERRγ versus mdx 
suggests that ERRγ may help in restoring the defective process known to be 
pathological drivers in dystrophic muscle. Although gene expression studies can 
be highly informative, their biological interpretation is limited. For example, most 
of transcriptomic studies employing RNA-seq methodology of microarrays 
presume that change in the abundance of mRNA are matched by corresponding 
alterations in protein expression; this is not always consistent (Zhang et al., 2010, 
Maier et al., 2009, Gygi et al., 1999). Therefore, multilevel analysis which 
investigate the transcriptome and proteome concomitantly will have greater 
potential for providing an understanding of gene regulation and cellular 
metabolism that might not be possible with any single analysis (Schwanhausser 
et al., 2011).    
2.  Cmap analyses generated a list of FDA approved pharmaceuticals that may 
act mimetics for the over-expression of ERRγ, providing alternative approaches 
to an AAV gene medicine approach.   
3. The first study of local administration of AAV8-ERRγ into TA muscles at 6 
weeks of age, active period of regeneration and degeneration, has no effect on 
oxidative capacity or vasculature of mdx mice. However, there was a reduction 
of pro-inflammatory cytokines (TNF-α and IL-1β). 
4. Systemic administration of AAV8-ERRγ into 6 week-old mdx for short period 
of time (4 weeks) has no effect on muscle force, oxidative capacity and 
angiogenesis. However, there was a reduction in the centrally nucleated fibres.  
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5. Systemic administration of AAV8-ERRγ into 3 week-old mdx and recovered at 
10 weeks of age, showed improvement in specific force, over-expression of 
mitochondrial proteins, angiogenesis markers and increases in capillary density.  
6. Sequence optimized ERRγ plasmid showed 20 fold over-expression of ERRγ 
protein following in-vitro transfection of HEK-293T cells with plasmid mediated 
expression of sequence optimized ERRγ.  
Limited outcomes of the 6-week cohort study: 
Local administration of AAV8-ERRγ into TA muscles at 6 week-old mdx mice 
showed no difference in the genes of oxidative metabolism, mitochondrial 
biogenesis and angiogenesis, inconsistent with the results obtained from 
systemic administration at 6 week-old mdx but with a different dose. Although, 
the highest level of ERRγ from the systemic administration was detected in 
gastrocnemius muscle, this did not seem to have any effect in the genes 
associated with oxidative metabolism or angiogenesis. In addition, functional 
output in terms of specific force was unaffected with the over-expression of ERRγ 
in EDL muscles. Therefore, we have no evidence to support that ERRγ has any 
effect on oxidative metabolism or angiogenesis during active period of 
degeneration and regeneration following postnatal over-expression in mdx mice. 
These results were particularly surprising as it was an age/sex matched study 
consistent with the transcriptomic study in which the PCA and gene ontology data 
was particularly encouraging. 
Although, the reduction in central nucleation was consistent in TA and 
gastrocnemius muscles from local and systemic administration, respectively, 
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however, this reduction was moderate. Considering the constant damage of the 
muscle, moderate improvement in the level of damage may dilute any change in 
other parameters such as, IgG and MYH-3, ending upp in non-significant 
difference. At the end, these results raise a question about how many fibres per 
muscle overexpress ERRγ. The answer for this question was not possible 
because none of the protocols we used were successful to detect the Ha-tag 
protein, as the AAV8-ERRγ fused with Ha-tag. This limitation represents one of 
the weaknesses in this thesis. Therefore, there is a need to develop a protocol to 
detect the positive fibres overexpressing ERRγ and then we will have a better 
idea whether the increase was per muscle or per fibre. In addition and more 
importantly, we should consider the validity of ERRγ antibody, which will be 
discussed later.  
Subsequently, assessing the effect of ERRγ over-expression on younger, pre-
crisis mice helped to rescue deficits in muscle function, with potentially 
coordinateted improvements in the oxidative capacity and angiogenic potential. 
Hence, the observed differences between the two studies should reflect the 
impact of the time of intervention and dosing strategies in DMD therapeutic 
regimens. Further assessment of the EDL histology from 6 weeks study will 
conclude the difference between the muscles of different ages. 
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Comparison between EDL from 6 weeks and 3 weeks studies: 
This thesis has demonstrated that EDL muscles from the two systemic 
administration studies showed similar over-expression of ERRγ which resulted in 
improving specific force of 3 weeks treated mdx but not of 6 weeks, in the 
absence of dystrophin restoration. Several reasons may help to explain that 
difference.  
1) Prior to crisis vs ongoing crisis. 3 weeks of age is considered a prior to onset 
pathology of mdx life compared to regenerative/degenerative period at 6 weeks. 
Therefore, it is acceptable to suggest that during active period of regeneration 
and degeneration, any transgene may eventually be lost following damage and 
repair. In preclinical trials of DMD using AAV mediated exon skipping therapy, 
dystrophin restoration was declined after six months. This reduction was 
correlated with loss of virus due to alteration of myofibre membrane (Peccate et 
al., 2016). According to the authors of that work, pre-treating mice with cell 
penetrating peptide conjugated to a phosphorodiamidate morpholino antisense 
oligonucleotides led to early dystrophin restoration, thus allowing more efficient 
maintenance of AAV cargo, leading to improved long term viral mediated 
restoration of dystrophin and improved muscle force. However, in our study of 
systemic administration of AAV-ERRγ, in the absence of dystrophin restoration, 
it is possible that virus cargo was lost due to active cycles of 
degeneration/regeneration and then the benefits from any therapeutic transgene 
will only establish a transient improvement. For the next future long term-study 
based on AAV-ERRγ, we are suggesting a combined approach to improve the 
transgene efficiency.  
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2) The length of the studies. 4 weeks post administration recovery vs 6 weeks 
post administration recovery, subsequent to AAV8-ERRγ gene transfer could 
affect the force production despite similar over-expression of ERRγ in the EDL 
muscles of the two ages, possibly of greater time for positive adaptive response.    
3) Increasing the expression of mitochondrial proteins complex; I, II and III. The 
increase in the expression of mitochondrial protein complex, possibly, results in 
more ATP generation that can be match the demand at cross bridge level. As 
mentioned previously, mdx exhibited a deficit in mitochondrial ATP synthesis 
(Rybalka et al., 2014), which is one reason for impaired force production in mdx 
muscles. Furthermore, we could speculate that increased ATP production 
following over-expression of mitochondrial protein complex means increased 
volume or/and number of mitochondria and this increase will limit the contribution 
of free radicals and calpain into disease pathology. Further, as a consequence 
of increased mitochondrial volume, it was hypothesized that there is less 
Ca+2/mitochondrial leading to less mitochondrial dysfunction throughout the cell 
which allow more ATP production (Selsby et al., 2012). 
4) Increasing expression of angiogenesis factors; VEGF-165 and VEGF-189 and 
improving the capillary number per fibre. Angiogenic factors have been shown to 
promote regeneration and cell survival (Messina et al., 2007). Speculatively, 
angiokines promote activation of SC to activate and proliferate through its 
regenerative effects. It has been hypothesized that the vasculature is important 
for regulating cellular energy homeostasis, through delivering substances such 
as oxygen, carbohydrates and fatty acid oxygen, thus determining cellular 
metabolism (Fraisl et al., 2009). Therefore, improving pro-angiogenic potential in 
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skeletal muscle will probably improve the metabolic activity by providing oxygen 
and fuel to the surrounding tissue, hence improving oxidative metabolism may 
improve antioxidant status and improve oxidative stress. Under this condition, 
there will be less ROS and the available ATP will be sufficient to maintain muscle 
contraction.  
In the current study, increasing number of capillary per fibre will increase the 
capacity of skeletal muscle to use oxygen supplied through increasing blood flow 
for regeneration of ATP. Given that we showed an increase in capillary density, 
we hypothesise that the muscle fibres will receive more oxygen in order to 
support more ATP production for its metabolic and contractile activities which 
provides further reasons for improved force production following AAV8-ERRγ 
administration. Given that following a yearlong treatment with antisense 
oligonucleotides in mdx mice to restore dystrophin to muscle by exon skipping, 
mdx mice have shown foci of dystrophin negative muscle that reflect the poor 
vascularisation of dystrophic muscle (Malerba et al., 2011). Based on the results 
shown in this thesis of increasing angiogenic markers and improving capillary 
density, we can speculate that ERRγ upregulation could be adjuvant therapy as 
a pre-treatment to allow better pharmacodynamics of subsequent treatments to 
enhance cargo delivery.  
5) Increasing expression of RYR-1 calcium marker. Increasing expression of 
RYR-1 may be another reason that mediate an increase in specific force. In 
theory, reduced RYR-1 expression or function lead to reduced SR storage of 
Ca+2, reduced Ca+2 binding capacity of troponin C, reduced ATP availability and 
could reduce contractility of skeletal muscle (Cong et al., 2016). During the early 
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stage of myofibre damage in DMD, the overall function of RYR-1 is reduced which 
lead to reduced Ca+2 release and hence the generated action potential (Lovering 
et al., 2009, Hernandez-Ochoa et al., 2015). As the level of myofibre contraction 
and subsequent force production are controlled in part by intracellular Ca+2 
release (Chin, 2010), a gradual decrease of RYR-1 Ca+2 release in DMD 
contributes to the development of muscle weakness. Speculatively, the increase 
in RYR-1 expression facilitates the release of Ca+2 available for muscle 
contraction.  
6) Increasing expression of inflammatory cytokines. Cruz-Guzmán et al., has 
reported a study that systemic inflammation is increased in patients with better 
muscle function and decreased in patients with poorer muscle function (Cruz-
Guzmán et al., 2015). Therefore, increasing inflammatory cytokines is possibly 
involved in repair process. Speculatively, increased expression of pro-
inflammatory markers in young mdx mice in this thesis could be another factor of 
improved function, as there is a relationship between inflammation and 
angiogenesis pathways. For example; studies have showed that IL-6 induce 
VEGF expression, leading to enhanced angiogenesis and vasculature in synovial 
fibroblast, which are specialized cells located inside joints and play crucial role in 
the chronic inflammatory diseases (Nakahara et al., 2003). We could hypothesize 
that increasing expression of IL-6 in young mdx muscle improves function 
through modulating angiogenesis. Future work should address quantity of 
different immune cells to understand the role of inflammation in muscle function.  
As inflammatory cytokines were assessed using qRT-PCR, there are 
disadvantages encountered on using this technique. It does not directly measure 
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proteins levels as the secretion of some cytokines such as IL-10 is regulated at 
the translational level and IL-1β is regulated post-translationally. Moreover, 
classifying the source of cytokines required a separate isolation of different cell 
types (Amsen et al., 2009). However, the results reported in this thesis 
represented the secreted cytokines from whole muscles, which highlighted a 
question of which cells types are affected by ERRγ over-expression. Although, 
the implication of more advanced method such as; cytokine bead array allow for 
detection of a whole panel of cytokines using small volume of sample, the high 
cost and low sensitivity of such approach represent the main disadvantage, which 
may affect the interpretation. During the analysis of inflammatory cytokines, I 
have tried to optimize this approach on blood serum from 6 weeks study. The low 
sensitivity of the kit despite using the lowest possible concentration of the sample 
represent the main hurdle of using such approach. Another protocol based on in-
situ hybridization on fresh tissue samples has been recommended in order to 
specify the localization and type of cytokines-producing cells, but, this method is 
not quantitative and does not reflect the protein levels (Amsen et al., 2009). 
Further fluorescence-activated cell sorting (FACS) analysis and histology 
analysis on damaged sections would be required to quantify the number of 
different immune cells within the tissue. 
Interestingly, inflammatory cytokines showed different expression pattern 
following ERRγ over-expression between muscles of different ages. Specifically, 
expression of pro-inflammatory cytokines were reduced after 4 weeks of ERRγ 
over-expression in TA muscles obtained from IM of AAV8- ERRγ into 6 week-old 
mdx. On the contrary, EDL muscles from mice treated at the same age, with 
different dose but, for the same length of time showed no difference in pro-
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inflammatory cytokines. However, EDL muscles from mice treated at 3 weeks of 
age showed reduced expression of the same cytokines. Therefore, the 
inconsistency in these results reflect how complex is the immune system in DMD 
pathology, suggesting that inflammatory cytokines may increase or decrease 
dependent on the level of damage of the cells and the time of the damage as well 
as the time of any therapeutic intervention in dystrophic muscle.  
The status of the cells will determine the need to upregulate, down regulate or 
unchanged expression of inflammation pathway. Since the muscles are under 
ongoing asynchronous degeneration/regeneration cycles, the interpretation of 
these data is difficult taking into account that fibres are not going into damage at 
the same time. Moreover, the regeneration of the muscle depends on the balance 
between pro-inflammation and anti-inflammatory factors that determine whether 
the damage will be repaired with the muscle replacement and functional 
contractility or with scar tissue formation (Loell and Lundberg, 2011, Wynn and 
Vannella, 2016, Karin and Clevers, 2016). Therefore, even if the anti-
inflammation cytokines increased at some points, once the other fibre starts 
damaging, the pro-inflammatory cytokines will increase, which ensures a failure 
of the transition from the M1 pro-inflammatory phenotype to the M2 repairs 
phenotype. 
Another factor to consider for future work is the autophagy assessment. To 
assess autophagy, for future work, we should consider autophagy as a multistep 
pathway with each step characterized by a particular rate. Using approach of a 
single cell fluorescence live-cell imaging based approach that describes the 
autophagosome pool size, autophagosome flux and the transition time required 
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to continue the intracellular autophagosome pool. This method will provide 
quantitative measurement of autophagosome flux (Loos et al., 2014).  
Generally, two main outcomes were highlighted from these two studies; the 
efficient therapy implemented at early time of intervention and the significance of 
using high dose. In one hand, Head et al., recommended that therapy need to be 
implemented in the early phase of disease as he suggested two stages of muscle 
damage in mdx. The absence of dystrophin, in young muscles, activates 
channels that elevate Ca+2 followed by damage caused by this increase. This 
damage later, causes splitting of fibres that leads to further damage and weaken 
muscle force. Due to imbalances of force generation around the split site, fibres 
from mdx exhibit branches sides, possibly due to abnormal or incomplete 
regeneration (Head, 2010, Chan and Head, 2011). The notion of age-dependent 
limitations in the effectiveness of any intervention has been reported in exon 
skipping as the effectiveness is limited in more damaged muscles (Wu et al., 
2014). 
Since the effectiveness of activating ERRγ approach was limited to younger 
mice, therefore, early time of intervention through AAV-ERRγ is one of the 
important factors that potentially results in the increase in specific force and 
improvements in pathology. 
Noteworthy, therapeutic applications based on AAV gene therapy will require 
high viral titre loads e.g. potentially 1X1015 to 1X1016 vector particles/kg (Hinderer 
et al., 2018). Therefore, the highest dose in this thesis (2X1012 vg of AAV8) was 
conducted in the youngest mice in an attempt to achieve greatest vector 
particles/kg. Recently, severe toxicity was reported following high dose of AAV. 
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Although, targeting liver via systemic administration of AAV vectors was 
successful in term of reaching therapeutic level of transduction efficiency using 
doses range between 1012-1013 vg/kg. However, in poor capillary network organs 
such as skeletal muscle, targeting therapeutic level requires high dose, which is 
equal to 1014 or more of viral genome. As demonstrated recently, systemic 
administration of high dose of AAV9 variant (AAVhu68) expressing SMN gene 
targeting spinal muscular atrophy (SMA) showed unexpected toxicity in monkeys 
and piglets. The researchers reported sensory motor degeneration and elevated 
transaminases in both species whereas acute inflammation, coagulation defects 
and hepatic toxicity were observed in monkeys. This toxicity was due to reasons 
does not involve immune response to viral capsid or the transgene. Whether the 
toxicity was due to the high dose, or a contamination or a procedure of tittering 
the virus or human gene in non-human tissues, is a future work to address 
(Hinderer et al., 2018). Similar toxic events was observed using high dose of 
AAV-PHP.B (7.5x1013 GC/kg), another AAV9 variant into nonhuman primates 
(Hordeaux et al., 2018). However, there are two possible explanation for the 
reported toxicity as suggested by the authors; 1) large numbers of vector genome 
lead to toxicity and contamination of the vector to hepatocytes through activation 
of DNA damage response or activation of endoplasmic reticulum (ER) stress 
pathways by transgene over-expression. However, since different labs use 
different methods to measure the dose, it would be more practical that key 
stakeholders in the gene therapy field work together to develop reference 
standards and standardized methods, as this would eliminate the variation of 
virus sources and production facilities and therefore, we will have more 
comparative studies. 2) Activation of adaptive immunity and destruction of 
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hepatocytes through antigen specific-T-cell responses to either the transgene 
product or vector capsid (Hordeaux et al., 2018). On the other hand, regarding 
the dose effect, the modest dose of 2X1012 vg/kg of AAV8 expressing factor IX 
in haemophiliaX clinical trials showed an increased level of transaminase, which 
associate with adaptive immune response but that does not meet the criteria of 
toxic effects (Manno et al., 2006). The peak of transaminase was different 
between these two studies, where in the former, the toxicity was reminiscent of 
that observed with acute acetominophen  poisoning that result from diffuse 
hepatocellular injury caused by release of excessive ROS and decreased 
antioxidants molecules (Jaeschke et al., 2012).  
In the absence of dystrophin restoration, vector copies will likely be lost due to 
muscle cell turnover, re-administration of virus will become an increasing 
translational bottleneck to overcome. However, AAV vectors at high does have 
the potential to elicit immune response against vector capsid and transgene. The 
fact that most people developed an immune response against a particular 
variants, resulting in pre-exciting of adaptive response. This can include the 
presence of neutralizing antibodies or T cells dependent B-cell response that will 
eliminate the cells that have been transduced or diminish the efficacy of re-
administration approach with AAV (Naso et al., 2017). To date, this represent one 
of the biggest challenge to therapeutic AAV. Therefore, nowadays several 
transient immune modulatory regimens have been applied in gene therapy 
researches to prevent humoral and cellular immune response. For example, 
treatment with antibody against CD4 allows transgene expression (Chirmule et 
al., 2000). Combined immunosuppression drugs of anti-thymocyte globulin 
(ATG), cyclosporine (CSP) and mycophenolate mofetil (MMF) have been used 
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to suppress the immune response to vector and transgene in the muscle 
transduced with AAV mediated expression of µDys in canine X-linked muscular 
dystrophy (cxmd) dog (Wang et al., 2007). In addition, although, immune 
response to transgene product can be affected by the innate immune response 
to vector. However, immune response against the transgene were not detected 
in most of the clinical trials following IM gene transfer using AAV in muscular 
dystrophy, hemophilia B, lipoprotein lipase deficiency (Mingozzi and High, 2013). 
The work conducted in this thesis was based on a single administration of AAV. 
The future direction may consider re administration of AAV combined with 
immunosuppressant drugs to reduce the immune response.  
Then, the next step to finalize the experiment of sequence optimized ERRγ gene 
transfer is to solve the problem encountered with qRT-PCR primers and to 
assess the histological outcomes in terms of SDH, MYH-3, IgG and H&E. 
Although, the western blot data in that chapter does not fully support the increase 
in ERRγ, however, we cannot draw a full conclusion from that results in the 
presence of an increase in the functional output. Moreover, other studies have 
been solely dependent on RNA data only with no demonstrable evidence of 
protein over-expression. For example, three studies of AAV6-PGC-1α did not 
showed any data of PGC-1α protein level and confirmed the increase of PGC-1α 
using qRT-PCR data only (Hollinger and Selsby, 2015, Hollinger et al., 2013, 
Selsby et al., 2012). Further, because sequence analysis reveals that ERRs share a 
high degree of homology within their DNA and ligand-binding domains (LBDs), (Dufour 
et al., 2007, Misawa and Inoue, 2015), there is high chance of amino-acid 
overlapping, hence, limit the efficiency of antibody detection. It should be noted 
for example that the antibody used to detect ERRβ binding sites in the mouse 
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embryonic stem cells study also recognized ERRγ (Chen et al., 2008). Further, 
to detect ERRα in tissues of cancer, an antibody was generated specific to a 
sequence in LBD to minimize the overlapping detection with other ERR receptors 
(Gaillard et al., 2007). For future work, we should consider trying another 
antibody for ERRγ. 
Moreover, it is also possible that the method of preparing samples need further 
optimization. Therefore, using a different protocol to fractionate samples into 
nuclear and cytosolic fractions will give better indication of the level of change in 
the markers assessed in this thesis. (Figure 2, (A-B)) in (Wan et al., 2012), for 
example, showed different pattern of protein level of PGC-1α and ERRγ between 
the different fractions at different time points.  
In conclusion, AAV-ERRγ approach could provide transient benefits when 
administration takes place at 3 weeks of age as shown in this thesis, however, 
we should consider assessing different time points. Moreover, due to loss of 
virus, minimal benefits and possible immune response to AAV, we should also 
consider the data from the cMap list. On the basis of cMap list, an emerging drugs 
could be a suitable target to mimic ERRγ over-expression as an alternative 
pharmaceuticals approach especially those with known established effect. The 
advantage of reconsidering established drugs is that they have already been 
approved and hence they can potentially be re-marketed in a faster and more 
efficient way by skipping Phase I clinical trials (Iorio et al., 2013).  
Generally, for efficient gene transfer, critical parameters should be considered; 
vector design, capsid selection, desired target cells and tissue type and route of 
administration. The transgene to be delivered optimized for expression, the right 
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AAV variant with an appropriate capsid for target cell transduction and immunity 
profiles and the appropriate delivery approach to maximize target tissue 
exposure. Understanding the disease mechanism, the turnover rate of the target 
cell, the effect of the therapeutic transgene, all of these factors will allow better 
designing of the trials, optimization of vector construction and developing the right 
gene therapeutic. Toxicities will require to be monitored in the course of any AAV 
clinical development. 
6.2. Future works: 
 Assess the mtDNA to investigate the role of postnatal over-expression of 
ERRγ on mitochondrial biogenesis, as there is no direct evidence has 
been addressed here.   
 Completion of assessing factors associated with oxidative capacity, 
angiogenesis, inflammation and pathology in muscles from 3 weeks old 
mdx of intraperitoneal administration of AAV9-ERRγ. 
 Assess the long-term effect changes in pathology, function and biomarker 
profiling in dystrophic skeletal muscle following AAV mediated ERRγ 
expression. 
 Assess the pathological and functional changes in dystrophic skeletal 
muscle following re-administration of AAV-ERRγ. 
 Assess the pathological and functional changes in dystrophic skeletal 
muscle following dual administration of AAV-ERRγ and AAV-µdystrophin 
 Assess the pathological and functional changes in dystrophic muscle 
following administration of AAV-ERRγ followed by administration of 
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antisense oligonucleotides to restore dystrophin to muscle by exon 
skipping, as over-expression of ERRγ reflect an increase in the capillary 
density which potentially will improve delivery of antisense 
oligonucleotides.  
 Developing the mimetic drug approaches that achieve similar effects as 
AAV mediated over-expression of ERRγ 
6.3. Limitations: 
Study One:  
The main limitation of this work is inability to count the number of positive fibres 
for ERRγ in sections as the ERRγ construct was fused with Ha-tag and no 
increase in the ERRγ protein level was detected. Part two of that study has no 
western blot for ERRγ, as the samples have been lost.  
Study two:  
Two glycolytic muscles only were assessed as gastrocnemius showed the 
highest over-expression of ERRγ and EDL was used for functional measurement. 
I think assessment of diaphragm as an example of sever pathophysiology 
resembles disease feature in humans would be a good comparison. 
Study 3:  
Assess the oxidative stress using oxyblot to measure carbonylated proteins as a 
measure of a reduction in oxidative stress as there is evidence of increased 
mitochondrial proteins and enhancement of vasculature, which potentially help 
on reducing mitochondrial stress.  
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7.1. List of Equipment: 
- Countess Cell Counter machine (Life Technology) 
- Cryostat Bright OTF5000 
- Image J software 
- Image Quanta  
- Nanodrop: Thermo Scientific NanoDrop 2000 spectrophotometer 
- PCR machine T100 Thermal cycler B10-Rad 
- Step one Plus Real time PCR system (Applied Biosystems) 
7.2. List of materials: 
- ABC kit (Vector laboratory, PK-6100) 
- Agar (Sigma A1296) 
- Agarose (Sigma A9539) 
- Avidin-Biotin Blocking kit (Vector laboratory, SP2001) 
- Benzonase (Sigma E8263 Ultrapure) 
- Beta gal assay #11 539 426 001-Roche) 
- β-mercaptoethanol (Sigma 63689) 
- CK assay Randox Laboratory limited, CK522 (#1530). 
- Clarity western ECL substrate (Bio-Rad 170-5060) 
- Dako fluorescent (Dako S3023) 
- DC assay (Bio-Rad DCTM Protein Assay) 
- DMEM (Sigma D6429) 
- DNA gel stain (Invitrogen S33102) 
- DNase 1: 10 mg/ml in H20 or RQ1 DNase 1 (1 U/μl Promega) 
- DPX (VWR 360294H) 
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- Fetal Calf Serum FCS (Sigma F2442) 
- Gel extraction kit (QIAEX II Gel Extraction Kit, # 20051, QIAGEN). 
- Gel loading buffer (Sigma G2526) 
- Glucose (Sigma G 8270) 
- Glycogen (invitrogen) 
- Housekeeping genes (Primer design HK-SY-mo-600). 
- Isopentane (VWR) 
- KCN (Fisher 1059938) 
- LB-agar  
- LB-Broth (Sigma L7658) 
- Linear polyethylenimine (PEI) (408727, Sigma) 
- Mayers haematoxylin (MHS80-Sigma) 
      -      Non-fat milk powder 
      -      MOPS running buffer (Sigma PCG 3003) 
- Nitroblue tetrazolium (Sigma 74032) 
- Nitrocellulose membrane: (Hybond-C Extra; GE Healthcare Life Science, 
Pittsburgh, PA, USA) 
- Novex sharp Pre-stained Protein standard (Invitrogen LC5800) 
- NP-40 
- NuPAGE LDS sample buffer (4X) (Novex, NP0008) 
- OCT (Tissue Tek 4583) 
- PBS tablet (Gibco, Life Technology 18912-014) 
- Penicillin-Steptomycin (Sigma P4333) 
- Perfecta SYBR Green FastMix (# 019358, Quantabio). 
- Peroxidase substrate kit (DAB) kit (Vector Laboratory SK-4100) 
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- Phosphatase inhibitors (Sigma P5726)  
- Ponceau (Sigma P7170) 
- Proliferation assay (G3582, Promega) 
- Protease inhibitors (Sigma S8820)  
- Proteinase K: (10 mg/ml in water. Sigma P2038) 
- QIAprep Spin Miniprep Kit (Quanta- 27106) 
- QScript cDNA Synthesis Kit (Quanta-733-1174P)  
- Quick-Seal ultra-clear: Beckman 361 625 
- RNA extraction protocol (Sigma T9424) 
- SDS (Sigma 05030) 
- Sodium deschocloalte 
- Succinate stock (Fisher 11418852) 
- Transfer buffer (Sigma TruPAGETM Transfer PCG3011) 
- TRI-reagent (Sigma 9424) 
- Triton X100 (Sigma T9284) 
- TruPAGE Precast Gel (4-12% SDS), (Sigma, PCG2003-10EA) 
- Tween-20 (Sigma P7949) 
- Trypsin/EDTA (sigma T4174) 
- XL-10 gold (Agilent echnologies) 
- Xylene (Fisher X/025/17) 
- 25:24:1 phenol/chloroform/isoamyl alcohol (Sigma P2069) 
7.3. Buffer formulation: 
- 40% Polyethylene glycol (PEG) 8000:  
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 40% [w/v] PEG 8000 with 2.5 M NaCl in water. (For 500 ml – 200 g PEG 8000, 
73.05 g NaCl). Sterilise by passing through a 0.22 μm filter. Store at room 
temperature  
- Lysis buffer (500 ml):  
          4.38 g NaCl (0.15 M), 25 ml 1M Tris.Cl pH8.5 (50 mM). and autoclaved. 
- 5X PBS-MK (100 ml):  
Take 5 Phosphate Buffered Saline Tablets and add to 90 ml of distilled water. 
Autoclave, cool, and add 0.5 ml 1M MgCl2 (5 mM) and 1.25 ml of 1 M KCl (12.5 
mM). Make up to 100 ml with sterile water. (It is important not to add the MgCl2 and 
KCl before autoclaving as these salts will precipitate out of solution and will not go 
back in even when the solution is cooled.) 
- 2x Proteinase K buffer:  
            20 mM Tris.Cl (pH 8.0), 20 mM EDTA (pH8.0), 1% (w/v) SDS. Store at RT  
- 20x SSC (1 litre):  
             175 g NaCl (1.5 M), 88 g Na3 citrate (0.3M) 
- Hybridisation buffer:  
(Nonradioactive labelling of probe and detection (Amersham RPN3000) required 
volume of ECL gold hybridisation buffer to cover blot, 0.5 M NaCl, 5% (w/v) 
blocking agent (usually use 34 ml ECL hybridisation buffer, 1 g NaCl, 1.7 g 
blocking agent). Mix at RT until dissolved (0.5-1 hr) and heat to 42C (0.5 hr). 
- Primary wash buffer (1litre):  
             360 g urea (6 M), 4 g SDS (0.4%), 25 ml 20x SSC (0.5x SSC). Store at 4C.   
- 3 M NaAc pH 5.2:  
81.66 g sodium acetate. 3H2O in 150 ml water, Adjust to pH5.2 with glacial acetic 
acid. Adjust volume to 200 ml with H2O. Sterilize by autoclaving 
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- Formol calcium: 
            100 ml of 40% formaldehyde, 20g calcium chloride and with 900 ml of water 
- Permeabilization buffer: 
(200 mM Hepes, 300 mM sucrose, 50 mM NaCl, 0.5%TX100, 3 mM MgCl2 and 
0.05% Na azide) 
- Washing buffer: 
(5% fetal calf serum, 200 mg Na azide, 0.05% TritonX and 500 ml PBS) 
- RIPA lysis buffer: 
(50 mM tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% w/v sodium 
deoxycholate, protease inhibitors  (1:10) and phosphatase inhibitors (1:100) 
- Western blot blocking buffer:  
             5% milk in Tris buffered saline, 0.1% Tween 20 (TBST) 
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7.4.   Native pAAV-ERRγ  
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7.5. pAAV SO 3F’ ERRγ 
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7.6. Sequence optimization: 
5’F SO ERRγ: 
AccggtgccaccATGGACTACAAAGATCACGATGGGGACTATAAGGACCATGACATCG
ACTACAAAGACGATGACGACAAAATGGATAGCGTCGAACTGTGTCTGCCAGAGAG
CTTCTCTTTGCATTACGAAGAGGAGCTGTTGTGCAGAATGAGCAATAAGGATAGG
CACATCGATTCCTCTTGTTCATCCTTCATCAAAACCGAACCCAGCTCACCAGCTTC
CCTGACTGACTCAGTGAACCACCATTCTCCTGGTGGCAGTTCAGACGCATCCGG
GTCATATAGCTCTACTATGAATGGGCATCAGAATGGCCTGGACAGTCCACCACTG
TATCCCTCTGCCCCTATACTGGGTGGTTCTGGACCTGTTCGCAAACTGTACGACG
ATTGCAGCAGTACTATCGTTGAGGATCCGCAGACAAAATGCGAGTACATGCTGAA
CAGTATGCCCAAACGTCTGTGCTTGGTGTGCGGAGATATCGCCAGTGGGTATCAC
TACGGAGTGGCTTCCTGTGAAGCCTGTAAGGCCTTCTTTAAGCGGACAATTCAGG
GGAACATCGAGTACTCCTGTCCGGCTACCAATGAGTGCGAGATCACCAAACGGA
GGCGGAAATCTTGCCAGGCATGTCGCTTCATGAAGTGCCTCAAAGTGGGGATGC
TGAAAGAGGGCGTTCGTTTGGACCGGGTGAGAGGAGGCAGGCAGAAGTACAAGA
GGAGAATTGACGCGGAAAACTCCCCATATCTGAATCCCCAGCTCGTTCAACCAGC
CAAGAAGCCCTACAACAAGATTGTGAGCCATCTGCTGGTAGCTGAACCTGAGAAG
ATATACGCAATGCCTGACCCTACAGTACCTGACAGCGACATCAAAGCGCTTACGA
CTCTGTGTGATCTCGCCGATAGGGAACTTGTGGTGATTATTGGCTGGGCCAAGCA
CATTCCCGGCTTTAGCACACTGTCTCTCGCTGATCAGATGTCCCTGCTTCAATCC
GCTTGGATGGAGATCCTGATTCTGGGAGTCGTGTATCGATCACTGTCTTTCGAGG
ATGAGCTCGTCTACGCCGATGACTATATCATGGATGAAGATCAGAGTAAACTTGC
GGGTTTGCTCGACCTGAACAACGCCATCCTGCAGCTGGTGAAGAAGTATAAGAG
CATGAAGCTCGAGAAAGAGGAATTTGTCACACTGAAGGCTATTGCCCTTGCCAAT
AGCGACAGCATGCACATAGAAGATGTTGAGGCTGTCCAGAAGTTGCAGGACGTG
CTGCATGAAGCTCTCCAGGATTATGAAGCAGGCCAACACATGGAGGACCCAAGA
CGCGCAGGAAAGATGCTCATGACCCTTCCGCTGTTGCGACAAACCAGTACGAAA
GCAGTACAGCACTTCTACAACATAAAGCTTGAAGGCAAGGTGCCCATGCACAAGC
TCTTTCTGGAGATGCTGGAGGCAAAGGTCTGAttaattaa 
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3’F SO ERRγ: 
AccggtgccaccATGGATAGCGTCGAACTGTGTCTGCCAGAGAGCTTCTCTTTGCATT
ACGAAGAGGAGCTGTTGTGCAGAATGAGCAATAAGGATAGGCACATCGATTCCTC
TTGTTCATCCTTCATCAAAACCGAACCCAGCTCACCAGCTTCCCTGACTGACTCAG
TGAACCACCATTCTCCTGGTGGCAGTTCAGACGCATCCGGGTCATATAGCTCTAC
TATGAATGGGCATCAGAATGGCCTGGACAGTCCACCACTGTATCCCTCTGCCCCT
ATACTGGGTGGTTCTGGACCTGTTCGCAAACTGTACGACGATTGCAGCAGTACTA
TCGTTGAGGATCCGCAGACAAAATGCGAGTACATGCTGAACAGTATGCCCAAACG
TCTGTGCTTGGTGTGCGGAGATATCGCCAGTGGGTATCACTACGGAGTGGCTTC
CTGTGAAGCCTGTAAGGCCTTCTTTAAGCGGACAATTCAGGGGAACATCGAGTAC
TCCTGTCCGGCTACCAATGAGTGCGAGATCACCAAACGGAGGCGGAAATCTTGC
CAGGCATGTCGCTTCATGAAGTGCCTCAAAGTGGGGATGCTGAAAGAGGGCGTT
CGTTTGGACCGGGTGAGAGGAGGCAGGCAGAAGTACAAGAGGAGAATTGACGC
GGAAAACTCCCCATATCTGAATCCCCAGCTCGTTCAACCAGCCAAGAAGCCCTAC
AACAAGATTGTGAGCCATCTGCTGGTAGCTGAACCTGAGAAGATATACGCAATGC
CTGACCCTACAGTACCTGACAGCGACATCAAAGCGCTTACGACTCTGTGTGATCT
CGCCGATAGGGAACTTGTGGTGATTATTGGCTGGGCCAAGCACATTCCCGGCTTT
AGCACACTGTCTCTCGCTGATCAGATGTCCCTGCTTCAATCCGCTTGGATGGAGA
TCCTGATTCTGGGAGTCGTGTATCGATCACTGTCTTTCGAGGATGAGCTCGTCTA
CGCCGATGACTATATCATGGATGAAGATCAGAGTAAACTTGCGGGTTTGCTCGAC
CTGAACAACGCCATCCTGCAGCTGGTGAAGAAGTATAAGAGCATGAAGCTCGAGA
AAGAGGAATTTGTCACACTGAAGGCTATTGCCCTTGCCAATAGCGACAGCATGCA
CATAGAAGATGTTGAGGCTGTCCAGAAGTTGCAGGACGTGCTGCATGAAGCTCTC
CAGGATTATGAAGCAGGCCAACACATGGAGGACCCAAGACGCGCAGGAAAGATG
CTCATGACCCTTCCGCTGTTGCGACAAACCAGTACGAAAGCAGTACAGCACTTCT
ACAACATAAAGCTTGAAGGCAAGGTGCCCATGCACAAGCTCTTTCTGGAGATGCT
GGAGGCAAAGGTCATGGACTACAAAGATCACGATGGGGACTATAAGGACCATGA
CATCGACTACAAAGACGATGACGACAAATGAttaattaa 
SO ERRγ=Gray 
Flag sequence=Turquoise 
Kozak=Red 
AgeI=Green 
PacI=Pink 
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7.7. List of primers: 
Table 7.1. List of primers 
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7.8. CMap List: 
Table 7.2. List of drugs from cMap 
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